Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 1 Clinical Study Protocol 
KCP-330-012 
A Phase 2b, Open -Label, Single-Arm Study of Selinexor (KPT-330) Plus 
Low-Dose Dexamethasone (Sd) in Patie nts with Multiple Myeloma Previously 
Treated  with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and 
Daratumumab, and Refractory to Prior Treatment with Glucocortic oids, an 
Immunomodulatory Agent, a Prot easome Inhibitor, and the anti -CD38 mAb 
Daratumumab  
Study Name:  [CONTACT_555291] (Selinexor Treatment  of Refractory Myeloma)  
Drug Development Phase: Phase 2b 
Investigational Product: Selinexor (KPT-330) 
Indication: Multiple myeloma (MM) previously treated with 
lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and the anti
-CD38 mAb 
daratumumab  
EudraCT Number: 2016-003094-18 
Sponsor: Karyopharm Therapeutics Inc. 
[ADDRESS_728946]  
Newton, MA [ZIP_CODE] [LOCATION_003]  
Tel. + ([PHONE_11540]  
Protocol Date and Version: [ADDRESS_728947]  2016, Version 4.0- ROW (Rest of World)  
06 February 2017, Version 4.1 US (Country -specific) 
[ADDRESS_728948] 
In accordance with the ethical principles that originate from t he Declaration of Helsinki and that 
are consistent with International Conference on Harmonisation ( ICH) guidelines on Good Clinical 
Practice (GCP) and regulatory requirements as applicable.  
CONFIDENTIAL INFORMATION  
This document is the sole property of Karyopharm Therapeutics I nc. (Karyopharm). This document 
and any and all information contained herein has to be consider ed and treated as strictly 
confidential. This document shall be used only for the purpose of the disclosure herein provided. 
No disclosure or publication shall be ma de without the prior written consent of Karyopharm.  
[COMPANY_003]
[COMPANY_003] [COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003] [COMPANY_003]
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 3 PRINCIPAL INVESTIGAT OR‚ÄôS AGREEMENT  
I have read and understand the contents of this clinical protocol for Study No. KCP-330-[ADDRESS_728949] the Study in accordance 
with current Good Clinical Practices, ICH E6, and applicable FD A regulatory requirements: 
Name [CONTACT_4007] [INVESTIGATOR_678]: 
[INVESTIGATOR_678]‚Äôs Signature:   
[INVESTIGATOR_678]‚Äôs Name:   
[CONTACT_16277]:  
Date:  
  
 
 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 4 PROTOCOL SYNOPSIS 
Sponsor: 
Karyopharm Therapeutics Inc. Investigational Product: 
Selinexor (KPT-330) Developmental Phase: 
Phase 2b 
Title of Study:   
A Phase 2b, Open -Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose 
Dexamethasone (Sd) in Patients with Multiple Myeloma Previously  Treated with 
Lenalidomide, Pomalidomide, Bort ezomib, Carfilzomib, and Daratu mumab, and  
Refractory to Prior Treatment with Glucocorticoids, an Immunomodulatory Agent, a 
Proteasome Inhibitor, and the anti-CD38 mAb Daratumumab 
Protocol Number:  KCP-330-012: STORM (Selinexor Treat ment of Refractory Myeloma) 
Indication:  Multiple myeloma previously treated with lenalidomide, pomalid omide, 
bortezomib, carfilzomib, and daratumumab, and refractory to pri or treatment with 
glucocorticoids, an immunomodulatory agent (IMiD), a proteasome  inhibitor (PI), and the 
anti-CD38 mAb daratumumab (penta-refractory MM) 
Objectives: 
Primary:  
Evaluate the efficacy (overall response rate [ORR]) for treatme nt with selinexor 80 mg 
plus low -dose dexamethasone (20 mg) (Sd) twice weekly (four- week cycles) in patients 
with MM previously treated with  lenalidomide, pomalidomide, bortezomib, carfilzomib, 
and daratumumab, and refractory to prior treatment with glucoco rticoids, an 
immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and  the anti -CD38 mAb 
daratumumab (herein referr ed to as penta-refractory MM). 
ORR will include patients who experience partial response (PR),  very good partial 
response (VGPR), complete response (CR), or stringent complete response (sCR), based 
on International Myeloma Working Group (IMWG) response criteria  (Kumar 2016 ) for 
patients with penta-refractory MM in Part 2 (Expansion). 
Secondary:  
The following endpoints will be analyzed separately for (a) Part 1 patients with quad -
refractory MM (i.e., previously treated with lenalidomide, poma lidomide, bortezomib, 
carfilzomib,  but not an anti-CD38 mab), (b) Part 1 patients with penta- refractory MM, and 
(c) Part 2 (expansion) patients with penta -refractory MM. Additionally, analyses of safety 
and tolerability will be performed on the overall population of patients from Pa rts [ADDRESS_728950] one dose of study treatment.  
x Duration of response (DOR = Dur ation from first observation of at least PR to time 
of disease progression, or deaths due to disease progression, whichever occurs first.  
DOR will be censored for death due to any causes other than disease progression. 
x Clinical Benefit Rate (CBR = sCR + CR + VGPR + PR + minimal response [MR]), 
and duration of clinical benefit (Duration from first observation of at least MR to 
time of disease progression or death due to disease progression, whichever occurs 
first. Duration of clinical benefit will be censored for death due to any causes other 
than disease progression) 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6SRQVRU
.DU\RSKDUP7KHUDSHXWLFV,QF,QYHVWLJDWLRQDO3URGXFW
6HOLQH[RU.37'HYHORSPHQWDO3KDVH
3KDVHE
x'LVHDVH&RQWURO5DWH'&5 &%5VWDEOHGLVHDVH>6'IRUDPLQ LPXPRI
ZHHNV@
x3URJUHVVLRQ)UHH6XUYLYDO3)6 'XUDWLRQIURPVWDUWRIVWXG\W UHDWPHQWWR3'RU
GHDWK>UHJDUGOHVVRIFDXVH@ZKLFKHYHUFRPHVILUVW
x7LPHWR3URJUHVVLRQ773 'XUDWLRQIURPVWDUWRIVWXG\WUHDWPH QWWRWLPHRI
GLVHDVHSURJUHVVLRQREWDLQHGZLWKVHO LQH[RUSOXVGH[DPHWKDVRQHYV773RQPRVW
UHFHQWSULRUWKHUDS\
x7LPHWRQH[WWUHDWPHQW7717
x2YHUDOO6XUYLYDO26 'XUDWLRQIURPVWDUWRIVWXG\WUHDWPHQWW RGHDWK
x4XDOLW\RI/LIH4R/XVLQJWKH)XQFWLRQDO$VVHVVPHQWRI&DQFHU 7KHUDS\
0XOWLSOH0\HORPD)$&700
x6DIHW\DQGWROHUDELOLW\XVLQJ1DWLRQDO&DQFHU,QVWLWXWH1&,& RPPRQ
7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(Y
x'HVFULEHWKH3.SURSHUWLHVRIVHOLQH[RULQWKLVSDWLHQWSRSXODW LRQ3DUWRQO\
 


 
 


 
 

 

 
 


 
 
 
%DFNJURXQGDQG6WXG\5DWLRQDOH
Background  
0XOWLSOHP\HORPD00LVWKHVHFRQGPRVWFRPPRQKHPDWRORJLFDOP DOLJQDQF\DIWHU
QRQ+RGJNLQ¬∂VO\PSKRP DUHSUHVHQWLQJRIDOOFDQFHUVDQGRIDOOFDQFHUGHDWKV 
'HVSLWHWKHLQFUHDVHGHIIHFWLYHQHVVRIDYDULHW\RIDJHQWVQHD UO\DOOSDWLHQWVZLOOCCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 6 Sponsor: 
Karyopharm Therapeutics Inc. Investigational Product: 
Selinexor (KPT-330) Developmental Phase: 
Phase 2b 
eventually relapse with their disease becoming drug-resistant. With over 12,600 deaths 
from MM anticipated in 2016 in the US alone, there is an unmet medical need for therapi[INVESTIGATOR_555222]/or refractory (RR) MM that has progressed on available 
treatments.  
Selinexor is an orally bioavailable, selective inhibitor of nuc lear export (SINE) compound 
that specifically blocks exportin 1 (XPO1). Selinexor and other  SINE compounds have 
demonstrated anti -MM activity in preclinical studies.  In the Phase- 1 study, selinexor alone 
(all doses) showed an ORR of 5%, and with low -dose dexamethasone (Sd; all do ses) the 
ORR was 32%.   Therefore, the Sd regimen was carried forward in to this ongoing Phase 2 
study.   
Rationale for Expansion (protocol version 4.0)  
For Part [ADDRESS_728951] been evaluated 
([ADDRESS_728952] measurable MM at baseline): 
48 patients with quad-refractory MM (IMIDs and PIs) and 30 patients with penta-
refractory MM (quad + anti-CD38 refractory). Patients were initially dosed with 6 doses of  
Sd per cycle, and this was increased to 8 doses of Sd per cycle . The ORR adjudicated by a 
four-physician Independent Review Committee (IRC) across all patients was 21% and the 
clinical benefit rate (CBR) is 33%. Similar ORR were seen in th e patients with ‚Äúpenta‚Äù and 
‚Äúquad‚Äù MM, with higher CBR in patients who received 8 vs. 6 doses/cycle consist ent with 
improved disease control with c ontinuous dosing. The median dur ation of response (DOR) 
was ~5  months, with 9 patients continuing on study. There was a trend  towards higher 
ORR in the 8-dose per cycle Sd regimen, with lit tle difference in tolerabili ty. Furthermore, 
there was a trend to increased time on study in patients with b aseline hemoglobin (Hb) 
‚â• 8.5 gm/dL. Therefore, based on the current unmet medical need for p atients with RR 
MM and these preliminary clinical re sults, this study is now being  expanded to evaluate 
the efficacy and safety of twice-weekly Sd in patients with pen ta-refractory MM.  
Methodology : 
This is a Phase 2b, single -arm, open- label, multicenter study of Sd, dosed twice weekly 
each week in four -week cycles, in patients with penta- refractory MM (Parts 1 and 2) or 
quad -refractory MM (Part 1 only).  
The population for the primary efficacy analys is will contain only patients with penta-
refractory MM enrolled in Part 2. Response results for patients  with quad -refractory MM 
and patients with penta -refractory MM enrolled in Part [ADDRESS_728953] one dose of study drug, presented overall and by [CONTACT_555251], and separately for Part 1 
penta -refractory and quad-refractory patient populations. 
Patients will receive treatment until progressive disease (PD),  death, toxicity that cannot be 
managed by [CONTACT_555252], or withdrawal, whichever occurs first. 
Inclusion/Exclusion Criteria: 
Inclusion: 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 7 Sponsor: 
Karyopharm Therapeutics Inc. Investigational Product: 
Selinexor (KPT-330) Developmental Phase: 
Phase 2b 
Patients must meet all of the following inclusion criteria to b e eligible to enroll in this 
study:  
1. Written informed consent in accordance with federal, local, and  institutional 
guidelines. 
2. Age ‚â• [ADDRESS_728954] o ne of the 
following: 
a. Serum M- protein ‚â• 0.5 g/dL by [CONTACT_9656] (SPEP) or, for IgA 
myeloma, by [CONTACT_9657] 
b. Urinary M- protein excretion ‚â• 200 mg/24 hours  
c. FLC ‚â• 100 mg/L, provided that the FLC ratio is abnormal.  
d. If serum protein electrophoresis is felt to be unreliable fo r routine M-protein 
measurement, then quantitative Ig levels by [CONTACT_555253]. 
4. Patients must have previously received ‚â• 3 anti -MM regimens including: an alkylating 
agent, lenalidomide, pomalidomid e, bortezomib, carfilzomib, dar atumumab, and a 
glucocortico id. There is no upper limit on the number of prior therapi[INVESTIGATOR_555223]/exclusion criteria are met. 
5. MM refractory to previous treatment with one or more glucocorticoi ds, parenteral PI 
(i.e., bortezomib and/or carfilzomib), IMiD (i.e. , lenalidomide and/or pomalidomide), 
and daratumumab . Refractory is defined as ‚â§  25% response to therapy, or progression 
during therapy or progression within 60 days after completion o f therapy. 
6. Multiple myeloma that is refractory to the patient‚Äôs most rec ent anti-MM regimen. 
(Documented severe intolerance t o the patient‚Äôs last therapy is  allowed upon approval 
by [CONTACT_1689].) 
7. Any clinically significant non-hematological toxicities (except  for peripheral 
neuropathy as described in exclu sion criterion #17) that patien ts experienced from 
treatments in previous clinical studies must have resolved to G rade ‚â§ 2 by [CONTACT_51199] 1 
Day 1. 
8. Adequate hepatic function within 21 days prior to Cycle 1 Day 1 : total bilirubin < 2x 
upper limit of normal (ULN) (except patien ts with Gilbert‚Äôs syndrome who must have 
a total bilirubin of < 3x ULN), AST < 2.5x ULN and ALT < 2.5x U LN.  
9. Adequate renal function within 21 days prior to Cycle 1 Day 1: estimated creatinine 
clearance of ‚â• 20 mL/min, calculated using the formula of Cockr oft and Gault.  
10. Female patients of childbearing potential must agree to use 2 methods of contraception 
(including 1 highly effective and 1 effective method of contrac eption) and have a 
negative serum pregnancy test at Screening. Male patients must use an e ffective barrier 
method of contraception if sexually active with a female of chi ld-bearing potential.  
For both male and female patients, effective methods of contrac eption must be used 
throughout the study and for three months following the last do se of s tudy treatment. 
11. Eastern Cooperative Oncology Group (ECOG) Performance Status of  ‚â§ 2. 
12. Adequate hematopoietic function within 21 days prior to Cycle 1  Day 1 (See Exclusion 
Criterion #20 for transfusion washout periods for RBCs and plat elets):  
a. Total WBC count > 1,000/mm3 
b. ANC ‚â• 1000/mm3 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 8 Sponsor: 
Karyopharm Therapeutics Inc. Investigational Product: 
Selinexor (KPT-330) Developmental Phase: 
Phase 2b 
c. Platelet count ‚â•  75,000/mm3 (patients in whom < 50% of bone marrow nucleated 
cells are plasma cells) or ‚â• 50,000/mm3 (patients in whom ‚â• 50% of bone marrow 
nucleated cells are plasma cells.  [Platelet transfusions < 1 week prior to Cycle 1 
Day 1 are prohibited (see below).] 
13. Hemoglobin level ‚â• 8.5 g/dL. In certain cases, patients with st able baseline 
hemoglobin level > 8.0 may be included following approval by [CONTACT_1689]. 
[Red blood cell transfusions < 2 weeks prior to Cycle 1 Day 1 a re prohibited (see 
below).] 
14. Confirmation of patient eligibility for specific key criteria for study participation with 
the Medical Monitor. 
Exclusion Criteria:  
1. Active smoldering MM. 
2. Active plasma cell leukemia. 
3. Documented systemic amyloid light chain amyloidosis. 
4. Active central nervous system (CNS) MM. 
5. Pregnancy or breastfeeding. 
6. Radiation, chemotherapy, or immunotherapy or any other anticanc er therapy ‚â§ [ADDRESS_728955] disease (after allogeneic stem cell transplantation) at Cycle 1 
Day 1  
8. Life expectancy of < 4 months. 
9. Major surgery within four weeks prior to Cycle 1 Day 1. 
10. Active, unstable cardiovascular function: a. Symptomatic ischemia, or  b. Uncontrolled clinically-
significant conduction abnormalities (e.g., patients with 
ventricular tachycardia on antia rrhythmics are excluded; patien ts with 1st degree 
atrioventricular (AV) block or asymptomatic left anterior fasci cular block/right 
bundle branch block (LAFB/RBBB) will not be excluded), or 
c. Congestive heart failure (CHF) of [LOCATION_001] Heart Association (N YHA) Class ‚â• 3, 
or 
d. Myocardial infarction (MI) within [ADDRESS_728956] dose. 
13. Known HIV seropositive.  
14. Known active hepatitis A, B, or C infection; or known to be pos itive for HCV RNA or 
HBsAg (HBV surface antigen). 
15. Prior malignancy that required treatment, or has shown evidence  of recurrence (except 
for non- melanoma skin cancer or adequately treated cervical carcinoma i n situ) during 
the 5 years prior to enrollment . Cancer treated with curative i ntent > 5 years previ ously 
and without evidence of recurrence will be allowed. 
16. Active GI dysfunction interfering with the ability to swallow t ablets, or any GI 
dysfunction that could interfere with absorption of study treat ment. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 9 Sponsor: 
Karyopharm Therapeutics Inc. Investigational Product: 
Selinexor (KPT-330) Developmental Phase: 
Phase 2b 
17. Grade ‚â• 3 peripheral neuropathy, and Grade  ‚â• 2 painful neuropathy, within 21 days 
prior to Cycle 1 Day 1. 
18. Serious, active psychiatric or medical conditions which, in the  opi[INVESTIGATOR_684], could interfere with treatment. 
19. Participation in an investigational anti-cancer study within 21  days prior to Cycle 1 
Day 1.  
20. Receipt of transfusions as follows: 
a. Platelet infusion within 1 week prior to Cycle 1 Day 1. 
b. RBC transfusion within 2 weeks prior to Cycle 1 Day 1. 
21. Receipt of the following blood growth factors within 2 weeks pr ior to Cycle 1 Day 1: 
Granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-
CSF), erythropoietin (EPO), or megakaryocyte growth factor. 
22. Known intolerance to or contrai ndication for glucocorticoid the rapy at Cycle [ADDRESS_728957] documented  evidence  of 
previous treatment for MM that substantiates disease status as follows:  
x Refractory to a glucocorticoid 
x Refractory to lenalidomide and/or pomalidomide (only 1 required ) and evidence of 
prior treatment* with both lenalidomide and pomalidomide 
x Refractory to bortezomib and/or carfilzomib (only 1 required) and evidence of prior 
treatment* with both  bortezomib and carfilzomib 
x Refractory to daratumumab 
* Prior treatment is defined as either refractory, treatment wi th ‚â• [ADDRESS_728958] one of the following:   
1. Medical records that support start and stop dates (month/year) of prior treatment (both 
dose and schedule), best response on prior treatment and, if applicable, date of progression (including both dose and schedule at the time of pr ogression). 
2. Myeloma marker values (SPEP, UPEP, Immunoglobulin, FLC) at the time of prior 
treatment start, stop and time  of progression (accompanied by # 1). 
3. Formal, signed physician letter by [CONTACT_10670] (on hospi[INVESTIGATOR_307]/clinic letterhead ), to be 
included in the patient‚Äôs medical and research record, indicating start/stop dates of 
prior treatment (both dose and schedule), best response on trea tment and, if applicable, 
date of progression (including bot h dose and schedule at the ti me of progression). 
4. Formal, signed physician letter from referring physician (on hospi[INVESTIGATOR_307]/clinic letterhead), 
to be included in the patient‚Äôs medical and research record, that includes prior treatment history indicating s tart/stop dates of prior treatmen t (both dose and 
schedule), best response on prior t reatment and, if applicable,  date of progression 
(including both dose and schedule at the time of progression). 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012 
13 December 2017, Version 6.0 Confidential Page 10 Sponsor: 
Karyopharm Therapeutics Inc. Investigational Product: 
Selinexor (KPT-330) Developmental Phase: 
Phase 2b 
Test Product, Dose and Mode of Administration: 
Selinexor will be given at an oral fixed milligram (mg) dose of  80 mg twice weekly each 
week for four -week cycles (total of 8 selinexor doses per cycle).  
Dexamethasone 20 mg will be given with each dose of selinexor . If a patient develops 
partial intolerance to glucoc orticoids (as determined by [CONTACT_108899]) during the study, 
a minimum dose of dexamethasone [ADDRESS_728959] cases (e.g., for patients showing SD, MR or PR and tolerating treatment 
particularly well), the selin exor dose may be increased by 20 mg (i.e., to 100 mg twice 
weekly) after consultation with the Medical Monitor. The dose level for an individual 
patient may be escalated based on e fficacy considerations after  completing a minimum of 
2 cycles of study therapy. However, in no case may the dose for  a given patient exceed 
70 mg/m2.   
Concomitant Medications: 
To minimize nausea, unless contra indicated, all patients should  receive 5-
hydroxytryptamine  (5-HT3) antagonists (e.g., ondansetron 8 mg or equivalent) startin g on 
Day [ADDRESS_728960] dose of selinexor and con tinued 2-3 times daily, as needed. 
Alternative anti -emetic agents should be used if t he patient does not tolerate 5-HT3 
antagonists. Additional anti -nausea and anti- anorexia agents may be given as needed (per 
National Comprehensive Cancer Network¬Æ [NCCN] Clinical Practice Guidelines¬Æ for 
Antiemesis and NCCN Clinical Practice Guidelines¬Æ for Palliative Care). Patients will also 
receive therapy as needed to mit igate selinexor side effects, a s part of best supportive care.  
Blood product transfusions, antimicrobials, and (as appropriate ) growth factors including 
granulocyte colony -stimulating factors for neutropenia, erythropoietins for anemia , and/or 
platelet -stimulating factors for throm bocytopenia are also permitted. 
Patients may continue  their baseline medi cation(s). Medications to treat concomitant 
diseases such as diabetes, hypertension, etc., are allowed. Pat ients will also receive 
concomitant medications that are medically necessary as standar d care to treat symptoms, 
AEs and intercurrent illnesses. Patients may receive red blood cell or platelet transfusions, 
or blood growth factors, if clinically indicated, per institutional guidelines.  
Concurrent therapy with any other approved or investigational a nti-cancer therapy is not 
allowed. Other investigational agents should not be used during  the study.  
Study Numbers: 
Approximately 210 patients will  be enrolled overall, including 79 patients (with quad -
refractory MM and penta -refractory MM) in Part 1 and ~130 patients (with penta-
refractory MM o nly) in Part 2 (to achieve the target population size of N = 12 2 for the 
primary efficacy analysis). 
Study Duration: 
The enrollment period for this study is expected to be approxim ately 24 months. There is 
no maximum treatment duration for t he study or pre-defined numb er of treatment cycles 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6SRQVRU
.DU\RSKDUP7KHUDSHXWLFV,QF,QYHVWLJDWLRQDO3URGXFW
6HOLQH[RU.37'HYHORSPHQWDO3KDVH
3KDVHE
SHUSDWLHQW7KHVWXG\ZLOOHQGZKHQDOOSDWLHQWVKDYHFRPSOHWH GWKHRQH\HDU)ROORZXS
3HULRGLHZKHQWKHODVWSDWLHQWKDVH[SLUHGEHHQIROORZHG IRUPRQWKVDIWHUODVWGRVH
RIVWXG\GUXJEHHQORVWWRIROORZ XSRUKDVZLWKGUDZQFRQVHQWZKLFKHYHURFFXUVILUVW
&ULWHULDIRU(YDOXDWLRQ  
Safety:  
6DIHW\DQGWROHUDELOLW\ZLOOEHHYDOXDWHGE\DGYHUVHHYHQW$( UHSRUWVSK\VLFDO
H[DPLQDWLRQVDQGODERUDWRU\VDIHW\HYDOXDWLRQV7KH1DWLRQDO& DQFHU,QVWLWXWH1&,
&RPPRQ7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(YHUVLRQ ZLOOEHXVHG
IRUJUDGLQJRI$(V)RUDOO$(V, QYHVWLJDWRUVZLOOSURYLGHWKHLUDVVHVVPHQWRIFDXVDOLW\
ZLWKVWXG\WUHDWPHQWDVHLWKHUUHODWHGRUQRWUHODWHG  
Efficacy:  
5HVSRQVHZLOOEHDVVHVVHGSHU,0:*IRU00 Kumar 2016 DV
x6WULQJHQWFRPSOHWHUHVSRQVHV&5
x&RPSOHWHUHVSRQVH&5
x9HU\JRRGSDUWLDOUHVSRQVH9*35
x3DUWLDOUHVSRQVH35
x6WDEOHGLVHDVH6'
x3URJUHVVLYHGLVHDVH3'
x0LQLPDOUHVSRQVH05
(IILFDF\HQGSRLQWVLQFOXGHWKHIROORZLQJ 
x255DQG'25
x&%5DQGGXUDWLRQRIFOLQLFDOEHQHILW
x'&5DQGGXUDWLRQRIGLVHDVHFRQWURO
x3)6
x26
x773
x4R/XVLQJWKH)$&700
Pharmacokinetics  
¬á3KDUPDFRNLQHWLF3.SURSHUWLHVRIVHOLQH[RULQSDWLHQWVHQUROO HGLQ3DUWRQO\
x 
x0LQLPDOUHVLGXDOGLVHDVH05'LQSDWLHQWVZKRDFKLHYHV&5CCI
CCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6SRQVRU
.DU\RSKDUP7KHUDSHXWLFV,QF,QYHVWLJDWLRQDO3URGXFW
6HOLQH[RU.37'HYHORSPHQWDO3KDVH
3KDVHE
&ULWHULDIRU7UHDWPHQW'LVFRQWLQXDWLRQ  
$WWKHGLVFUHWLRQRIWKH,QYHVWLJDWRUWKH,QYHVWLJDWRUPD\UHP RYHDSDWLHQWIURPVWXG\
WUHDWPHQWIRUDQ\RIWKHIROORZLQJUHDVRQV  
x'LVHDVHSURJUHVVLRQ  
x8QDFFHSWDEOH$(VRUIDLOXUHWRWROHUDWHWKHVWXG\WUHDWPHQW  
x3DWLHQWGHFLGHVWRGLVFRQWLQXHVWXG\WKHUDS\DQGZLWKGUDZVFRQV HQW 
x$Q\PHGLFDOO\DSSURSULDWHUHDVRQRUVLJQLILFDQWSURWRFROYLRODW LRQSHUWKH
,QYHVWLJDWRU
3DWLHQWVPD\GHFLGHWRGLVFRQWLQXHVWXG\WUHDWPHQWIRUDQ\UHDV RQ3DWLHQWVZKRHOHFWWR
GLVFRQWLQXHVWXG\WUHDWPHQWVKRXOGEHHQFRXUDJHGWRFRQWLQXHLQ WKHVWXG\VRWKDWIROORZ
XSLQIRUPDWLRQRQGLVHDVHSURJUHVVLRQDQGVXUYLYDOVWDWXVPD\E HREWDLQHG+RZ HYHU
SDWLHQWVPD\HOHFWWRZLWKGUDZFRQVHQWDQGGHFOLQHIXUWKHUSDUW LFLSDWLRQLQWKHVWXG\7KH
UHDVRQIRUGLVFRQWLQXDWLRQVKRXOGEHFOHDUO\GRFXPHQWHG,IFOL QLFDORUELRORJLFDO
SURJUHVVLRQVWXG\GDWDPXVWEHDYDLODEOH,IWKHSDWLHQWZLWKG UDZVFRQVHQWRULVUHPRYHG
E\WKHVWXG\,QYHVWLJDWRUWKHUHDVRQIRUZLWKGUDZDOVKRXOGEH GRFXPHQWHG 
6WDWLVWLFDO0HWKRGV 
 







 







CCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6SRQVRU
.DU\RSKDUP7KHUDSHXWLFV,QF,QYHVWLJDWLRQDO3URGXFW
6HOLQH[RU.37'HYHORSPHQWDO3KDVH
3KDVHE
Efficacy Evaluation: 
7KHSULPDU\VWDWLVWLFDODQDO\VLVRIHIILFDF\ZLOOEHSHUIRUPHG RQ255SURSRUWLRQRI
SDWLHQWVZKR DFKLHYHV&5&59*35RU35XVLQJWKHPRGLILHGLQWHQWWR WUHDWP,77
SRSXODWLRQGHILQHGDV3DUWSDWLHQWVZLWKSHQWD UHIUDFWRU\00ZKRPHWDOOHOLJLELOLW \
FULWHULDRUGLGQRWPHHWDOOHOLJLELOLW\FULWHULDEXWUHFHLYHG ZDLYHUIURP6SRQVRUWR
SDUWLFLSDWHLQWKHVWXG\DQGUHFHLYHGDWOHDVW GRVHRIVWXG\WUHDWPHQWSDUWLDORU
FRPSOHWH 7KHSULPDU\DQDO\VLVZLOOEHSHUIRUPHGRQWKH3DUWSDWLHQWVZ LWK
SHQWDUHIUDFWRU\00RQO\
$SHUSURWRFRO33SRSXODWLRQZLOOFRQVLVWRIDOOSDWLHQWV LQWKHP,77SRSXODWLRQZKR
PHHWWKHIROORZLQJFULWHULD 
x+DYHVHOLQH[RUFRPSOLDQFH¬ï 
x+DYHDWOHDVWDGHTXDWHSRVWEDVHOLQHUHVSRQVHDVVHVVPHQWXQOH VVGLHGRU
ZLWKGUHZIURPVWXG\EHIRUHWKDW 
x1RPDMRUSURWRFROYLRODWLRQVWKDWZRXOGFRPSURPLVHWKHDVVHVVPH QWRI
HIILFDF\7KHOLVWRIPDMRUSURWRFROYLRODWLRQVWKDWDIIHFWVWD WLVWLFDODQDO\VLVZLOO
EHILQDOL]HGEHIRUHGDWDEDVHORFN 
7KH33SRSXODWLRQZLOOEHXVHGIRUVXSSRUWLYHLQIHUHQFHVFRQFHU QLQJHIILFDF\ 
6HFRQGDU\ HQGSRLQWVZLOOEHDVVHVVHGXVLQJWKHP,77SRSXODWLRQ DQGWKH
33SRSXODWLRQ7LPHWRHYHQWHQGSRLQWVLQFOXGLQJ'25ZLOOEHD VVHVVHGXVLQJ.DSODQ
0HLHUPHWKRGV 
4XDOLW\RIOLIH4R/ZLOOEHDVVHVVHGXVLQJWKH)XQFWLRQDO$VV HVVPHQWRI&DQFHU7KHUDS\
ZLWK00VSHFLILFVXEVFDOH)$&7007KHWULDORXWFRPHVLQGH[72,ZL OOEHWKH
SULPDU\PHDVXUHPHQWRILQWHUHVWFRPSULVHGRIWKHSK\VLFDODQG IXQFWLRQDOVXEVFDOHVSOXV
WKH00VSHFLILFVXEVFDOH
Safety Evaluation:  
6DIHW\DQDO\VHVZLOOEHSHUIRUPHGRQWKHRYHUDOOSRSXODWLRQRI SDWLHQWVZKRUHFHLYHGDQ\
DPRXQWRIVWXG\WUHDWPHQWSUHVHQWHGRYHUDOODQGE\VWXG\SDUW CCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
13 December 2017, Version 6.0 Confidential Page 14 Table 1: Schedule of Assessments and Study Activities  
Activity/Assessment  Screenin
g Cycle 1 Cycle 2 Cycles ‚â• 3  End- of-
Treatment 
(EoT) Visit Safety 
Follow-up 
Call Durability 
of Response 
and Survival 
Follow-up15 
Day -21 
to Day -1 Day 1 Day 314 Day 8 Day 15 Day 1 Day 15 Day 1 ‚â§ [ADDRESS_728961] 
Dose Every 3 mo.  
-1 day +1 day ¬± 1 day ¬± 1 day ¬± 2 days ¬± 2 days ¬± 2 days + 7 days ¬± 14 days 
Informed consent1 X           
Inclusion/exclusion criteria X           
Demographics X           
Medical history2 X X          
Patient height  X           
Patient weight X X  X X X X X X   
Body Surface Area (BSA)3 X           
Physical examination, full 
including vital signs4  X        X    
Physical examination, symptom-
directed, including vital signs4  X  X X X X X    
ECOG5 X    X  X X   
Echocardiogram or MUGA6 X          
12-lead ECG X       X   
Ophthalmic exam7 X       X   
Clinical Labs 
Urinalysis5 X       X   
CBC with differential5 X   X X X X X   
TSH5 X       X   
Complete serum chemistry5 X    X  X X   
Limited serum chemistry    X X  X     
Coagulation tests5 X       X   
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH$FWLYLW\$VVHVVPHQW 6FUHHQLQ
J&\FOH &\FOH &\FOHV¬ï (QGRI
7UHDWPHQW
(R79LVLW6DIHW\
)ROORZXS
&DOO'XUDELOLW\
RI5HVSRQVH
DQG6XUYLYDO
)ROORZXS
'D\
WR'D\'D\'D\'D\'D\ 'D\ 'D\ 'D\ ¬î'D\V
3RVW/DVW
'RVH'D\V
3RVW/DVW
'RVH(YHU\PR 
GD\GD\¬ìGD\¬ìGD\ ¬ìGD\V ¬ìGD\V ¬ìGD\V GD\V ¬ìGD\V
6HUXPK&*SUHJQDQF\WHVW;;'RI
HDFKF\FOH
RQO\;'RI
HDFKF\FOH
RQO\; 
&UHDFWLYHSURWHLQ ;;; ; ;  
0XOWLSOH0\HORPD$VVHVVPHQWV 
63(3DQGVHUXPSURWHLQ
LPPXQRIL[DWLRQ;;; ; ;  ; 
83(3KUXULQHIRUWRWDO
SURWHLQDQGXULQHSURWHLQ
LPPXQRIL[DWLRQ;;; ; ;  ; 
4XDQWLWDWLYH,JOHYHOV ;;;  ; ;  ;
6HUXP)/& ;;;; ; ; ;  ;
»ïPLFURJOREXOLQ;    ;  
6NHOHWDOVXUYH\ ; ;  ; ;  ;
3ODVPDF\WRPDDVVHVVPHQW; ;  ; ;  ;
)$&700TXHVWLRQQDLUH ; ;  ; ;  
6WXG\GUXJGRVLQJ6HOLQH[RUPJGH[DPHWKDVRQHPJERWKWZLFHZHHNO\IRU 
ZHHNVHDFKZHHNRIZHHNF\FOHV  
$GYHUVHHYHQWV ;;;;;; ; ; ; ; 
&RQFRPLWDQWPHGLFDWLRQV ;;;;;; ; ; ;  
1XWULWLRQDOFRQVXOWDWLRQ ;       
7HOHSKRQHFRQWDFW  ;     ; ;
$QWLQHRSODVWLFWKHUDS\DIWHU(R7      ; ; ;CCI
CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH;LQGLFDWHVWKDWDGGLWLRQDOLQIRUPDWLRQLVSURYLGHGLQWKHIR RWQRWHV0HUJHGFHOOVLQGLFDWHWKDWWKHSURFHGXUHPD\EHSHUIRU PHGGXULQJHLWKHU6FUHHQLQJRUWKH
&'YLVLW
$EEUHYLDWLRQV%6$ ERG\VXUIDFHDUHD(&* HOHFWURFDUGLRJUDP (&2* (DVWHUQ&RRSHUDWLYH2QFRORJ\*URXS(R7 (QGRI7UHDW PHQW,J 
LPPXQRJOREXOLQ00 PXOWLSOHP\HORPD63(3 VHUXPSURWHLQHOH FWURSKRUHVLV83(3 XULQHSURWHLQHOHFWURSKRUHVLV&%& FRPSO HWHEORRGFRXQW)/& 
IUHHOLJKWFKDLQ
3ULRUWRWKHILUVWVWXG\VSHFLILFPHDVXUH
,QFOXGLQJGHWDLOVRIDOOSULRUDQWLP\HORPDWKHUDSLHV,QFOXGHV EDVHOLQHV\PSWRPVDVZHOODVDGHWDLOHGKLVWRU\RISULRUFDQFH UWKHUDSLHVHVSHFLDOO\00
WKHUDSLHVLQFOXGLQJVWDUWDQGVWRSGDWHVGLVHDVHSURJUHVVLRQ GXULQJRUDIWHUWKHUDS\DVZHOODVGLVFRQWLQXDWLRQVGXHWRLQW ROHUDELOLW\RUDQ\RWKHUVHULRXV
LOOQHVV5HVXOWVRISUHVFUHHQLQJ00DVVHVVPHQWVDW'D\Z LQGRZ6FUHHQLQJ ¬±ZHHNVDQG'D\¬ìGD\VZLOOEHSURYLGHG
%RG\6XUIDFH$UHD%6$ZLOOEHFDOFXODWHGE\ Dubois 1916 RUMosteller 1987 PHWKRGGXULQJ6FUHHQLQJDQGSULRUWRDQ\GRVHHVFDODWLRQ1RS DWLHQWPD\
UHFHLYHDGRVHRIVHOLQH[RU!PJP
&RPSOHWHSK\VLFDOH[DPLQDWLRQ3(GXULQJ6FUHHQLQJDQG(R7YLV LW/LPLWHG3(VGXULQJWKHVWXG\VKRXOGEHV\PSWRPGLUHFWHG$O O3(VWRLQFOXGHYLWDOVLJQV
EORRGSUHVVXUHSXOVHDQGERG\WHPSHUDWXUH
7KHIROORZLQJSURFHGXUHVPD\EHSHUIRUPHGDW6FUHHQLQJRUSUHG RVHRQ&'DQGDVVKRZQLQWKH6FKHGXOHGXULQJWKHVWXG\(&2* SHUIRUPDQFH
DVVHVVPHQWHFKRFDUGLRJUDPRU08*$VFDQOHDG(&*RSKWKDOPL FH[DPXULQDO\VLV&%&ZLWKGLIIHUHQWLDO76+FRPSOHWHVHUXP FKHPLVWU\FRDJXODWLRQV
WHVWVDQGQXWULWLRQDOFRQVXOWDWLRQ
(FKRFDUGLRJUDPRU08*$VFDQDW6FUHHQLQJDQGDVFOLQLFDOO\LQGL FDWHGGXULQJWKHVWXG\
$IXOORSKWKDOPLFH[DPLQDWLRQZLOOLQFOXGHSULRUWRGLODWLRQ EHVWFRUUHFWHGYLVXDODFXLW\VOLWODPSH[DPLQDWLRQLQFOXGLQJW RQRPHWU\IROORZLQJGLODWLRQ
IXQGRVFRS\DQGVOLWODPSWRGRFXPHQWOHQVFODULW\ .
)RUIHPDOHVRIFKLOGEHDULQJSRWHQWLDOQHJDWLYHVHUXPK&*SUHJQ DQF\WHVWPXVWEHREWDLQHGZLWKLQGD\VEHIRUHWKHILUVWGRVH RIVWXG\WUHDWPHQW3UHJQDQF\
WHVWLQJVHUXPK&*RUXULQHLVDOVRUHTXLUHGIRUIHPDOHVRIFK LOGEHDULQJSRWHQWLDOSULRUWRGRVLQJRQ'D\ RI&\FOHV¬ïDQGDWWKH(R79LVLWVHUXPK&*
3UHJQDQF\WHVWLQJPD\DOVREHSHUIRUPHGDVFOLQLFDOO\LQGLFDWHG GXULQJWKHVWXG\
5HVSRQVHFULWHULDLQFOXGH63(383(3KUXULQHVHUXPDQGX ULQHLPPXQRIL[DWLRQTXDQWLWDWLYH,JOHYHOVDQGVHUXP)/&DVVD \RQ&'DQGPXVWEH
WDNHQHLWKHURQ'D\RUSUHGRVHRQ&'7KHDVVHVVPHQWVPXV WEHUHSHDWHGDWWKHWLPHRIGLVHDVHSURJUHVVLRQRUVXVSHFWHGU HVSRQVHLQRUGHUWRFRQILUP
UHVSRQVH1RWH)RUSDWLHQWVZKRDFKLHYH&5RUV&5DVDVVHVVHG E\WKHORFDOODEDVVHVVPHQWVZLOOEHFRQILUPHGE\DFHQWUDOO DEXVLQJSRUWLRQVRIWKHVDPSOHV
FROOHFWHG6HHWKH Study Manual IRUDGGLWLRQDOLQIRUPDWLRQ5HVXOWVRISUHVFUHHQLQJ00DVVHV VPHQWVDW'D\ZLQGRZ6FUHHQLQJ ¬±ZHHNVDQG'D\
¬ìGD\VZLOOEHSURYLGHGDVSDUWRI0HGLFDO+LVWRU\
6NHOHWDOVXUYH\WREHSHUIRUPHGXVLQJ[UD\VSHULQVWLWXWLRQDO JXLGHOLQHV,I[UD\VDUHXVHGWKH\VKRXOGLQFOXGHDODWHUDOU DGLRJUDSKRIVNXOODQWHULRSRVWHULRU
DQGODWHUDOYLHZVRIWKHVSLQHDQGDQWHULRSRVWHULRUYLHZVRIW KHSHOYLVULEVIHPRUDDQGKXPHUL,IFOLQLFDOO\DSSURSULDWH 05,&7RU3(7&7ZLWKWXPRU
PHDVXUHPHQWVPD\EHXVHGLQVWHDGRIRULQDGGLWLRQWR[UD\V ,IERQHOHVLRQVRUSODVPDF\WRPDVDUHREVHUYHGDWEDVHOLQHWK HLUQXPEHUDQGVL]HVKRXOGEH
UHFRUGHGLQWKH&5)%RQHOHVLRQVDQGRUSODVPDF\WRPDVVHHQDW EDVHOLQHXVLQJLPDJLQJVKRXOGEHDVVHVVHGDVFOLQLFDOO\DSSURS ULDWHSHU,QYHVWLJDWRU¬∂V
GLVFUHWLRQGXULQJWKHVWXG\6NHOHWDOVXUYH\UHVXOWVZLOOEHUH DGE\WKHORFDOODERUDWRU\
,ISODVPDF\WRPDVDUHGHWHFWHGDWEDVHOLQHE\3(WKH\VKRXOGEH PHDVXUHGDQGUHFRUGHGDQGUHDVVHVVHGGXULQJWKH3(RQ'D\ RIHDFKF\FOH(R7YLVLWDQG
HYHU\PRQWKVLIFOLQLFDOO\DSSURSULDWHGXULQJIROORZXS


 
 CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH 
 

 



7HOHSKRQHFDOORUYLVLWZLWKSDWLHQWWRHYDOXDWHVXSSRUWLYHF DUHPHGLFDWLRQVFRQFRPLWDQWPHGLFDWLRQVDQGDGYHUVHHYHQWVDQ GWRDGMXVWVXSSRUWLYHFDUHDV
DSSURSULDWH7KHWHOHSKRQHFRQWDFWZLWKWKHSDWLHQWPXVWWDNHS ODFHRQ&'IROORZLQJDGPLQLVWUDWLRQRIILUVWGRVHRIVHOLQH[ RURQ&'
$IWHUWUHDWPHQWGLVFRQWLQXDWLRQLISRVVLEOHIRUSDWLHQWVZKR DUHQRWSURJUHVVLQJ63(3ZLWKVHUXPLPPXQRIL[DWLRQ83(3K UZLWKXULQHSURWHLQ
LPPXQRIL[DWLRQVHUXP)/&DQGTXDQWLWDWLYH,JOHYHOVDQGSK\V LFDOH[DPLQDWLRQVDQGLPDJLQJIRUERQHOHVLRQVDQGSODVPDF\WRPD VLIFOLQLFDOO\DSSURSULDWH
VKRXOGEHSHUIRUPHGHYHU\PRQWKVIRU\HDUWRDVVHVVGXUDELO LW\RIUHVSRQVH,IWKHVHDVVHVVPHQWVFDQQRWEHSHUIRUPHGDQG IRUSDWLHQWVZLWK3'D
WHOHSKRQHFDOOZLOOEHPDGHWRWKHSDWLHQWRUWKHSDWLHQW¬∂VID PLO\HYHU\PRQWKVIRURQH\HDUWRLQTXLUHDERXWWKHSDWLHQW¬∂ VVXUYLYDO00VWDWXVZHOO EHLQJ
DQGLQIRUPDWLRQRQDQ\DQWLQHRSODVWLFWKHUDSLHVXWLOL]HGVLQFH GLVFRQWLQXDWLRQRIVHOLQH[RUVWXG\WUHDWPHQW
6HULRXVDGYHUVHHYHQWVWKDWRFFXUDIWHUVLJQLQJSDWLHQWVLJQVW KH,&)LQFOXGLQJSULRUWRILUVWGRVHRQ&'DQGDGYHUVHHYHQ WVWKDWRFFXUDIWHUILUVWGRVHRQ
&'CCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 18TABLE OF CONTENTS
PROTOCOL APPROVAL SIGNATURE [CONTACT_1783] ............................... ........................ 2  
PRINCIPAL INVESTIGAT OR‚ÄôS AGREEMENT ..................................................... [ADDRESS_728962] OF ABBREVIATIONS.......................................... .......................................... 25  
1. OVERVIEW ....................................................... .................................... 31  
2. MULTIPLE MYELOMA............................................... ........................ 32  
3. NUCLEAR EXPORT............................................................................. 33  
3.1. Inhibition of XPO1 in Human Cancer ............................. ....................... 33  
4. SELINEXOR (KPT-330)........................................................................ 34  
4.1. Introduction............................................................................................. 34  
4.2. Preclinical Data............................................... ........................................ 35  
4.2.1.  Selinexor plus Dexamethasone Combination Studies ............... ............. 35  
4.3. Clinical Experience................................................................................. 36  
4.3.1.  Preliminary Results for Patient s with MM, Study KCP-330-001, as  of 
13 December 2016................................................ .................................. 36  
[IP_ADDRESS].  Preliminary Efficacy Results for Patients with MM, Study KCP-330-
001 ............................................................ .............................................. 36  
[IP_ADDRESS].  Preliminary Safety Results for Patients with MM, Study KCP-330- [ZIP_CODE]  
[IP_ADDRESS].  Preliminary Efficacy (Response) Results for Patients with MM, Study KCP-330-012.......................................................................................... 37
 
[IP_ADDRESS].  Preliminary Safety Results for Patients with MM, Study KCP-330- [ZIP_CODE]  
[IP_ADDRESS].  Summary........................................................ ......................................... 38  
4.4. Potential Risks ................................................ ........................................ 38  
4.4.1.  Reproductive Risks................................................................................. 39  
5. RATIONALE FOR THE STUDY........................................ .................. 39  
5.1. Rationale for Selinexor Dose Schedule .......................... ........................ 39  
6. STUDY OBJECTIVES ............................................... ........................... 40  
6.1. Primary Objectives ............................................. .................................... 40  
6.2. Secondary Objectives ........................................... .................................. 40  
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH  
 678'<'(6,*1   
 2YHUYLHZ   
 'DWD6DIHW\0RQLWRULQJ%RDUG   
 ,QGHSHQGHQW5HYLHZ&RPPLWWHH   
 6WRSSLQJ5XOHV   
 6WXG\(QGSRLQWV   
 %OLQGLQJDQG5DQGRPL]DWLRQ   
 (QGRI6WXG\   
 6(/(&7,212)3$7,(176   
 1XPEHURI3DWLHQWV   
 5HFUXLWPHQW   
 'RFXPHQWDWLRQ5HTXLUHPHQWV   
 ,QFOXVLRQ&ULWHULD   
 ([FOXVLRQ&ULWHULD   
 6FUHHQ)DLOXUHV   
 6WXG\3DWLHQW1XPEHUV   
 6WXG\3DWLHQW1XPEHU   
 0(7+2'62)$66(660(17$1'(1'32,176  
 6WDQGDUG6WXG\$VVHVVPHQWV   
  'HPRJUDSKLF'DWD   
  0HGLFDO+LVWRU\   
  &RQFRPLWDQW0HGLFDWLRQV   
  3K\VLFDO([DPLQDWLRQ   
  (&2*6FRUH   
 0XOWLSOH0\HORPD'LVHDVH6SHFLILF$VVHVVPHQWV   
 0XOWLSOH0\HORPD5HVSRQVH&ULWHULD   
 6DIHW\$VVHVVPHQWV   
  /HDG(&*   
  2SKWKDOPLF([DP   
  &OLQLFDO/DERUDWRU\$VVHVVPHQWV   
  3UHJQDQF\7HVWLQJ   
 3KDUPDFRNLQHWLF 3URFHGXUHV  CCI
CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH  %ORRG6DPSOLQJDQG3URFHVVLQJ   
 3KDUPDFRNLQHWLF(QGSRLQWV   
  
  6XSSRUWLYH(IILFDF\(QGSRLQWV   
  
  
  
  
  
 
 
 (IILFDF\3URFHGXUHV   
  2EMHFWLYH'LVHDVH$VVHVVPHQW   
 (IILFDF\(QGSRLQWV   
  5HVSRQVH&ULWHULD   
  4XDOLW\RI/LIH$VVHVVPHQW   
 ',6&217,18$7,21&5,7(5,$   
  (DUO\'LVFRQWLQXDWLRQRIWKH6WXG\   
  (DUO\'LVFRQWLQXDWLRQRI,QGLYLGXDO3DWLHQWV   
 75($70(17   
  'RVLQJDQG$GPLQLVWUDWLRQ   
  'RVH0RGLILFDWLRQV   
  /DEHOLQJ   
  'RVLQJ,QIRUPDWLRQ   
  'RVH0RGLILFDWLRQVIRU3DWLHQWVZLWK9*35   
  'RVH5HGXFWLRQ*XLGHOLQHVIRU7R[LFLW\   
  6HOLQH[RU'RVH5HGXFWLRQIRU'HFUHDVHG*ORPHUXODU)LOWUDWLRQ5D WH
*)5   
  6HOLQH[RU'RVH$GMXVWPHQWLQWKH6HWWLQJRI,QIHFWLRQ   
  &RQGLWLRQV1RW5HTXLULQJ6HOLQH[RU'RVH5HGXFWLRQ   
  0LVVHGRU9RPLWHG'RVHV   
  'RVH(VFDODWLRQ   
  6WXG\'UXJ6WRUDJH   CCI
CCICCI
CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH  6WXG\'UXJ$FFRXQWDELOLW\   
  &RQFRPLWDQW7UHDWPHQWV   
  5HTXLUHG+7$QWDJRQLVWV   
  6XSSRUWLYH&DUH   
  OQIHFWLRQ   
  2WKHU*OXFRFRUWLFRLG6LGH(IIHFWV   
  &RQFRPLWDQW0HGLFDWLRQDQG7UHDWPHQW   
  3HUPLWWHG&RQFRPLWDQW0HGLFDWLRQ   
  5HVWULFWHG0HGLFDWLRQV   
  3URKLELWHG0HGLFDWLRQV   
  &RQWUDFHSWLRQ5HTXLUHPHQWV   
  5DGLDWLRQ7UHDWPHQW   
  7UHDWPHQW&RPSOLDQFH   
 $'9(56((9(176   
  6HULRXV$GYHUVH(YHQWV   
  $(DQG6$()ROORZXS   
  3RVW6WXG\$GYHUVH(YHQWVDQG6HULRXV$GYHUVH(YHQWV   
  6HULRXV$GYHUVH(YHQW5HSRUWLQJ   
  5HSRUWLQJ5HTXLUHPHQWV   
  2YHUGRVH   
  3UHJQDQFLHV   
 67$7,67,&$/0(7+2'6   
  *HQHUDO&RQVLGHUDWLRQV   
  6WDWLVWLFDODQG$QDO\WLFDO3ODQV   
  
  'LVSRVLWLRQRI3DWLHQWV   
  %OLQGLQJDQG5DQGRPL]DWLRQ   
  'RVH$GMXVWPHQW   
  $QDO\VLV'DWDVHWV   
  3RSXODWLRQVWREH$QDO\]HG   
  0RGLILHG,QWHQWWR7UHDWP,773RSXODWLRQ   
  3HU3URWRFRO3RSXODWLRQ   
  6DIHW\3RSXODWLRQ   CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH  6XEJURXS(IILFDF\$QDO\VHV   
  'DWD$QDO\VLVDQG3UHVHQWDWLRQ   
  'HPRJUDSKLF&KDUDFWHULVWLFV   
  %DVHOLQH&KDUDFWHULVWLFVDQG0HGLFDO+LVWRU\   
  3ULPDU\(QGSRLQW   
  6HFRQGDU\(QGSRLQWV   
  
  3KDUPDFRNLQHWLF 'DWD  
  6DIHW\'DWD   
  $GYHUVH(YHQWV   
  /DERUDWRU\'DWD   
  9LWDO6LJQV3K\VLFDO([DPLQDWLRQVDQG(&2*3HUIRUPDQFH6WDWXV   
  (OHFWURFDUGLRJUDP5HVXOWV   
  2SKWKDOPLF([DPLQDWLRQV   
  &RQFRPLWDQW0HGLFDWLRQV   
  3URFHGXUHVIRU+DQGOLQJ0LVVLQJ'DWD   
  &KDQJHVLQWKH&RQGXFWRIWKH6WXG\RU3ODQQHG$QDO\VLV   
 5(*8/$725<(7+,&$/$1'/(*$/2%/,*$7,216  
  5HJXODWRU\DQG(WKLFDO&RPSOLDQFH   
  ,QVWLWXWLRQDO5HYLHZ%RDUGV(WKLFV&RPPLWWHHV   
  5HJXODWRU\$XWKRULW\$SSURYDO   
  3URWRFRO$GKHUHQFH   
  $PHQGPHQWVWRWKH3URWRFRO   
  ,QIRUPHG&RQVHQW   
  3DWLHQW&RQILGHQWLDOLW\DQG'LVFORVXUH   
  &ROOHFWLRQ$XGLWLQJ6WXG\'RFXPHQWDWLRQDQG'DWD6WRUDJH   
  6WXG\'RFXPHQWDWLRQ5HFRUG.HHSLQJDQG5HWHQWLRQRI'RFXPHQWV  
  $XGLWLQJ3URFHGXUH   
  'LVFORVXUHRI,QIRUPDWLRQ   
  'LVFRQWLQXDWLRQRIWKH6WXG\   
  5HSRUWLQJDQG3XEOLFDWLRQRI6WXG\'RFXPHQWDWLRQ   
 5()(5(1&(6   CCI
CCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 23APPENDIX 1.  EASTERN COOPERATIVE ONCOLOGY GROUP (ECOG)
PERFORMANCE STATUS CRITERIA ............................................... 88  
APPENDIX 2.  INTERNATIONAL STAGING SYSTEM FOR MULTIPLE
MYELOMA............................................................................................ 89  
APPENDIX 3.  INTERNATIONAL MYELOMA WORKING GROUP 
RESPONSE CRITERIA, MYELOMA .................................................. 90  
APPENDIX 4.  SELINEXOR FORMULATION AND ADMINISTRATION ...... 94  
APPENDIX 5.  LENS OPACITIES CLASSIFICATION SYSTEM ...................... 96  
APPENDIX 6.  GLUTATHIONE (GSH)-, S-ADENOSYLMETHIONINE (SAM)-,
OR N-ACETYLCYSTEINE (NAC)-CONTAINING PRODUCTS 
(REPRESENTATIVE LIST).......................................... ........................ 97  
APPENDIX 7.  SUMMARY OF CHANGES ............................................. ............ 98  
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-[ADDRESS_728963] OF TABLES
Table 1:  Schedule of Assessments and Study Activities ................... ................... 14  
Table 2:  Effect of XPO1 Inhibition on Oncogenic and Inflammatory Pathway s.3 4  
Table 3:  Response by [CONTACT_555254] 01 D ec 
2016 ........................................................... ............................................. 37  
Table 4:  Multiple Myeloma Disease-specific Assessments.................. ................ 50  
Table 5:  Pre-specified Dose/Schedule Modifications for Adverse Events Re lated 
to Study Drug.................................................. ........................................ 59  
Table 6:  Supportive Care and Dose Adjustment Guidelines ................. ............... 59  
Table 7:  Classification of Adverse Events by [CONTACT_67983].................. ..................... 70  
Table 8:  Eastern Cooperative Oncology Group (ECOG) Performance Status 
Criteria ....................................................... ............................................. 88  
Table 9:  International Staging System for Multiple Myeloma .............. ............... 89  
Table 10:  International Myeloma Working Group Response Criteria (Kumar 2016).......................................................... ............................................. 90
 
Table 11:  Lens Opacities Classification System........................... .......................... 96  
Table 12:  Glutathione (GSH)-, S-Adenosyl methionine (SAM)-, OR N-
Acetylcysteine (NAC)-Containing Products (Representative List). ....... 97  
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_728964] OF ABBREVIATIONS 
Abbreviation Definition 
5-HT3 5-hydroxytryptamine 
ACS acute cerebellar syndrome 
AE adverse event 
ALT alanine transaminase (SGPT) 
AML acute myeloid leukemia 
ANC absolute neutrophil count 
aPTT activated partial thromboplastin time 
ASCT autologous stem cell transplantation 
AST aspartate transaminase (SGOT) 
AUC last area under the curve, first-last measurement 
AUC (0-‚àû) area under the curve, time zero to last 
AV arterioventricular 
bid twice daily 
BMSC bone marrow stroma cells 
BP blood pressure 
BSA body surface area 
BSC best supportive care 
BUN blood urea nitrogen 
qC degrees Centigrade 
CBC complete blood count 
CBR clinical benefit rate 
CD cluster of differentiation 
anti-CD38 mAb monoclonal antibodies against CD38 antigen expressed by [CONTACT_555255]-ROM compact disc, read-only-memory 
CFR Code of Federal Regulations  
CHF congestive heart failure 
CI confidence interval 
CLL chronic lymphocytic leukemia 
Cm centimeter 
Cmax maximum serum concentration 
CML chronic myeloid leukemia 
CNS central nervous system 
CR complete response 
CRA clinical research associate 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 26 Abbreviation Definition 
CRF case report form 
CRM1 chromosomal region maintenance protein 1 
CSF cerebrospi[INVESTIGATOR_555224] B-cell lymphoma 
DLT dose limiting toxicity 
DM diabetes mellitus 
DNA deoxyribonucleic acid 
DOR duration of response 
Dox doxorubicin 
DSMC Data Safety Monitoring Committee 
DT dexamethasone + thalidomide 
ECG electrocardiogram 
eCRF electronic case report form 
eDC electronic data capture 
ECOG Eastern Cooperative Oncology Group 
EDTA ethylenediaminetetraacetic acid 
F% oral bioavailability 
qF degrees Fahrenheit 
FACT-G Functional Assessment of Cancer Therapy (general version) 
FACT-MM Functional Assessment of Cancer Therapy - Multiple Myeloma 
FDA Food and Drug Administration 
FFPE formalin fixed paraffin embedded 
FISH fluorescent in situ hybridization 
FLC free light chain (kappa/lamba ratio) 
FLT3 fms-like tyrosine kinase 
GCP Good Clinical Practice 
G-CSF granulocyte-colony stimulating factor 
GGT gamma-glutamyl transferase 
GI gastrointestinal 
GM-CSF granulocyte macrophage-colony stimulating factor 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_728965] 
HIV human immunodeficiency virus 
HPLC/MS-MS high performance liquid chromatography/tandem mass spectrometry 
hr hour 
IC50 inhibitory concentration, 50% (ha lf maximal inhibitory concentr ation) 
ICF informed consent form 
ICH International Conference on Harmonisation 
IEC Independent Ethics Committee 
IFNŒ± interferon alpha 
IFNŒ≥ interferon gamma 
IgA immunoglobulin A 
IgVH immunoglobulin heavy chain variable region 
IL-1Œ± interleukin 1 alpha 
IL-6 interleukin 6 
IL-8 interleukin 8 
IL-10 interleukin 10 
IMiD immunomodulatory drug 
IMWG International Myeloma Working Group 
INR international normalization ratio 
IRC Independent Review Committee 
ISS International Staging System 
ITT intent-to-treat 
IV intravenous 
kg kilogram 
KM Kaplan-Meier 
LAFB left anterior fascicular block 
LDH lactate dehydrogenase 
LMW low molecular weight 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 28 Abbreviation Definition 
LOCSIII Lens Opacities Classification System 
m2 square meters 
MAb monoclonal antibody 
MCP1 monocyte chemo-attractant protein-1 
MedDRA Medical Dictionary for Regulatory Activities 
mg milligram 
MHRA Medicines and Healthcare Products Regulatory Agency 
MI myocardial infarction 
min minute 
miRNA microRNA 
mL milliliter 
mITT modified intent-to-treat 
MM multiple myeloma 
mmHg millimeters of mercury 
MTD maximum tolerated dose 
MR minimal response 
mRNA messenger ribonucleic acid 
MUGA multiple gated acquisition 
5'NT 5'-nucleotidase 
NAC N-acetylcysteine 
NCCN National Comprehensive Cancer Network 
NCI National Cancer Institute 
NES nuclear export sequences 
NHL non-Hodgkin‚Äôs lymphoma  
NK1R neurokinin 1 receptor 
NPC nuclear pore complex 
NPM1 nucleophosmin 
NYHA [LOCATION_001] Heart Association 
OPG osteoprotegerin 
ORR overall response rate  
OS overall survival 
PCR polymerase chain reaction 
PD progressive disease 
PDn pharmacodynamic 
PE physical examination 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 29 Abbreviation Definition 
PFS progression free survival 
PI [INVESTIGATOR_555225] (within drug treatment context) 
PI [CONTACT_22660] (within clinical context) 
PK pharmacokinetic 
po by [CONTACT_555256] [INVESTIGATOR_555226]-PCR quantitative real time pol ymerase chain reaction 
RBBB right bundle branch block 
RBC red blood cell 
RNA ribonucleic acid 
RP2D recommended Phase 2 dose 
RPPA reverse phase protein array 
RR resistant/refractory 
RT Richter‚Äôs transformation  
SAE serious adverse event 
SAM S-adenosylmethionine 
sCR stringent complete response 
Sd selinexor 80 mg plus dexamethasone 20 mg (‚Äúlow -dose‚Äù 
dexamethasone) 
SD  stable disease 
SIADH Syndrome of Inappropriate Antidiuretic Hormone Secretion 
SINE selective inhibitor of nuclear export 
SOC  standard of care (within treatment context) 
SOC  system organ class (within adverse event context) 
SOP standard operating procedure 
SPEP serum protein electrophoresis 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_728966] upper limit of normal 
UPEP urine protein electrophoresis 
VEGF Œ± vascular endothelial growth factor alpha 
VGPR very good partial response 
WBC white blood cell 
XPO1 exportin 1 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 31 1. OVERVIEW 
Multiple myeloma (MM) is the second most common hematological m alignancy (after 
non-Hodgkin‚Äôs lymphoma), representing 1% of all cancers and 2% of all cancer deaths. 
Despi[INVESTIGATOR_555227]-line agents, the m ajority of patients will 
eventually relapse and become resistant to all classes of avail able anti-MM therapi[INVESTIGATOR_014]. With 
over 30,000 new cases and approximately 12,600 deaths from MM a nticipated in 2016 in the 
[LOCATION_003] alone ( ACS 2016), there remains a need for novel therapi[INVESTIGATOR_502200] o f 
refractory MM that can improve the overall survival rate.  
Selinexor is a Selective Inhibitor of Nuclear Export (SINE) com pound that binds and 
inactivates Exportin 1 (XPO1), thereby [CONTACT_555257] (TSPs). XPO1 protein levels are significantly elevated  in MM, leading to the nuclear 
exclusion of TSPs, the glucocorticoid receptor (GR), and enhanc ed translation of certain 
oncogene mRNAs ( Tai 2014 ). Transient retention of TSPs in the nucleus at high levels via  
XPO1 blockade activates their cell cycle checkpoint and genome surveying actions. This 
leads to the death of nearly all types of malignant cells, wher eas normal cells undergo 
transient cell cycle arrest and recovery when the export block is released. XPO1 also exports 
the GR, leading to attenuation of its transcriptional activity.  In the presence of 
glucocorticoids, XPO1 blockade leads to nuclear accumulation and activation of the GR. In addition, XPO1 inhibition leads to the nuclear entrapment of ca p-binding protein 
(eIF4E)-dependent oncogene mRNAs, thus preventing their translation into proteins in the 
cytoplasm. In this way, SINEs lead to reduction in key oncoprot eins such as c-Myc, Cyclin 
D, hDM2 and others. The reactivati on of multiple TSP pathways a s well as glucocorticoid 
signaling, along with reduced translation of key oncoproteins t hrough inhibition of a non-
redundant, single protein, i.e., XPO1, represents a novel appro ach to the treatment of 
neoplastic diseases including t hose with multiple genomic alter ations and resistance 
mechanisms. 
Single-agent Phase [ADDRESS_728967] been cond ucted in advanced 
hematological malignancies including MM, acute myeloid leukemia  (AML), non- Hodgkin‚Äôs 
leukemia (NHL) and chronic lym phocytic leukemia (CLL) (KCP-330- 001), in solid tumors 
(KCP-330-002), and in soft tissue and bone sarcomas (KCP-330-00 3). Broad antitumor 
activity has been observed in all of these studies.  In additio n, Phase 2 studies are ongoing in 
MM, AML, DLBCL, Richter‚Äôs transformation, glioblastoma, gynecol ogical malignancies, 
and dedifferentiated liposarcoma (DDLS). More than 2,[ADDRESS_728968] frequently reported side effects of selinexor seen in clinical studies to date are 
anorexia, fatigue, nausea, vomit ing, and thrombocytopenia. Thes e adverse events (AEs) may 
be mitigated or eliminated wit h standard supportive care. In ad dition, their prevalence and 
intensity typi[INVESTIGATOR_555228] 4-[ADDRESS_728969] not been observed during long term treatment, with more th an 28 patients receiving 
single-agent selinexor for over 1 year and 6 patients for over 2 years. Please see the current 
Selinexor Investigator‚Äôs Brochure (IB) for more information. 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 32Selinexor has shown single-agent, durable, anti-cancer activity  in patients with multiple RR 
hematologic and solid tumor malignancies, including MM, at dose s of ‚â• 6m g / m2body 
surface area (BSA) in initial Phase 1 dose-escalation studies. In addition, results from a small 
number of patients suggests that selinexor in combination with dexamethasone 20 mg has 
increased efficacy in RR MM patients relative to selinexor alon e (Chen 2014 , Data on file ).
In the current study, patients will receive low-dose dexamethas one (20 mg) to both improve 
the tolerability of selinexor and provide additional efficacy benefit as selinexor has been 
shown to activate glucocorticoid signaling through its receptor . Dexamethasone has been 
shown in previous studies to be a n effective prophylactic treat ment for the common AEs of 
selinexor described abov e. While untreated MM is exquisitely se nsitive to glucocorticoids, 
this benefit wanes over time with treatment, which usually incl udes glucocorticoids in 
combination therapy. Patients with MM which has relapsed after multiple treatments are
unlikely to respond to glucocorticoid treatment alone, but dexa methasone should provide 
symptomatic relief of selinexor-associated toxicity. In additio n, dexamethasone may provide 
synergistic efficacy in combination with selinexor, which can r eactivate glucocorticoid 
receptor (GCR) signaling. The curr ent study will evaluate selin exor combined with 
dexamethasone for the treatment of MM in patients whose disease is refractory to previous 
treatment with a glucocorticoid, proteasome inhibitor (PI), an immunomodulatory agent 
(IMiD), and the anti-CD38 monoclonal antibody (anti-CD38 mAb) da ratumumab.
2. MULTIPLE MYELOMA 
Multiple myeloma (MM) is a hema tological malignancy characteriz ed by [CONTACT_555258] t he bone marrow, the presence of monoclonal 
immunoglobulin, or M protein in the serum or urine, bone diseas e, kidney disease, and 
immunodeficiency. It is more common in elderly patients (median  age at diagnosis is 
65-70 years; only 2% of patients are younger than 40 years) ( Raab 2009 ).
MM is the second most common hematological malignancy (after no n-Hodgkin‚Äôs 
lymphoma), representing 1% of all cancers and 2% of all cancer deaths. With current 
therapy, median survival is 5.2 years after diagnosis ( Kumar 2014 ).
Although the cause of MM is unknown, a number of mutated genes have been found with 
significant frequency in patients with MM. These include mutati ons in NRAS, KRAS, TP53 
and BRAF, which are well known onc ogenic drivers for other cancers ( Lohr 2014 ) and 
mutations in many genes associated with NFŒ∫B activation ( Keats 2007 ). Also, certain risk 
factors make patients more susceptible to the disease. MM is mo re common in individuals 
over the age of 65, in males, and in those with family members affected by [INVESTIGATOR_224673]. Fifty 
percent (50%) of patients with MM harbor mutations in the immun oglobulin heavy-chain 
locus on chromosome 14q32, partia l or complete loss of chromosome 13, and partial loss of 
chromosome 17 ( Raab 2009 ;Kyle 2004 ).
The diagnosis of MM is based on the key characteristics of the disease, occupation of the 
bone marrow cavity, the presence of space occupying bone lesion s, and the production of 
paraprotein ( Raab 2009 ;IMWG 2003 ). The staging of MM is based on Œ≤ 2-microglobulin 
level, which is directly correlated to renal function, tumor ma ss, and albumin level 
(Greipp 2005). The stages are summarized in Appendix 2.
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_728970] 20 years due to th e use of high-dose 
chemotherapy (i.e., alkylating agents) and autologous stem cell  transplantation, the 
introduction of immunomodulatory agents, such as thalidomide, l enalidomide, and 
pomalidomide, and the proteasome inhibitors, bortezomib and car filzomib. However, despi[INVESTIGATOR_555229], most patients deve lop highly resistant MM and 
succumb to the disease. With over 12,500 deaths from MM expecte d in the [LOCATION_003] in 2016 
(ACS 2016 ), there remains a high unmet medical need to develop anti-MM a gents with novel 
mechanisms.  
3. NUCLEAR EXPORT 
3.1. Inhibition of XPO1 in Human Cancer 
Many important tumor suppressing proteins (TSPs) have been iden tified in cancer 
pathogenesis, including but not limited to TP53, FOXO3a, IŒ∫B, B RCA1, APC, PP2A, and 
Rb (Turner 2012 ; Senapedis 2014 ; Tan 2014 ; Yang 2014 ). TSPs mediate tumor suppression 
pathways via various functions including recognition of cellula r damage, arrest of the cell 
cycle until repairs can be made, and induction of apoptosis in cells that are beyond repair  
(Brown 2011 ). Similarly, glucocorticoid binding to, and nuclear localizati on of, the GCR is 
required for its signaling.  
The tumor suppression and anti-cancer activity of these TSPs an d the GCR requires their 
presence in the nucleus. Conversely, export to the cytoplasm by  [CONTACT_555259]1 can inactivate their abilities to regulate cellula r processes ( Xu 2010 ) and 
cancer cells exploit these func tions to successfully evade norm al DNA-damage controls as 
well as anti-neoplastic therapy. XPO1 is the only known nuclear  export protein for the vast 
majority of TSPs and the GCR. Of no te, XPO1 has been identified  as a selective survival 
gene in MM by [CONTACT_555260]-throughput short interfering ribonu cleic acid (siRNA) 
screening ( Tiedemann 2012 ) and is commonly overexpressed in MM ( Tai 2014 ).  
XPO1 blockade causes transient nuclear retention of TSPs, the G CR, and other growth 
modulators, re-establishing their tumor suppressing and growth regulating effects on cancer 
cells and potentially reversing mechanisms leading to chemother apy resistance (which holds 
possible future implications  for combination therapi[INVESTIGATOR_014]) ( Lain 1999 ).  
Certain growth-promoting (incl uding oncogene) messenger RNAs (m RNAs) require 
specialized nuclear export via a ‚Äúcap -binding complex‚Äù in order to exit the nucleus into the 
cytoplasm where they are translated into proteins ( Culjkovic  2013; Koehler 2007 ). Several 
key MM genes including c-Myc, Cyclin D1, hDM2 and others utiliz e this complex via 
binding to the protein eIF4E in order to exit the nucleus and u ndergo efficient translation into 
protein. The cap-binding complex protein eIF4E is exported out of the nucleus into the cytoplasm exclusively by [CONTACT_67990]1. As these proteins tend to have v ery short half-lives, 
constant translation is required t o maintain their cellular lev els. Inhibition of XPO1-mediated 
nuclear export leads to reduced translation of these growth-pro moting proteins, and 
subsequently significant drops in their levels. 
In normal cells, XPO1 inhibition transiently arrests the cell cycle without cytotoxicity 
followed by [CONTACT_555261] r the inhibitor is removed ( Lain 1999 ; van der Watt 2009 ; Gray 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 342007). Several attempts to develop this class of anti-cancer drug ha ve failed due to off-target 
effects of the drugs which led to significant weight loss, diar rhea, and marked fatigue and 
asthenia in the early clinical trials ( Mutka 2009 ;Newlands 1996 ;Roberts 1986) .
It is now well recognized that forced nuclear retention of TSPs can counteract a multitude of 
oncogenic, growth stimulatory (and inflammatory) pathways that perpetuate the neoplastic 
phenotype. Similarly, nuclear retention of the GR in the presen ce of glucocorticoids could 
restore its activity. Finally, inhibition of eIF4E/XPO1-mediate d mRNA export of 
oncoproteins lead to reductions in their levels. Because restor ation of TSP ¬± GR activity and 
reduction in oncogenic signals are relevant to essentially any cancer, XPO1 inhibition is 
expected to have activity against MM and many other malignancie s (Table 2 ).
Table 2: Effect of XPO1 Inhibition on Oncogenic and Inflammatory Pathways
Pathway Affected Effect of XPO1 Inhibition Reference
XPO1 overexpression XPO1 reduction Walker 2013
Glucocorticoid Receptor (GR) 
Inactivation (nuclear export)Nuclear GR retention (in presence of 
glucocorticoids) and reactivationChen 2014
p53 mutation p73 activation, p21 activation Ranganathan 2012
hDM2 (MDM2) activation Nuclear p53 retention and activation, hDM2 
protein reductionKojima 2013
c-Myc amplification MYC protein reduction Schmidt 2013
Cyclin D1 overexpression Cyclin D1 reduction Gao 2014
NPM1 mutation Restoration of nuclear NPM1 Falini 2007
CEBPA down-regulation Nuclear retention and activation Ranganathan 2012
CDKN2A reduction p53/p73 stabilization Azmi 2013
Rb reduction Rb hypophosphorylation, p14/p16 elevation Fragomeni 2013
FLT3 activation FLT3 reduction Ranganathan 2012
c-KIT activation c-KIT reduction Ranganathan 2012
NF-NB activation INB nuclear retention and activation Lapalombella 2012
PIK3 or AKT activation FOXO1, -3, -4 activation Lapalombella 2012
Survivin ‚Äìcytoplasmic Survivin nuclear retention Altura 2003
Bcr-Abl activation PP2A activation Walker 2013
4. SELINEXOR (KPT-330)
4.1. Introduction
Selinexor is an oral, first-in-class, slowly reversible, potent selective inhibitor of nuclear 
export (SINE) compound that specifically blocks exportin 1 (XPO 1). XPO1 is responsible 
for the unidirectional export of ~220 different cargo proteins from the nucleus to the 
cytoplasm ( Xu et al., 2010 ). The anti-neoplastic activi ty of SINE compounds is mediated 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_728971] pathways involving tumor suppre ssor proteins (TSPs), 
oncoproteins, and the glucocorticoid receptor. First, SINE compounds induce nuclear 
localization and functional activa tion of multiple TSPs, leading to rapid apoptosis of multiple 
myeloma (MM) ( Tai et al., 2014 ) and other malignant cells. By [CONTACT_555262], all cell types exposed to SINE compounds undergo G1 ¬± 
G2 cell cycle arrest, followe d by a ‚Äògenomic fidelity‚Äô review . Cells with genomic damage (ie , 
malignant cells) are induced to undergo apoptosis both in vitro  and in vivo. Normal cells, 
with an intact genome, remain in transient, reversible cell cycle arrest until the XPO1 block is relieved. A second anti-neoplastic effect of SINE compounds is mediated through the 
mRNA cap-binding protein eIF4E, which is also an XPO1 cargo. Am ongst other functions, 
eIF4E is responsible for the e fficient nuclear export and deliv ery of several growth-
promoting (oncoprotein) mRNAs to cytoplasmic ribosomal for tran slation. By [CONTACT_555263]43 bound to XPO1, SINE compounds re duce the cytoplasmic 
ribosomal synthesis of oncoprotein mRNAs including c-Myc, hDM2,  Cyclin D1 and Bcl-
XL. Finally, SINE compounds also lead to restoration of anti-my eloma glucocorticoid 
receptor (GR) signaling in the presence of glucocorticoids; selinexor and other SINE 
compounds do not appear to exacerbate  the hyperglycemic effects  of glucocorticoids.  Thus, 
by [CONTACT_555264]/cytoplasmic control protein XPO1,  SINE compounds exhibit 
broad and deep anti-cancer activities. 
4.2. Preclinical Data 
In this section, a brief summary of preclinical data is provided. Additional information is 
presented in the current Selinexor/KPT- 330 Investigator‚Äôs Brochure . 
In vitro  experiments with continuous (~72 hour) exposure to selinexor d emonstrated potent 
pro-apoptotic activity across a  broad panel of tumor-derived ce ll lines and patient samples in 
culture, including multidrug-resistant cancers. Moreover, selin exor demonstrated cytotoxicity 
in MM and CLL cells in the absence or presence of bone marrow s troma cells (BMSC).  
Pharmacokinetic (PK) studies w ere conducted in mice, rats and monkeys. Selinexor showed 
dose proportional exposure with no accumulation. Please see the  current 
Selinexor/KPT-330 Investigator‚Äôs Brochure for more information. 
Several studies were conducted to evaluate the effect of SINE c ompounds on MM in vivo . In 
MM1.S xenograft tumors, treatment with the SINE compound KPT-27 6 showed a marked 
decreased in tumor volume (40%) whe reas tumor volume increased by 36% with placebo 
(Schmidt 2013 ). KPT-276 was also active in the Vk*MYC mouse model of MM, whi ch has a 
positive predictive value of 67% for the activity of single-agent compounds in clinical trials 
(Schmidt 2013 ; Chesi 2012 ).  
4.2.1. Selinexor plus Dexamethasone Combination Studies 
In vitro  studies showed selinexor and dexamethasone in combination were found to have a 
synergistic effect on reducing MM1.S human MM cell viability re lative to either drug alone 
(Chen 2014). Increased GR nuclear localization and concomitantly activated GCR-mediated 
transcription in the presence of glucocorticoids were at least partly responsible for the 
synergistic cytotoxicity of this combination. ( Gao 2014). 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 36Enhanced activity of the selinexor plus dexamethasone combination was also observed in 
two xenograft models of human MM. The addition of dexamethasone  to selinexor enhanced 
activity (86%) relative to selinexor alone. 
In summary, the combination of selinexor and dexamethasone is s ynergistic in vitro and 
in vivo in MM cell cytotoxicity assays through increased nuclear localization of GCR and 
amplified GCR transcriptional activity. Taken together, these studies demonstrate that SINE 
compounds are active anti-MM co mpounds that cause decreased cel l viability, increased 
apoptosis, and cell cycle arrest in vitro and potent inhibition of MM tumor growth in vivo ,
and that the addition of dexamethas one can augment these effect s.
4.3. Clinical Experience
As part of a Phase [ADDRESS_728972] udy of selinexor in patients wi th advanced hematological 
malignancies (KCP-330-001), 68 patients with MM that was relapsed  and/or refractory to all 
available classes of approved therapi[INVESTIGATOR_555230] a twice-weekly dose schedule. Preliminary results, as of 13 December 2016, are 
summarized below.
4.3.1. Preliminary Results for Patients with MM, Study KCP-330-0 01, as of 
13 December 2016
[IP_ADDRESS]. Preliminary Efficacy Results for Patients with MM, Stud y KCP-330-[ADDRESS_728973] responses among the 22 evaluabl e patients who received 
selinexor plus dexamethasone (Sd) were: 1 CR (5%), 5 PRs (23%), 3 MRs (14%), 8 SDs 
(36%), and 5 PDs (23%). The ORR was 27% and the CBR was 41%. Several patients remained on study for >9 months and one patient remained on stu dy for >[ADDRESS_728974] efficacy as a single-agent with 4% of p atients achieving an 
objective response (‚â•PR in 2 of 46 patients) and 26% showing cl inical benefit (‚â• MR in 12 
of 46 patients). Overall, these pre liminary Phase [ADDRESS_728975] that selinexor ¬± 
dexamethasone has clear anti-MM activity in heavily pretreated patients. 
[IP_ADDRESS]. Preliminary Safety Results for Patients with MM, Study KCP-330-[ADDRESS_728976] 79 patie nts were presented at the 2016 
American Society of Hematology  annual meeting and are summarize d below (Vogl et al., 
2016).
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page [IP_ADDRESS]. Preliminary Efficacy (Response) Results for Patients with MM, Study KCP-
330-012
Response rates in patients with MM previously treated with lenal idomide, pomalidomide, 
bortezomib, carfilzomib, and refractory to one proteasome inhibitor (PI), one 
immunomodulatory drug (Imid) and glucocorticoids (‚Äúquad‚Äù refrac tory) and in patients with
MM refractory t o the ‚Äúquad‚Äù agents as well as to an anti -CD38 Ab (‚Äúpenta‚Äù refactory) were 
adjudicated by [CONTACT_555265] (IRC) and are pre sented in Table 3. for 
the first portion of the study overall, for 8 vs. 6 doses per 2 8-day cycle and ‚Äúpenta‚Äù vs. 
‚Äúquad‚Äù MM (Vogl et al., 2016 ). One patient did not have measurable myeloma at baseline 
and is not included in the efficacy analyses. The ORR across al l patients is 21% and the 
clinical benefit rate (CBR) is 33%. Similar ORR were seen in the patients with ‚Äúpenta‚Äù and 
‚Äúquad‚Äù MM, with higher CBR in patients who received 8 vs. 6 dos es/cycle consistent with 
improved disease control with continuous dosing.  The additiona l 122 patients with ‚Äúpenta‚Äù 
MM to be added will receive 8 doses  / cycle based on these anal yses.
Table 3: Response by [CONTACT_555266] o f 01 Dec 2016
Category NaORR 
(%)CBR 
(%)VGPR 
(%)PR   
(%)MR 
(%)SD   
(%)PD  
(%)NE (%)
Overall 78 16
(21%)26
(33%)4
(5%)12
(15%)10
(13%)27
(35%)9
(12%)16
(21%)
8 doses/cycle 27 6
(22%)11
(41%)1
(4%)5
(19%)5
(19%)6
(22%)5  
(19%)5
(19%)
6 doses/cycle 51 10
(20%)15
(29%)3
(6%)7
(14%)5
(10%)21
(41%)4
(8%)11
(22%)
Pentab 30 6
(20%)12
(40%)2
(7%)4
(13%)6
(20%)6
(20%)5  
(17%)7
(23%)
Quadc 48 10
(21%)14
(29%)2
(4%)8
(17%)4
(8%)21
(44%)4
(8%)9
(19%)
CBR=Clinical Benefit Rate (sCR+PR +MR), MR=Minor Response, NE=No n-Evaluable, ORR=Overall 
Response Rate (sCR+PR), PD=Progre ssive Disease, PR=Partial Resp onse, SD=Stable Disease, VGPR=Very 
Good Partial Response
aone patient not included, did not  have measurable myeloma at ba seline
bthe majority of these patients (19 of 30) received 8 doses per cycle
cthe majority of these patients (40 of 48) received 6 doses per cycle
[IP_ADDRESS]. Preliminary Safety Results for Patients with MM, Study KCP-330-012
Common treatment-related advers e events (TRAEs) based on a preliminary analysis of safety 
and tolerability (N=92; safety data cut off 31 March 2017):
xHematological: thrombocytopenia (overall: 64%, Grades 3/4: 51%) , neutropenia 
(overall: 26%, Grades‚â• 3 19%), and anemia (overall: 39%, Grade 3/4: 22%). 
There was one case of febrile neutropenia (1%) and one case of clinically 
significant bleeding related to thrombocytopenia (1%). 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 38 x Non-hematological: nausea (overall: 68%, Grade 3: 8%), fatigue (overall: 64%, 
Grade 3: 14%) anorexia (overall: 51%, Grade 3: 2%), vomiting (o verall 41%, 
Grade 3: 2%), hyponatremia (overa ll 33%, Grade 3: 18%), diarrhe a (overall 40%, 
Grade 3: 4%), and weight loss  (overall: 33%, Grade 3: 1%).  
These results are generally consistent with the overall TEAE re sults reported for all selinexor 
studies in patients with hematological malignancies (see the Selinexor/KPT-330 IB ). 
[IP_ADDRESS]. Summary 
Based on the promising preliminary efficacy results described a bove and on the considered 
feedback from MM experts that the population of patients with p enta-refractory MM 
represents a current and growing high unmet medical need where there are no approved 
agents and there is no established standard of care, Karyopharm is expanding the number of 
patients with penta-refractory  MM enrolled in this single-arm study to a total of 
~160 patients with penta-refractory MM to receive Sd twice week ly for every week of each 
four-week cycle (8 doses/cycle). 
4.4. Potential Risks 
Selinexor is currently in clinical development and has not been  approved by [CONTACT_555267]. Over 2,[ADDRESS_728977] received selinexor (as  of 31 March 2017), however 
the entire safety profile is not known at this time. Measures will be taken to ensure the safety 
of the patients participating in this trial, including the use of stringent inclusion and exclusion 
criteria and close monitoring.  
If toxicities are encountered, adjustments will be made to the study treatment as detailed in 
the sections that follow. All A Es and serious adverse events (S AEs) will be recorded during 
the trial and for up to [ADDRESS_728978] common AEs possibly related to 
selinexor are anorexia, fatigue, nausea, vomiting, diarrhea, an d thrombocytopenia. Virtually 
all of these side effects can be managed effectively with dose modification and/or supportive care initiated prior to first dosing. Overall, the most frequen tly observed laboratory 
abnormalities include thrombocyt openia, hyponatremia, and a dec rease in red blood cells. 
The majority of these have been mild to moderate. Please refer to the current 
Selinexor/KPT- 330 Investigator‚Äôs Brochure  for more information.  
Acute cerebellar syndrome (ACS) was reported at high doses in o ne adult (85 mg/m
2) and 
two pediatric (70 mg/m2) patients in two phase 1 studies.  The maximum doses in adults  
(70 mg/m2) and children (55 mg/m2) have been established large ly based on these events.  An 
adult patient, heavily pre-treated for recurrent pancreatic can cer, developed ACS following 
3 doses of selinexor at 85 mg/m2 twice weekly. The patient expe rienced abnormal speech, 
loss of coordination, and was unable to walk. Selinexor was dis continued and the patient‚Äôs 
symptoms resolved to near baseline by ~6 weeks.  A five-year ol d with refractory AML 
developed ACS following 4 doses of selinexor (70 mg/m2) followed by 5 days of fludarabine 
and cytarabine (without intrathrecal therapy). The patient was empi[INVESTIGATOR_555231] 5 days, improved significantly o ver the next 3 weeks, and 
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJHKDGUHVROXWLRQRIV\PSWRPVDIWHUZHHNV$UHSHDW05,GD\V DIWHUWKHLQLWLDOLPDJH
VKRZHGQHDUFRPSOHWHUHVROXWLRQRIGLIIXVLRQDEQRUPDOLWLHV$ PRQWKROGPDOH
PJPZLWKUHODSVHG$0/GHYHORSHG$&6DIWHUUHFHLYLQJGRVHVRIVH OLQH[RU%HFDXVH
WKHFOLQLFDODQGLPDJLQJILQGLQJVZHUHFRQVLVWHQWZLWKFHUHEHOO DUWR[LFLW\SURWRFROWKHUDS\
ZDVGLVFRQWLQXHGDQGKLVDWD[LDVKRZHGLPSURYHPHQWRYHUWKHFRX UVHRIWZRZHHNV
1RRWKHUSDWLHQWVKDYHUHSRUWHGVXFKV\PSWRPVWRGDWH$OOFDVH VRIFHUHEHOODUWR[LFLW\RI
*UDGHRUKLJKHUPXVWEHFDSWXUHGDVDQ6$(DQGUHSRUWHGLQDQ H[SHGLWHG6DIHW\5HSRUW
ZLWKLQGD\VRIDZDUHQHVVRIWKHHYHQW
 5HSURGXFWLYH5LVNV
0DFURVFRSLFDQGPLFURVFRSLFFKDQJHVLQUHSURGXFWLYHRUJDQVZHUH QRWHGGXULQJUDWDQG
PRQNH\WR[LFRORJ\VWXGLHVPRVWUHVROYHGRUSDUWLDOO\UHVROYHG GXULQJWKHUHFRYHU\SHULRG
7KHORQJWHUPHIIHFWVRIWKHVHFKDQJHVRQUHSURGXFWLYHSRWHQWLD ODUHXQNQRZQ6HFRQGDU\
GHYHORSPHQWDOHIIHFWVGXHWRUHGXFHGPDWHUQDOERG\ZHLJKWVZHUH DOVRQRWHGGXULQJDVWXG\
RQUDWHPEU\RIHWDOGHYHORSPHQW3OHDVHVHHWKH6HOLQH[RU.37 ,QYHVWLJDWRU
V%URFKXUH
IRUDGGLWLRQDOLQIRUPDWLRQ$VLWLVXQNQRZQLIVHOLQH[RUSURGX FHVDQ\UHSURGXFWLYHWR[LFLW\
LQKXPDQVDOOSDWLHQWVPXVWDJUHHWRXVHHIIHFWLYHFRQWUDFHSWL RQVHH6HFWLRQ GXULQJ
WKHVWXG\DQGIRUPRQWKVDIWHUWKHHQGRIWUHDWPHQW
 5$7,21$/()257+(678'<
0XOWLSOHP\HORPDLVWKHVHFRQGPRVWFRPPRQKHPDWRORJLFDOPDOLJQ DQF\:LWK
FRQYHQWLRQDOWUHDWPHQWPHWKRGVPHGLDQVXUYLYDOLV\HDUVDI WHUGLDJQRVLV Kumar 2014 
0XOWLSOHP\HORPDLVKLJKO\WUHDWDEOHEXWLVQRWFRQVLGHUHGWRE HFXUDEOHZLWKFXUUHQWO\
DYDLODEOHWKHUDSLHV&RPPRQWUHDWPHQWVLQFOXGHJOXFRFRUWLFRLGV FKHPRWKHUDS\SURWHDVRPH
LQKLELWRUVLPPXQRPRGXODWRU\GUXJVVWHPFHOOWUDQVSODQWVDQGU DGLDWLRQWKHUDS\
6HOLQH[RUKDVGHPRQVWUDWHGDQWL00DFWLYLW\LQSUHFOLQLFDOVWX GLHVin vitroDQGin vivo$
VX[COMPANY_003]U\RIFOLQLFDOUHVXOWVIRUSDWLHQWVZLWK00VHHQLQ6WX G\.&3DVRI
$XJXVWLVSURYLGHGLQ6HFWLRQ 
7KHRULJLQDOGHVLJQRIWKLVSURWRFRO.&3ZDVEDVHGRQ WKHSULPDU\WUHDWPHQW
RSWLRQVIRU5500LH,0L'VDQG3,VWKDWZHUHLQFRPPRQXVH DWWKHWLPHWKDWWKH
SURWRFROZDVGHYHORSHGLQRUGHUWRHYDOXDWHZKHWKHUVHOLQH[RU ZRXOGSURYLGHDXVHIXOQHZ
WKHUDSHXWLFRSWLRQWRSDWLHQWVZKRVHGLVHDVHZDV55WRWKHVHWU HDWPHQWVLHSDWLHQWVZLWK
TXDGUHIUDFWRU\00,QWKDWGHVLJQDVXEVHWRISDWLHQWVZLWK SHQWDUHIUDFWRU\00ZDVDOVR
LQFOXGHGDVDQ DVWUHDWPHQWZLWKDQWL&'P$EVZDVQRW\HW
FRPPRQ:LWKWKHUHFHQWDSSURYDORIGDUDWXPXPDEDQGRQJRLQJGHY HORSPHQWRILVDWX[LPDE
WKHFOLQLFDOXVHRIDQWL&'P$EVWRWUHDW5500KDVEHFRPHPR UHFRPPRQVXJJHVWLQJ
WKDWVHOLQH[RUZRXOGEHEHVWFRQVLGHUHGDVDWKHUDSHXWLFRSWLRQ LQSDWLHQWVZLWKSHQWD
UHIUDFWRU\00
 5DWLRQDOHIRU6HOLQH[RU'RVH6FKHGXOH
0RUHWKDQSDWLHQWVZLWKDGYDQFHGFDQFHUVKDYHUHFHLYHGVHOL QH[RULQ3KDVHDQG
3KDVHVWXGLHVDVRI0DUFK,QVWXG\.&3SDWLHQ WVZKRUHFHLYHGVHOLQH[RUCCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 4045 mg/m2(~80 mg) plus dexamethasone 20 mg, both dosed twice weekly, exp erienced 
durable response without clinically relevant cumulative toxicities. (See Section 4.3.)
Patients in the present study will receive selinexor 80 mg (45 m g/m2BSA) plus 
dexamethasone 20 mg, both dosed tw ice weekly, for each week of four-week cycles.
Dexamethasone 20 mg will be given with each dose of selinexor. For patients with partial 
intolerance to glucocorticoids (as determined by [CONTACT_148606]) a minimum dose of 
dexamethasone [ADDRESS_728979] cases (e.g., for patients showing SD or PR and tolera ting treatment particularly 
well), the selinexor dose may be increased by 20 mg to 100 mg, based on efficacy and safety 
considerations, after a minimum of two cycles of study therapy.  However, in no case may the 
dose for any patient exceed 70 mg/m2. Prior to any potential dose increase, the BSA for the 
patient should be calculated. Patients with BSA < 1.[ADDRESS_728980] their dose increased, 
as this would result in a dose > 70 mg/m2selinexor.
6. STUDY OBJECTIVES
6.1. Primary Objectives
Evaluate the efficacy (overall response rate [ORR]) for treatme nt with selinexor 80 mg plus 
low-dose dexamethasone (20 mg) (Sd) twice weekly (four-week cyc les) in patients with MM 
previously treated with lenalidomide, pomalidomide, bortezomib,  carfilzomib, and 
daratumumab; and refractory to prior treatment with glucocortic oids, an immunomodulatory 
agent (IMiD), a proteasome inhibitor (PI), and the anti-CD38 mA b daratumumab (herein 
referr ed to as ‚Äú penta-refractory ‚Äù MM).
ORR will include patients who experience partial response (PR), very good partial response 
(VGPR), complete response (CR), or s tringent complete response (sCR), based on 
International Myeloma Working Group (IMWG) response criteria ( Kumar 2016 ) for patients 
with penta-refractory MM in Part 2 (expansion phase).
6.2. Secondary Objectives
The following endpoints will be analyzed separately for (a) Part 1 patients with quad-
refractory MM, (b) Part 1 patients with penta-refractory MM, an d (c) Part 2 (expansion) 
patients with penta-refractory MM. Additionally, analyses of sa fety and tolerability will be 
performed on the overall population of patients from Parts [ADDRESS_728981] one
dose of study treatment.
xDuration of response (DOR = Durat ion from first observation of at least PR to 
time of disease progression, or death due to disease progressio n, whichever occurs 
first. DOR will be censored for death due to any causes other t han disease 
progression)
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJHx&OLQLFDO%HQHILW5DWH&%5 V&5&59*3535PLQLPDOUHV SRQVH
>05@DQGGXUDWLRQRIFOLQLFDOEHQHILW'XUDWLRQIURPILUVWRE VHUYDWLRQRIDWOHDVW
05WRWLPHRIGLVHDVHSURJUHVVLRQRUGHDWKGXHWRGLVHDVHSURJU HVVLRQZKLFKHYHU
RFFXUVILUVW'XUDWLRQRIFOLQLFDOEHQHILWZLOOEHFHQVRUHGIRU GHDWKGXHWRDQ\
FDXVHVRWKHUWKDQGLVHDVHSURJUHVVLRQ
x'LVHDVH&RQWURO5DWH'&5 &%5VWDEOHGLVHDVH>6'IRUDPLQ LPXPRI
ZHHNV@
x3URJUHVVLRQ)UHH6XUYLYDO3)6 'XUDWLRQIURPVWDUWRIVWXG\W UHDWPHQWWR3'RU
GHDWK>UHJDUGOHVVRIFDXVH@ZKLFKHYHUFRPHVILUVW
x7LPHWR3URJUHVVLRQ773 'XUDWLRQIURPVWDUWRIVWXG\WUHDWPH QWWRWLPHRI
GLVHDVHSURJUHVVLRQREWDLQHGZLWKVHOLQH[RUSOXVGH[DPHWKDVRQH YV773RQPRVW
UHFHQWSULRUWKHUDS\
x7LPHWRQH[WWUHDWPHQW7717
x2YHUDOO6XUYLYDO26 'XUDWLRQIURPVWDUWRIVWXG\WUHDWPHQWW RGHDWK
x4XDOLW\RI/LIH4R/XVLQJWKH)XQFWLRQDO$VVHVVPHQWRI&DQFHU 7KHUDS\
0XOWLSOH0\HORPD)$&700
x6DIHW\DQGWROHUDELOLW\XVLQJ1DWLRQDO&DQFHU,QVWLWXWH1&,& RPPRQ
7HUPLQRORJ\&ULWHULDIRU$GYHUVH(YHQWV&7&$(Y
x'HVFULEHWKH3.SURSHUWLHVRIVHOLQH[RULQWKLVSDWLHQWSRSXODW LRQ3DUWRQO\
 

 
 


 
 

 

 

 


 
 CCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 42  Lytic lesions as assessed by  [CONTACT_492368] (or similar bone i maging) 
7. STUDY DESIGN 
7.1. Overview 
This is a Phase 2b, single-arm, open-label, multicenter study o f Sd (selinexor 80 mg plus 
dexamethasone 20 mg), both dosed twice weekly, four weeks of ea ch four-week cycle, in 
patients with MM previously treated with lenalidomide, pomalido mide, bortezomib, 
carfilzomib, and daratumumab, and refractory to prior treatment  with glucocorticoids, an 
immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and  the anti-CD38 mAb 
daratumumab. (Note: Refractory is defined as ‚â§  25% response to therapy, progression during 
the previously described therapi[INVESTIGATOR_014], or progression within 60 days after completion of 
therapy.) 
This study consists of two parts and will enroll approximately 210 patients overall. Part 1 
(protocol V1.0-3.0) enrolled patients with both quad-refractory  MM and penta-refractory 
MM. Part 2 (protocol V‚â•4.0) will enroll patients with penta-refractory MM only, but 
continue all patients  enrolled in Part 1.  
The population for the primary efficacy analysis will contain only patients with penta-
refractory MM enrolled in Part 2. E fficacy results for patients  with quad-refractory MM and 
patients with penta-refractory MM enrolled in Part 1 will be an alyzed separately. Safety 
analyses will be performed on the overall population of patients who received any amount of study treatment, presented overa ll and by [CONTACT_16051], and separ ately for Part 1 penta-
refractory MM patients and quad-refractory MM patients. 
Patients will receive selinexor 80 mg (45 mg/m
2 BSA) plus dexamethasone 20 mg (Sd), both 
dosed twice weekly, for each wee k of four-week cycles. Patients  will receive treatment until 
PD, death, toxicity that cannot be managed by [CONTACT_555252], or  withdrawal, whichever 
occurs first.  
Patients will also receive best supportive care to mitigate sel inexor side effects, including 
blood product transfusions, antimicrobials, and (as appropriate) growth factors including 
granulocyte colony-stimulating factors for neutropenia, erythropoietins for anemia, and/or platelet-stimulating factors for thrombocytopenia. 
In select cases (e.g., for patients showing SD or PR and tolera ting treatment particularly 
well), the selinexor dose may be increased by 20 mg after consu ltation with the Medical 
Monitor. The dose level for an individual patient may be escala ted based on efficacy 
considerations only after a minimum of 2 cycles of study therap y. However, in no case may 
the dose for any patient exceed 70 mg/m
2. Prior to any potential dose increase, the body 
surface area (BSA) for the patient will be calculated and an in dividual patient‚Äôs dose may not 
be increased if it would result in a dose > 70 mg/m2. 
In Part 2, MM-specific assessments (i.e., SPEP, UPEP, serum/uri ne immunofixation, 
quantitative Ig levels, serum FLC, and bone marrow aspi[INVESTIGATOR_337]) mu st be confirmed by a central 
laboratory to confirm CR or sCR, and select VGPR, per IMWG. Additional information is 
provided in the Study Manual . 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-[ADDRESS_728982] determine  the primary reason for a patien t‚Äôs discontinuation of study 
treatment and record this information on the electronic case re port form (eCRF). Patients 
who are prematurely withdrawn from study treatment are not elig ible to re-initiate study 
treatment on this protocol at a later date.
7.2. Data Safety Monitoring Board
An independent Data Safety Monit oring Board (DSMB) will review the safety of study 
treatment and any SAEs that occur during the study. Details on how the DSMB will review 
safety and response data are provided in the DSMB Charter .
The DSMB will be comprised of a minimum of two oncologists (at least one of whom 
specializes in hematologic oncology) and a statistician. Follow ing their initial meeting, 
DSMB meetings will occur on a periodic basis in accordance with  their charter. 
7.3. Independent Review Committee
An Independent Review Committee (IRC), will review disease assessment data to 
independently assess disease response. The IRC will review data  that will be used for the 
analysis of the primary endpoint. The IRC‚Äôs assessments of disease response and time to 
progression (TTP) will be used as the basis for the evaluation of the primary endpoint.  
The IRC membership, functioning, and procedures (including reso lution of any 
disagreements with Investigators regarding disease assessments) will be described in the 
IRC Charter .
7.4. Stoppi[INVESTIGATOR_555232] i ndividual patients may be stop ped under defined 
circumstances as outlined in Section 10.
7.5. Study Endpoints
Study objectives and endpoints are provided in Section 6.
7.6. Blinding and Randomization
Not applicable; this is an open-label, single-arm, multicenter study. 
7.7. End of Study
The End of Study (EoS) will occur when all patients have completed the one-year Follow-up
Period (i.e., when the last patient has expi[INVESTIGATOR_5697], been followed for [ADDRESS_728983]).
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 448. SELECTION OF PATIENTS
8.1. Number of Patients
Approximately 210 patients will  be enrolled overall, including ~160 patients with 
penta-refractory MM (Part 1 [~30] and Part 2 [~130]) and ~50 patients with quad-refractory
MM (Part 1 only). See Section 7.1.
8.2. Recruitment
This study will be conducted at mu ltiple sites in the United St ates and Europe.
8.3. Documentation Requirements 
For enrollment consideration, patients may be eligible if they have documented evidence of
previous treatment for MM that substantiates disease status as follows:
xRefractory to a glucocorticoid
xRefractory to lenalidomide and/or pomalidomide (only 1 required ) andevidence 
of prior treatment* with both lenalidomide and pomalidomide
xRefractory to bortezomib and/or carfilzomib (only 1 required) andevidence of 
prior treatment* with both bortezomib and carfilzomib
xRefractory to daratumumab
* Prior treatment is defined as either refract ory, treatment with ‚â• [ADDRESS_728984] one of the following:
1. Medical records that support start and stop dates (month/year ) of prior treatment (both 
dose and schedule), best response on prior treatment and, if ap plicable, date of 
progression (including both dose and schedule at the time of pr ogression).
2. Myeloma marker values (SPEP, UPEP, Immunoglobulin, FLC) at th e time of prior 
treatment start, stop and time of progression (accompanied by # 1).
3. Formal, signed physician letter by [CONTACT_10670] (on hospi[INVESTIGATOR_307]/ clinic letterhead), to be 
included in the patient‚Äôs medical and research record, indicating start/stop dates of 
prior treatment (both dose and schedule), best response on trea tment and, if
applicable, date of progression (including both dose and schedu le at the time of 
progression).
4. Formal, signed physician letter from referring physician (on hospi[INVESTIGATOR_307]/clinic 
letterhead), to be included in the patient‚Äôs medical and resear ch record, that incl udes 
prior treatment history indica ting start/stop dates of prior tr eatment (both dose and 
schedule), best response on pri or treatment and, if applicable,  date of progression 
(including both dose and schedule at the time of progression).
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_728985] meet all of the following inclusion criteria to b e eligible to enroll in this study: 
1. Written informed consent in accorda nce with federal, local, and  institutional 
guidelines. 
2. Age ‚â•  [ADDRESS_728986] o ne of the 
following: 
a. Serum M- protein ‚â• 0.5 g/dL by [CONTACT_9656] (SPEP) or, for IgA 
myeloma, by [CONTACT_9657] 
b. Urinary M- protein excretion ‚â• 200 mg/24 hours  
c. FLC ‚â•  100 mg/L, provided that the FLC ratio is abnormal.  
d. If serum protein electrophoresis is felt to be unreliable for r outine M-protein 
measurement, then quantitative Ig levels by [CONTACT_555253]. 
4. Patients must have previously received ‚â• 3 anti -MM regimens including: an 
alkylating agent, lenalidomide, pomalidomide, bortezomib, carfi lzomib, 
daratumumab, and a glucocorticoid. There is no upper limit on t he number of prior 
therapi[INVESTIGATOR_555233]/exclusion criteria are met. 
5. MM refractory to previous treatment with one or more glucocorti coids, parenteral PI 
(i.e., bortezomib and/or carfilzomib), IMiD (i.e., lenalidomide  and/or pomalidomide), 
and daratumumab . Refractory is defined as ‚â§  25% response to therapy, or progression 
during therapy or progression within 60 days after completion o f therapy. 
6. Multiple myeloma that is refractory to the patient‚Äôs most recent anti -MM regimen. 
(Documented severe intolerance t o the patient‚Äôs last therapy is  allowed upon approval 
by [CONTACT_1689].) 
7. Any clinically significant non-hematological toxicities (except  for peripheral 
neuropathy as described in exc lusion criterion #17) that patien ts experienced from 
treatments in previous clinical studies must have resolved to G rade ‚â§ 2 by [CONTACT_51199] 1 
Day 1. 
8. Adequate hepatic function within 21 days prior to Cycle 1 Day 1 : total bilirubin < 2x 
upper limit of normal (ULN) ( except patients with Gilbert‚Äôs syndrome who must have 
a total bilirubin of < 3x ULN), AST < 2.5x ULN and ALT < 2.5x U LN.  
9. Adequate renal function within 21 days prior to Cycle 1 Day 1: estimated creatinine 
clearance of ‚â• 20 mL/min, calculated using the formula of Cockr oft and Gault.  
10. Female patients of childbearing potential must agree to use 2 m ethods of 
contraception (including 1 highly effective and 1 effective met hod of contraception) 
and have 
a negative serum pregnancy  test at Screening. Male pat ients must use an 
effective barrier method of contraception if sexually active wi th a female of 
child-bearing potential.  For both male and female patients, effective methods of 
contraception must be used t hroughout the study and for three m onths following the 
last dose of study treatment. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 46 11. Eastern Cooperative Oncology Group (ECOG) Performance Status of  ‚â§ 2. 
12. Adequate hematopoietic function within 21 days prior to Cycle 1 Day 1 (See 
Exclusion Criterion #20 for transfusion washout periods for RBC s and platelets):  
a. Total WBC count > 1,000/mm3 
b. ANC ‚â• 1000/mm3 
c. Platelet count ‚â•  75,000/mm3 (patients in whom <50% of bone marrow nucleated 
cells are plasma cells) or ‚â• 50,000/mm3 (patients in whom ‚â• 50% of bone marrow 
nucleated cells are plasma cells. (Platelet transfusions < 1 week prior to Cycle 1 
Day 1 are prohibited [see below].)  
13. Hemoglobin level ‚â• 8.5 g/dL. In certai n cases, patients with stable baseline 
hemoglobin level > 8.0 may be included following approval by [CONTACT_3433] e Medical Monitor. 
(Red blood cell transfusions < 2 weeks prior to Cycle 1 Day 1 a re prohibited [see 
below].) 
14. Confirmation of patient eligibility for specific key criteria f or study participation with 
the Medical Monitor. 
8.5. Exclusion Criteria 
1. Active smoldering MM. 
2. Active plasma cell leukemia. 
3. Documented systemic amyloid light chain amyloidosis. 
4. Active central nervous system (CNS) MM. 
5. Pregnancy or breastfeeding. 
6. Radiation, chemotherapy, or immunotherapy or any other anticanc er therapy ‚â§ [ADDRESS_728987] disease (after allogeneic stem cell transplantation) at Cycle 1 
Day 1  
8. Life expectancy of < 4 months. 
9. Major surgery within four weeks prior to Cycle 1 Day 1. 
10. Active, unstable cardiovascular function: 
a. Symptomatic ischemia, or  
b. Uncontrolled clinically-signif icant conduction abnormalities (e .g., patients with 
ventricular tachycardia on antia rrhythmics are excluded; patien ts with 1st degree 
atrioventricular (AV) block or asymptomatic left anterior fasci cular block/right 
bundle branch block (LAFB/RBBB) will not be excluded), or 
c. Congestive heart failure (CHF) of [LOCATION_001] Heart Association (N YHA) Class ‚â•  
3, or 
d. Myocardial infarction (MI) within 3 months prior to Cycle 1 Day  1. 
11. Active, uncontrolled hypertension. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_728988] dose. 
13. Known HIV seropositive.  
14. Known active hepatitis A, B, or C infection; or known to be pos itive for HCV RNA 
or HBsAg (HBV surface antigen). 
15. Prior malignancy that required treatment, or has shown evidence  of recurrence 
(except for non-melanoma skin cancer or adequately treated cerv ical carcinoma in 
situ) during the 5 years prior t o enrollment. Cancer treated wi th curative intent > 5 
years previously and without evi dence of recurrence will be all owed. 
16. Active GI dysfunction interfering with the ability to swallow t ablets, or any GI 
dysfunction that could interfere with absorption of study treat ment. 
17. Grade ‚â• 3 peripheral neuropathy, and Grade  ‚â• 2 painful neuropathy, within 21 days 
prior to Cycle 1 Day 1. 
18. Serious, active psychiatric or medical conditions which, in the  opi[INVESTIGATOR_684], could interfere with treatment. 
19. Participation in an investigational anti-cancer study within 21  days prior to Cycle 1 
Day 1.  
20. Receipt of transfusions as follows: 
a. Platelet infusion within 1 week prior to Cycle 1 Day 1. 
b. RBC transfusion within 2 weeks prior to Cycle 1 Day 1. 
21. Receipt of the following blood growth factors within 2 weeks pr ior to Cycle 1 Day 1: 
Granulocyte colony stimulating factor (G-CSF), granulocyte-macr ophage colony 
stimulating factor (GM-CSF), erythropoietin (EPO), or megakaryo cyte growth factor. 
22. Known intolerance to or contrai ndications for glucocorticoid th erapy at Cycle 1 Day 
1. 
23. Prior exposure to a SINE compound, including selinexor.  
24. Unable or unwilling to comply w ith protocol requirements, inclu ding providing a 24-
hour urine samples at the required study time points. 
8.6. Screen Failures 
Patients who sign an informed c onsent form and do not receive s tudy treatment for any 
reason are defined as screen failures. For all screen failures,  the Investigator will enter the 
screening number, patient initials; and reason(s) for screen fa ilure onto electronic case report 
forms (eCRFs). Screen failures will be replaced. Screen failure s may be re-screened. 
8.7. Study Patient Numbers 
Each patient will be assigned a  unique study number and will ke ep this number for the 
duration of the study. Patient numbers will not be reassigned o r reused for any reason. 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-[ADDRESS_728989] maintain a patient identificatio n master log.
8.8. Study Patient Number
Each patient will be assigned a  unique study number and will ke ep this number for the 
duration of the study. Patient numbers will not be reassigned o r reused for any reason. 
Patients will be identified to Karyopharm only by [CONTACT_555268] d number, initials, year of
birth (as allowed by [CONTACT_555269]),  and sex. The Investigator must 
maintain a patient identification master log.
9. METHODS OF ASSESSMENT AND ENDPOINTS
9.1. Standard Study Assessments
All assessments should be performed as outlined in Table 1.
9.1.1. Demographic Data
During Screening, patient demographic data will be collected. These  data include year of
birth, age, gender, race, and ethnicity.
9.1.2. Medical History
A complete medical history w ill be obtained from each patient. M edical history includes 
historic MM assessment values (Day -30 and Day -60), baseline sy mptoms as well as a 
detailed history of prior procedures for MM and other prior cancer therapi[INVESTIGATOR_014] (i.e., transplant, 
chemotherapy, hormonal therapy, immunotherapy, biotherapy, radi otherapy, and surgery)
including start and stop dates, be st response, disease progression dates (during or after 
therapy), as well as disconti nuations due to intolerability or toxicity. Smoking history will be 
recorded. Data should be reviewed by [CONTACT_555270] [ADDRESS_728990] taken any medication other than the study 
medication (from Screening through the end of the study). All c oncomitant medications 
including dietary supplements, over-the-counter medications, an d oral herbal preparations, as 
well as changes in medication, will be recorded on the eCRFs. 
Supportive care (such a s appetite stimulants , anti-emetics, and  anti-diarrheals, etc.) is 
encouraged (see Section 11.4.2).
9.1.4. Physical Examination 
Full physical examinations (PE) during Screening and the EoT Vi sit will be performed. All 
other PEs during the study should be symptom-directed PEs. Sign ificant findings that were 
present prior to the signing of informed consent must be included on the medical history page 
on the patient‚Äôs CRF. Significant new findings, including the p resence of plasmacytomas, 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-[ADDRESS_728991] be recorded on the Adverse Event or 
Plasmacytoma page of the patient‚Äôs CRF.
PEs, unless otherwise noted, will include the following:
xHeight (without shoes) in centimeters (cm) measured during Screening only 
xBody weight (indoor clothing without shoes) in kilograms (kg) 
xBody temperature 
xSystolic and diastolic BP and pulse rate measured at each visit  after the patient 
has been in a supi[INVESTIGATOR_159353] [ADDRESS_728992] be recorded on the AE eCRF.
9.1.5. ECOG Score
An ECOG Score Assessment (see Appendix 1) will be performed during Screening, Day 1 of 
each cycle, and the EoT visit.
9.2. Multiple Myeloma Disease Specific Assessments
Patient response will be assessed by [CONTACT_555271] T able 4 and graded 
according to the IMWG response criteria summarized in Table 10 (Appendix 3). Per IMWG, 
quantitative Ig levels by [CONTACT_159446] M-protein 
measurements for patients with
 IgA or IgD myeloma. Also, per IMWG, response may be 
confirmed if the patient fails to provide 24-hour urine sample collection after Screening 
activities occur.  All MM assessments outlined in this protocol ar e  required to be performed at 
each study visit, prior to dosing. If MM assessments are collected at unscheduled times, those 
results must be documented in the eCRF as unscheduled visits. Th is includes SPEP, UPEP, 
serum FLC, Œ≤ 2
 microglobulin, quantitative I g, and serum/urine protein immunofixation. 
Results of pre-screening MM assessments at Day -30 (window: Screening ‚Äì 2 weeks) and 
Day
 -60 (¬±15 days) will also be provided.
SPEP with serum protein immunofixation, quantitative Ig, serum FLC, and 24-hour UPEP, 
with immunofixation, must be collected at each required time po int. An aliquot of the blood 
and urine samples should be retain ed.  If the local laboratory results indicate a CR or sCR, 
sequential MM disease assessment samples, per IMWG, will be col lected. The sequential 
samples will be split ‚Äìone aliquot of each sample will be s ent to the local lab while the other 
aliquots, along with the initial assessment aliquots, will be se nt to the central laboratory to 
confirm CR or sCR. If the resu lts do not indicate CR or sCR, the n the aliquots may be 
destroyed. Refer to the Study Manual for details.
All disease assessments (SPEP, UPEP, FLC, quantitative Ig, and serum/urine protein 
immunofixation) should be performe d regardless of the diagnosis  that is being followed (e.g., 
[ADDRESS_728993] be collected at each time point ou tlined in the protocol even if 
the patient is being followed by [CONTACT_64827], Ig or FLC). 
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH7DEOH 0XOWLSOH0\HORPD'LVHDVHVSHFLILF$VVHVVPHQWV
3URFHGXUH 1RWHV
63(3ZLWK0VSLNHTXDQWLILFDWLRQDQG
VHUXPSURWHLQLPPXQRIL[DWLRQ3HU,0:*
83(3KRXUXULQHIRUWRWDOSURWHLQ
ZLWK0VSLNHTXDQWLILFDWLRQDQGXULQH
SURWHLQLPPXQRIL[DWLRQ3HU,0:*,IWKHSDWLHQWIDLOVWRSURYLGHWKHKRXUXULQHVDP SOH
WKLVVKRXOGEHGRFXPHQWHG$OODWWHPSWVVKRXOGEHPDGHWRFROOH FW
WKHKRXUXULQHVDPSOHDWWKHUHTXLUHGWLPHSRLQWV
83(3PXVWEHGHWHUPLQHGIURPDXULQHVDPSOHFROOHFWH GIRU
KRXUV¬±QRRWKHUPHWKRGLVDFFHSWDEOH
83(3PXVWEHSHUIRUPHGDWHDFKWLPHSRLQWRXWOLQHGLQWKHSURWR FRO
HYHQLIWKHSDWLHQWLVEHLQJIROORZHGE\63(3
6HUXP)/& 3HU,0:*
4XDQWLWDWLYH,JOHYHOV 3HU,0:*
)RU,J$DQG,J'P\HORPDV TXDQWLWDWLYHLPPXQRJOREXOLQ
PHDVXUHPHQWVDUHSUHIHUUHGIRUGLVHDVHDVVHVVPHQWV
WKHVDPHSHUFHQWDJHFKDQJHVDSSO\DVIRUVHUXP0 VSLNH2QO\
QHSKHORPHWU\FDQEHXVHGIRUWKHUHVSRQVHDVVHVVPHQWDQG63(3
DQGQHSKHORPHWULFYDOXHVFDQQRWEHXVHGLQWHUFKDQJHDEO\ 'XULHHW
DO
»ïPLFURJOREXOLQ )RU00VWDJLQJ $SSHQGL[ QRWIRUDVVHVVLQJUHVSRQVH
6NHOHWDOVXUYH\ $VNHOHWDOVXUYH\XVLQJ[UD\VDQGRURWKHUFOLQLFDOO\DSSURSU LDWH
LPDJLQJPRGDOLWLHV>05,ZKROHERG\&7RU3(7&7@DV
GHWHUPLQHGE\WKH,QY HVWLJDWRUZLOOEHSHUIRUPHGZLWKLQGD\VRI
&'DQGDVFOLQLFDOO\LQGLFDWHGSHU,QYHVWLJDWRUGLVFUHWLRQ GXULQJ
WKHVWXG\7KHVNHOHWDOVXUYH\ VKRXOGLQFOXGHDODWHUDOUDGLRJUDSKRI
VNXOODQWHULRSRVWHULRUDQGODWHUDOYLHZVRIWKHVSLQHDQG
DQWHULRSRVWHULRUYLHZVRIWKHSHOYLVULEVIHPRUDDQGKXPHUL
5HVXOWVZLOOEHUHDGE\WKHORFDOODERUDWRU\ 
,IO\WLFERQHOHVLRQVRUSODVPDF\WRPDVDUHREVHUYHGDW6FUHHQLQ J
WKHLUQXPEHUDQGVL]HVKRXOGEHUHFRUGHGLQWKH&5)%RQHOHVLR QV
DQGRUSODVPDF\WRPDV VHHQDWEDVHOLQHVKRXOGEHUH DVVHVVHGGXULQJ
WKHVWXG\DWDIUHTXHQF\GHWHUPLQHGE\WKH,QYHVWLJDWRU XVLQJWKH
VDPHLPDJLQJPRGDOLW\WKDWZDVXVHGDW6FUHHQLQJ
x)RUSDWLHQWVZLWKRXWVRIWWLVVXHSODVPDF\WRPDVLHERQH
OHVLRQVRQO\VNHOHWDOVXUYH\E\;UD\VRUORZ GRVH&7
VKRXOGEHSHUIRUPHG&RQWUDVWLVQRWUHTXLUHG
x)RUSDWLHQWVZLWKVRIWWLVVXHSODVPDF\WRPDVVNHOHWDOVXUYH\
E\;UD\VRUORZ GRVH&7VKRXOGEHSHUIRUPHGFRQWUDVW
QRWUHTXLUHGDQGLQDGGLWLRQ05,RU&7RU3(7&7
XVXDOO\UHTXLULQJFRQWUDVWHQKDQFHPHQWVKRXOGEH
SHUIRUPHG
&OLQLFDOSODVPDF\WRPD ,ISODVPDF\WRPDVDUHGHWHFWHGDW6FUHHQLQJE\SK\VLFDOH[DPLQDWLRQSDOSDWLRQWKH\VKRXOGEHFRXQWHGDQGPHDVXUHGSHU,0:*JXLGHOLQHVDQGUHFRUGHGDQGWKHQ
UHDVVHVVHG DQGUHFRUGHG
GXULQJV\PSWRPGLUHFWHGSK\VLFDO H[DPLQDWLRQV


CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH3URFHGXUH 1RWHV



 








)$&700 6HH6HFWLRQ  
 0XOWLSOH0\HORPD5HVSRQVH&ULWHULD
,0:*FULWHULD Kumar 2016 ZLOOEHXVHGLQWKLVVWXG\WRDVVHVVUHVSRQVH$OO00
DVVHVVPHQWVDUHUHTXLUHGDWHDFKWLPHSRLQWDVRXWOLQHGLQWKLV SURWRFRO7DEOH
5HVSRQVHZLOOEHDVVHVVHGSHU,0:*UHVSRQVHFULWHULDIRUPXOWLS OHP\HORPD $SSHQGL[ 
7ZRFRQVHFXWLYHVDPSOHVDUHUHTXLUHGWRFRQILUPWKHUHVSRQVH 7KHWLPHSHULRGEHWZHHQ
VDPSOHVPD\EHGLVFXVVHGZLWKWKH0HGLFDO0RQLWRUDQGFDQRFFXU RQWKHVDPHGD\DVORQJ
DVWKHVDPSOHVDUHDQDO\]HGVHSDUDWHO\
x&RPSOHWHUHVSRQVH&5
x6WULQJHQWFRPSOHWHUHVSRQVHV&5
x9HU\JRRGSDUWLDOUHVSRQVH9*35
x3DUWLDOUHVSRQVH35
x0LQLPDOUHVSRQVH05
x6WDEOHGLVHDVH6'
x3URJUHVVLYHGLVHDVH3'CCI
CCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-[ADDRESS_728994] 5 minutes prior to the ECG recording. The Investigator will interpret the ECG using one 
of the following categories: normal, abnormal but not clinicall y significant, or abnormal and 
clinically significant. The date and time the ECG was performed  and the following 
parameters will be recorded in the eCRF: heart rate, PR interval, QT interval, QRS interval, 
and QT corrected (QTc) using Bazett‚Äôs formula or calculated by [CONTACT_148997] ( Bazett 1920, Fridericia 1920 ). If Bazett correction is entered by [CONTACT_779], the 
Fridericia corrected QTc inte rval (QTcF) will be derived using the formula: QT/(RR^[1/3]), 
where RR = 60/heart rate.
9.4.2. Ophthalmic Exam
A full ophthalmic examination w ill be performed prior to the pa tient's first dose of selinexor. 
Prior to dilation, best corrected visual acuity (Snellen‚Äôs Equivalent based on either Snellen 
chart or ETDRS chart), slit la mp examination including tonometr y, following dilation, and 
fundoscopy. If a cataract is seen during the examination, the cataract will be graded as 
follows:
xLens Opacities Classification System III (LOCS III) ‚ÄìPatients who enrolled in 
this study under the original P rotocol or Protocol Amendments [ADDRESS_728995] 
been detected to date, if catarac ts are detected, they will be graded according to 
the Grade 1-4 scale.
xAmerican Optometric Association (AOA) Cataract Grading System ‚ÄìStarting 
with Protocol Amendment 3, new patients will be evaluated using  the AOA 
grading system until they complete the study. This system is modified from the Optometric Clinical Practice Guideline: Care of the Adult Patie nt with Cataract, 
which is available on the AOA website ( www.aoa.org )(See Appendix 5.)
9.4.3. Clinical Laboratory Assessments
The following clinical laboratory tests should be performed as indicated in Table 1.
xHematology (blood sample: ethylenediaminetetraacetic acid [EDTA]) tests 
including hemoglobin, hematocrit, mean corpuscular volume, mean  corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration, white bl ood cell 
(WBC) count, WBC differential, red blood cell count, lymphocyte s, monocytes, 
neutrophils, eosinophils, basophils, and platelets. WBC differe ntial may be 
automated or manual as per institutional standards.
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJHx6HUXP&KHPLVWU\EORRGVDPSOHVHUXP
&RPSOHWH6HUXP&KHPLVWU\ZLOOLQFOXGHVRGLXPSRWDVVLXPFKORUL GH
ELFDUERQDWH+&2 EORRGXUHDQLWURJHQ%81FUHDWLQLQHJOXFRVH
FDOFLXPSKRVSKDWHPDJQHVLXP$/7$67DONDOLQHSKRVSKDWDVH /'+WRWDO
SURWHLQDOEXPLQDP\ODVHOLSDVHFUHDWLQHNLQDVHDQGXULFDFL G
/LPLWHG6HUXP&KHPLVWU\ZLOOLQFOXGHVRGLXPSRWDVVLXPFKORULG H
ELFDUERQDWH%81FUHDWLQLQHJOXFRVH$/7$67DONDOLQHSKRVS KDWDVHWRWDO
ELOLUXELQDQG/'+XQOHVVRWKHUZLVHFOLQLFDOO\LQGLFDWHG
7K\URLGVWLPXODWLQJKRUPRQH76+
x&RDJXODWLRQSDUDPHWHUVZLOOLQFOXGHSURWKURPELQWLPH37LQWH UQDWLRQDO
QRUPDOL]DWLRQUDWLR,15DQGDFWLYDWHGSDUWLDOWKURPERSODVWLQ WLPHD377
x8ULQDO\VLVZLOOLQFOXGHDSSHDUDQFHFRORUXULQHELOLUXELQJOX FRVHKHPRJORELQ
NHWRQHVS+SURWHLQVSHFLILFJUDYLW\DQGXURELOLQRJHQ0LFUR VFRS\ZLOORQO\EH
SHUIRUPHGLIFOLQLFDOO\LQGLFDWHG
%ORRGFKHPLVWU\ZLOOEHDQDO\]HGDWHDFKVWXG\VLWHE\DFHUWLI LHGORFDOODERUDWRU\DQGD
UHSRUWRIWKHODERUDWRU\YDOXHVZLOOEHSURYLGHGWRWKH,QYHVWL JDWRU7KH,QYHVWLJDWRURU
GHVLJQHHZLOOUHYLHZWKHODERUDWRU\UHVXOWVDQGDVVHVVWKHFOLQ LFDOVLJQLILFDQFHRIDOODEQRUPDO
YDOXHV$SSURSULDWHDFWLRQZLOOEHWDNHQIRUDQ\FOLQLFDOO\VLJ QLILFDQWDEQRUPDOYDOXHV
9DOXHVZLOOEHGRFXPHQWHGRQWKHODERUDWRU\UHSRUWXQWLOVWDELO L]HGRUWKHODERUDWRU\YDOXH
UHWXUQVWRDFOLQLFDOO\DFFHSWDEOHUDQJHUHJDUGOHVVRIUHODWLR QVKLSWRVWXG\PHGLFDWLRQRU
EDVHOLQH$Q\ODERUDWRU\YDOXHWKDWUHPDLQVDEQRUPDODWWKH(R7 9LVLWDQGWKDWLVFRQVLGHUHG
FOLQLFDOO\VLJQLILFDQWZLOOEHIROORZHGDFFRUGLQJWRDFFHSWHGP HGLFDOVWDQGDUGVIRUXSWR
GD\VRUXQWLOUHVROXWLRQRIWKHDEQRUPDOLW\RUUHWXUQWREDV HOLQH7R[LFLW\ZLOOEHDVVHVVHG
XVLQJ&7&$(YHUVLRQ
3UHJQDQF\7HVWLQJ
)RUIHPDOHVRIFKLOGEHDULQJSRWHQWLDODQHJDWLYHVHUXPKXPDQF KRULRQLFJRQDGRWURSLQK&*
SUHJQDQF\WHVWPXVWEHREWDLQHGZLWKLQGD\VEHIRUHWKHILUVW GRVHRIVWXG\WUHDWPHQW7HVW
VHQVLWLYLW\IRUK&*PXVWEH¬ï P,8P/3UHJQDQF\WHVWLQJVHUXPK&*RUXULQHLVDOVR
UHTXLUHGIRUIHPDOHVRIFKLOGEHDULQJSRWHQWLDOSULRUWRGRVLQJ RQ'D\RI &\FOHV¬ïGXULQJ
WKHVWXG\DQGDWWKH(R79LVLWVHUXPK&*
3UHJQDQF\WHVWLQJPD\DOVREHSHUIRUPHGDVFOLQLFDOO\LQGLFDWHG GXULQJWKHVWXG\
3KDUPDFRNLQHWLF 3URFHGXUHV
%ORRG6DPSOLQJDQG3URFHVVLQJ
$VRISURWRFROYHUVLRQWKHVHVDPSOHVDUHQRORQJHUFROOHFW HG
3KDUPDFRNLQHWLF(QGSRLQWV
3KDUPDFRNLQHWLFDQDO\VLVRIVHOLQH[RUSODVPDOHYHOVZLOOEHSHU IRUPHGRQEORRGVDPSOHV
IURPSDWLHQWVHQUROOHGLQ3DUWRQO\3KDUPDFRNLQHWLFHQGSRLQW VWREHHYDOXDWHGLQFOXGH
VHOLQH[RUPD[LPXPSODVPDFRQFHQWUDWLRQDQGWLPHWRSHDNSODVPD FRQFHQWUDWLRQCCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH3ODVPDVDPSOHVZLOOEHDQDO\]HGYLDDYDOLGDWHGKLJKSHUIRUPDQF HOLTXLGFKURPDWRJUDSK\
WDQGHPPDVVVSHFWURPHWU\+3/&0606PHWKRGIRUSODVPDVHOLQH[ RU6HOLQH[RU
FRQFHQWUDWLRQGDWDZLOOEHDQDO\]HGLQDQRQOLQHDUPL[HGHIIHF WVSRSXODWLRQ3.PRGHOZLWK
SRWHQWLDOFRYDULDWHVLQFOXGLQJEXWQRWOLPLWHGWRDJHERG\Z HLJKWJHQGHUGLVHDVHVWDWH
EDVHOLQHKHSDWLFRUUHQDOIXQFWLRQDQGFRQFRPLWDQWPHGLFDWLRQV  
'HWDLOVRIWKHSRSXODWLRQ3.DQDO\VLVLQFOXGLQJVRIWZDUH
SRVWSURFHVVLQJDQGVWDWLVWLFDODQDO\VLVZLOOEHRXWOLQHGLQD VHSDUDWH'DWD$QDO\VLV3ODQWR
EHFRPSOHWHGSULRUWRGDWDEDVHORFN
















CCI
CCI
CCICCI
CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH











 (IILFDF\3URFHGXUHV
 2EMHFWLYH'LVHDVH$VVHVVPHQW
3URFHGXUHVIRUFRQILUPLQJUHVSRQVHDUHOLVWHGLQ 7DEOH
 (IILFDF\(QGSRLQWV
7KHSULPDU\HIILFDF\REMHFWLYHHQGSRLQWVDUHSURYLGHGLQ6HFWLRQ VHFRQGDU\HIILFDF\
HQGSRLQWVDUHSUHVHQWHGLQ6HFWLRQ 
 5HVSRQVH&ULWHULD
'LVHDVHUHVSRQVHZLOOEHDVVHVVHGXVLQJ,0:* Kumar 2016 7KHUHLVQRPD[LPXP
WUHDWPHQWGXUDWLRQ'LVHDVHUHVSRQVHZLOOEHDVVHVVHGFHQWUDOO\ E\DQLQGHSHQGHQW,5&
6HFWLRQ'HILQLWLRQVRILQGLYLGXDOUHVSRQVHFULWHULDDUHSURYLGHGLQ $SSHQGL[
 4XDOLW\RI/LIH$VVHVVPHQW
+HDOWKUHODWHG4R/DQGSRWHQWLDOIRULPSURYHPHQWRYHUWKHFRXUV HRIWKHVWXG\ZLOOEH
DVVHVVHGE\WKH)$&700SDWLHQWUHSRUWHGRXWFRPHTXHVWLRQQDLUH WKDWLVVSHFLILFDOO\
UHOHYDQWWR00$GGLWLRQDOLQIRUPDWLRQRQWKH)$&700LVSURYLG HGLQ6HFWLRQ 
3DWLHQWVVKRXOGFRPSOHWHWKH)$&700DVVHVVPHQW beforeWKH\XQGHUJRDQ\VWXG\UHODWHG
SURFHGXUHLQFOXGLQJRWKHUVWXG\UHODWHGHYDOXDWLRQVGLVFXVVLR QVZLWKPHGLFDOSHUVRQDO
SK\VLFLDQDQGVWXG\WUHDWPHQWDGPLQLVWUDWLRQCCI
CCICCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 5610. DISCONTINUATION CRITERIA
10.1. Early Discontinuation of the Study
The study may be discontinued at the sole discretion of the Spo nsor for any reason, including 
medical or ethical reasons affecting the continued performance of the study, or difficulties in 
the recruitment of patients. 
The DSMB will inform the sponsor if a safety signal is detected  (see Section 7.2). The 
sponsor, in conjunction with appropriate regulatory authorities , would then decide if the trial 
should be modified or terminated. If this occurs, the sponsor w ill notify IRB/REB/ECs and 
investigators.
10.2. Early Discontinuation of Individual Patients
The Investigator may remove a patient from study treatment at his/her discretion for any of 
the following reasons:
xDisease progression defined according to IMWG for progression o f MM, 
including confirmatory analysis to document progression. Disease progression must be confirmed by [CONTACT_555272](s) or failure to tolerate the study treatment
xPatient decides to discontinue study therapy
xAny medically appropriate reason or significant protocol violat ion, in the opi[INVESTIGATOR_555234] s ource and in the study CRFs, 
including reasons for patient withdrawal and Investigator decis ion to discontinue the patient.
Patients may discontinue study treatment for any reason. Patients who elect to discontinue study treatment should be encouraged to continue in the study so that follow-up information 
on disease progression and survival status may be obtained. How ever, patients may elect to 
withdraw consent and decline further participation in the trial .
11. TREATMENT
Selinexor study medication will be in the form of a coated, imm ediate-release tablet for oral 
administration. Selinexor tablets will be supplied as single-strength (20 mg) tablets in wallet-
size blister packs. Dexamethas one 20 mg will be given with each  dose of selinexor. 
Additional information is provided in Section 11.1.3.
11.1. Dosing and Administration
11.1.1. Dose Modifications
All dosing modifications should be discussed with the study Med ical Monitor prior to 
implementing the dosing change.
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH /DEHOLQJ
$OOGUXJFRQWDLQHUVZLOOEHODEHOHGLQDFFRUGDQFHZLWKFXUUHQW ,QWHUQDWLRQDO&RQIHUHQFHRQ
+DUPRQL]DWLRQ,&+*&3DQGUHJXODWRU\DJHQF\VSHFLILFUHTXLU HPHQWVHJ)'$
0+5$0HGLFDWLRQODEHOVZLOOLQFOXGHWKHPHGLFDWLRQQDPHVWRU DJHFRQGLWLRQVDQGEDWFK
QXPEHUDQGZLOOFRPSO\ZLWKODQJXDJHDQGOHJDOUHTXLUHPHQWVRI WKH86
 'RVLQJ,QIRUPDWLRQ
6HOLQH[RUZLOOEHDGPLQLVWHUHGDVDIL[HGRUDOVHOLQH[RUGRVHR IPJWZLFHZHHNO\HJ
0RQGD\DQG:HGQHVGD\RU7XHVGD\DQG7KXUVGD\HWFRQ:HHNV RIHDFKIRXUZHHN
F\FOH)RUGRVHVRQQRQFOLQLFGD\VWKHSDWLHQWZLOOEHSURYLG HGZLWKGRVHVE\WKHKRVSLWDO
SKDUPDF\WRWDNHKRPH
'H[DPHWKDVRQHPJZLOOEHJLYHQZLWKHDFKGRVHRIVHOLQH[RU )RUSDWLHQWVZLWKSDUWLDO
LQWROHUDQFHWRJOXFRFRUWLFRLGVDVGHWHUPLQHGE\WKH,QYHVWLJDW RUDPLQLPXPGRVHRIPJ
GH[DPHWKDVRQHLVSHUPLWWHG,IDQ\SDWLHQWLVQRWDEOHWRWROHU DWHWKLVGRVHWKHQDSRWHQWLDO
GLVFRQWLQXDWLRQRUIXUWKHUGHFUHDVHLQGRVDJHZRXOGEHDOORZHG DIWHUDGLVFXVVLRQZLWKWKH
0HGLFDO0RQLWRURQDFDVHE\FDVHEDVLV'H[DPHWKDVRQHZLOOEHS URYLGHGWRWDNHKRPHLQ
WKHIRUPRIWDEOHWV
,QVHOHFWFDVHVHJIRUSDWLHQWVVKRZLQJ6'05RU35DQGW ROHUDWLQJWUHDWPHQWSDUWLFXODUO\
ZHOOWKHVHOLQH[RUGRVHPD\EHLQFUHDVHGE\PJDIWHUGLVFX VVLRQZLWKWKHVSRQVRU7KH
GRVHOHYHOIRUDQLQGLYLGXDOSDWLHQWPD\EHHVFDODWHGEDVHGRQ HIILFDF\FRQVLGHUDWLRQVDIWHUD
PLQLPXPRIF\FOHVRIVWXG\WKHUDS\+RZHYHULQQRFDVHPD\W KHGRVHIRUDQ\SDWLHQW
H[FHHGPJP3ULRUWRDQ\SRWHQWLDOGRVHLQFUHDVHWKH%6$IRUWKHSDWLHQW VKRXOGEH
FDOFXODWHG3DWLHQWVZLWKPD\KDYHWKHLUGRVHLQFUHDVHGLILWZR XOGUHVXOWLQDGRVH
!PJP

6HOLQH[RUVKRXOGEHJLYHQZLWKRUZLWKLQPLQXWHVRIVROLG IRRGFRQVXPSWLRQWRRSWLPL]H
WROHUDELOLW\WRJHWKHUZLWKDWOHDVWP/RXQFHVRIIOXLG VZDWHUMXLFHHWF)RUGHWDLOV
RIGUXJIRUPXODWLRQSUHSDUDWLRQDQGDGPLQLVWUDWLRQSOHDVHUH IHUWR$SSHQGL[ .
6HOLQH[RUWDEOHWVVKRXOGEHVZDOORZHGZKROHDQGVKRXOGQRWEHF UXVKHGWRDYRLGLQFUHDVHG
ULVNRIGHUPDWRORJLFWR[LFLW\LIWKHSRZGHUFRPHVLQFRQWDFWZL WKVNLQ
&RPSOLDQFHWRVWXG\WUHDWPHQWZLOOEHDVVHVVHGE\WKH,QYHVWLJD WRURUGHOHJDWHDWHDFKSDWLHQW
YLVLWDQGUHFRUGHGLQVRXUFHGRFXPHQWVDIWHUGLVFXVVLRQZLWKWK HSDWLHQWDQGGUXJ
DFFRXQWDELOLW\7KHGDWHZLOOEHUHFRUGHGDVSHUVWXG\GUXJVFK HGXOH7KH,QYHVWLJDWRURUWKH
GHVLJQHHZLOODFFRXQWIRUWKHQXPEHURIWDEOHWVGLVSHQVHGDJDLQ VWWKRVHUHWXUQHGE\WKH
SDWLHQW$Q\GHYLDWLRQVDQGPLVVHGGRVHVZLOOEHUHFRUGHGLQWK HH&5)DQGGUXJ
DFFRXQWDELOLW\ORJVIRUYHULILFDWLRQZLWKWKHUHDVRQV7KH,QYH VWLJDWRUGHVLJQHHZLOODWWHPSW
WRHQVXUHFRPSOHWHFRPSOLDQFHZLWKWKHGRVLQJVFKHGXOHE\SURYL GLQJWLPHO\LQVWUXFWLRQVWR
WKHSDWLHQWV
3DWLHQWVPD\UHFHLYHDVWXG\WUH DWPHQWKROLGD\DWDQ\WLPHGXUL QJWKHIRXUZHHNF\FOHV
IROORZLQJSULRUFRQVXOWDWLRQZLWKWKH0HGLFDO0RQLWRUCCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 5811.1.4. Dose Modifications for Patients with VGPR
In an effort to improve long-term disease control and tolerability, this protocol allows for 
dose reductions in patients with very good anti-tumor activity of selinexor. Thus, for patients 
who achieve ‚â• VGPR for ‚â• 6 mont hs and who, in the opi[INVESTIGATOR_555235](s), the following modifications may be cons idered: (a) The dose of 
dexamethasone may be reduced by 40% or (b) the dose of selinexo r may be reduced by 
20 mg or (c) the frequency of selinexor may be reduced to once wee kly, after consultation 
with the Medical Monitor. In general, dexamethasone should always be given on the day(s) of selinexor dosing. Patients whose doses are reduced under thi s schema should have 
appropriate MM markers monitored a t least every two weeks (e.g. , with FLC) so that dose 
may be re-escalated to their initial dose if evidence of progre ssion occurs. These monitoring 
studies may be done at local laboratories. 
11.1.5. Dose Reduction Guidelines for Toxicity
Toxicity will be graded according to CTCAE v.4.03 criteria; the  therapy modifications 
described below are applied according to this severity grading.
If more than one type of toxicity occurs concurrently, the most  severe grade will determine 
the modification.
Re-escalation of the study dru g is allowed as outlined in the s ections that apply for the 
specific toxicity. If drug-related toxicity requires a treatmen t delay of more than [ADDRESS_728996] be documented in the eCRF, including the 
respective reason.
Based on observations from the ongoing Phase 1 studies in patie nts with advanced 
hematological and solid tumors, selinexor shows a reasonably wi de therapeutic range, with 
activities from ~6 mg/m
2to ‚â•60 mg/m2. Therefore, in order to optimiz e specific anti-tumor 
activity and the patient‚Äôs tolerability, dose reductions and/or schedule modifications will be 
allowed as described in Table 5 andTable 6. Patients should also be tre ated aggressively with 
supportive care to reduce toxicities.
For all Grade ‚â•3 hematological or non-hematological AEs that are NOT selinexor related, 
after consultation with the Medical Monitor and at the discretion of the Investigator, 
selinexor  dosing may be maintained, provided that the patient can continu e to take the agent 
by [CONTACT_1966]. 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 59Table 5: Pre-specified Dose/Schedule Modifications for Adverse Ev ents Related to 
Study Drug 
Dose 
LevelSelinexor Dosing
1 100 mg BIW (total dose of 200 mg per week) 
Starting 
Dose0 80 mg BIW (total of 160 mg per week)
Dose 
Reductions-1 60 mg BIW (120 mg total per week)
-2100 mg total per week: 100 mg one  day OR divided as 60 mg and 40 mg on separate 
days
-3 80 mg total per week: 80 mg one day OR divided as 40 mg per day on 2 days
-460 mg total per week: 60 mg one day OR divided as 40 mg one day  and 20 mg on 
another day 
-5 40 mg total per week: 40 mg one day OR divided as 20 mg per day  on separate days
Abbreviation: BIW = twice weekly
Table 6: Supportive Care and Dose Adjustment Guidelines 
Please note the following recommendations:
xAfter consultation with the Medical Monitor and at the discreti on of the 
Investigator, selinexor dosing may be maintained for all hematol ogical or non-
hematological AEs that are NOT related to selinexor.
xFor all selinexor-related AEs, if the prescribed dose reduction s/interruptions in
Table 8 result in a stabilization of ‚â• 4 weeks, a re -escalation may be considered 
after approval from the Medical Monitor.
Toxicity and Intensity Selinexor Dose Modification
Fatigue (common)
Grade 1 or
Grade 2 lasting ‚â§ 7 daysMaintain dose. Rule out other ca uses of fatigue, particularly dehydration and 
anemia.  If found to be anemic, consider transfusing for hemogl obin < 8 g/dL. 
Institute supportive care medica tions per institutional guideli nes and NCCN 
CPGO.
Patients with significant fatigue after several doses of seline xor may have an 
ongoing anti -tumor response.  If fatigue is significant, consider assessment  of 
tumor response as part of the patient‚Äôs evaluation.
Grade 2 lasting > 7 days or
Grade 3Rule out other causes of fatigue, particularly dehydration and anemia.  If found 
to be anemic, consider transfusin g for hemoglobin < 8 g/dL. Ins titute 
supportive care medications per ins titutional guidelines and NC CN CPGO.
Interrupt selinexor dosin g until resolved to Grade [ADDRESS_728997] occurrence, restart selinexor at current dose. 
For ‚â• second occurrence ,reduce selinexor by 1 dose level when resuming 
selinexor. (Table 5 ). 
Patients with significant fatigue after several doses of seline xor may have an 
ongoing anti -tumor response.  If fatigue is significant, consider assessment  of 
tumor response as part of the patient‚Äôs evaluation.
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 60Toxicity and Intensity Selinexor Dose Modification
Anorexia or Weight Loss
Grade 1 anorexia 
Grade 1 weight lossGrade 2 anorexiaMaintain dose. Rule out other causes and consider a repeat nutr itional 
consultation and nutritional supplements (e.g., Ensure ¬Æ, Boost ¬Æ, etc.).
Institute supportive care medica tions per institutional guideli nes and NCCN 
CPGO.
Grade 2 weight loss
Grade ‚â• 3 anorexia or 
weight lossRule out other causes and consider a repeat nutritional consult ation and 
nutritional supplements (e.g., Ensure ¬Æ, Boost ¬Æ, etc.). Institute supportive 
care medications per institutional guidelines and NCCN CPGO.
Interrupt dosing with selinexor until improves to Grade 1 or ba seline and 
weight stabilizes, then reduce selinexor by 1 dose level when r esuming 
selinexor ( Table 5 ). 
Consult Medical Monitor to discuss persistent or ‚â• second occurrence of 
weight loss after stabilization.
Nausea, Acute (common)
Grade 1 or 2
(If intolerable or persistent 
Grade 2 not responsive to 
supportive care, follow guidelines for Grade 3 below)Maintain dose. Rule out other causes of nausea. Implement addit ional 
anti-nausea medications to supplement the protocol-required 5-HT3 
antagoni sts using institutional guidelines and NCCN CPGO.  
Grade 3Rule out other causes of nausea. Implement additional anti -nausea medications 
to supplement the protocol -required 5-HT3 antagonists using institutional 
guidelines and NCCN CPGO.  
Interrupt selinexor dosing until resolved t o Grade ‚â§ 2 or baseline and re start 
selinexor at 1 dose level lower (Table 5 ).
Hyponatremia (common)
Grade 1 (sodium levels 
< Normal to 130 mmol/L)Maintain dose. Rule out other causes including drug (e.g., diur etic) effects. Be 
certain that reported sodium lev el is corrected for concurrent hyperglycemia 
(serum glucose > 150 mg/dL). 
Treat hyponatremia per institutiona l guidelines including dietary review. 
Consider addition of salt tablets to patient‚Äôs diet.
Grade 3 with sodium 
levels 120 to <130 mmol/L 
without symptoms Correct for hyperglycemia as outlined under Grade 1. Treat hypo natremia per 
institutional guideline s. If (corrected) sodium is Grade ‚â§ 3 and continues to be 
asymptomatic, then patient may continue current dosing provided  that 
intravenous saline a nd/or salt tablets (1 -3 times daily) are provided.
If Grade 3 is persistent or w orsens or does not respond to treatment, hold 
selinexor until resolved to Grade 1 or baseline and reduce selinexor by 1 dose 
level.
Grade 3 with sodium 
levels 120 to <130 mmol/L 
with symptoms or Grade 4 
(<120 mmol/L)Correct for hyperglycemia as outlined under Grade 1. Treat hypo natremia per 
institutional guidelines. Delay/hold selinexor until resolved to Grade 1 or 
baseline then reduce selinexor dose by 1 level ( Table 5 ).
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH7R[LFLW\DQG,QWHQVLW\ 6HOLQH[RU'RVH0RGLILFDWLRQ
'LDU[LOCATION_006]HDFRPPRQ
*UDGH 0DLQWDLQVHOLQH[RUGRVLQJ5XOHRXWRWKHUFDXVHVLQFOXGLQJGUXJ HIIHFWV
,QLWLDWHDQWL GLDU[LOCATION_006]HDOWUHDWPHQWSHULQVWLWXWLRQDOJXLGHOLQHV
*UDGH 5XOHRXWRWKHUFDXVHVLQFOXGLQJGUXJHIIHFWV7UHDWSHULQVWLW XWLRQDOJXLGHOLQHV
,QWHUUXSWVHOLQH[RUXQWLOUHVROYHGWR*UDGHRUEDVHOLQH
)RUILUVWRFFXUUHQFHUHVWDUWVHOLQH[RUDWFXUUHQWGRVH
)RU¬ïVHFRQGRFFXUUHQFHUHGXFHVHOLQH[RUE\GRVH OHYHO7DEOH
*UDGHRU 'HOD\VHOLQH[RUXQWLOUHVROYHGWR*UDGHDQGWKHSDWLHQWLVFOL QLFDOO\VWDEOH
WKHQUHGXFHVHOLQH[RUGRVHE\GRVHOHYHO 7DEOH
7KURPERF\WRSHQLD
*UDGHRU 0DLQWDLQGRVH5XOHRXWRWKHUFDXVHVLQFOXGLQJGUXJHIIHFWV
*UDGH
7KURPERF\WRSHQLDZLWKRXW
EOHHGLQJ&RQVLGHUSODWHOHWJURZWKIDFWRUVSHULQVWLWXWLRQDOJXLGHOLQHV
'RQRWLQWHUUXSWKROGVHOLQH[RUEXWGRVHUHGXFHDVEHORZ
)RUSDWLHQWVRQPJ%,:VWDUWLQJGRVH'RVH/HYHO
'RQRWKROGVHOLQH[RU
'RVHUHGXFHWRPJWRWDOGRVHSHUZHHN'RVH/HYHO ¬±EXWGRVHGDW
4:VFKHGXOHXQWLOUHFRYHU\WR*UDGH ¬îRUEDVHOLQHDQGWKHQPD\UHVXPH
WKHWRWDOZHHNO\GRVHVFKHGXOHGDV%,:PJGLYLGHGDVPJ DQG
PJ
)RUSDWLHQWVRQDOORWKHUGRVHOHYHOV
'RQRWKROGVHOLQH[RU
'RVHUHGXFHE\RQHGRVHOHYHOEXWGRVHWKHSDWLHQWDWWKHWRWDO ZHHNO\GRVH
DV4:XQWLOIXUWKHUUHFRYHU\WR*UDGH ¬îRUEDVHOLQHDQGWKHQUHVXPHWKH
WRWDOZHHNO\GRVHVFKHGXOHGDV%,:
)RUH[DPSOHSDWLHQWVZKRZHUHRQGRVHOHYHO ¬±PJ4:RUGLYLGHG
DVPJDQGPJDQGQHHGWRGHHVFDODWHWRGRVHOHYHO ¬±PJWRWDO
SHUZHHNVKRXOGEHGRVHGDWPJ4:XQWLOSODWHOHWVUHFRYHU WR
*UDGH¬îRUEDVHOLQHDQGWKHQPD\UHVXPHWKHVDPHWRWDOZHHNO\GRVHRI 
PJWRWDODVDGLYLGHGVFKHGXOHRIPJ%,:

)RU¬ïVHFRQGRFFXUUHQFHRUZRUVHQLQJWKURPERF\WRSHQLDGHVSL WHPHDVXUHV
DERYH+ROGVHOLQH[RUXQWLOUHFRYHU\WR *UDGH¬îRUEDVHOLQHDQGUHVXPHDW
GRVHOHYHOORZHUGRVHGDW4:VFKHGXOH
CCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH7R[LFLW\DQG,QWHQVLW\ 6HOLQH[RU'RVH0RGLILFDWLRQ
*UDGH
7KURPERF\WRSHQLDZLWKRXWEOHHGLQJ

6WURQJO\FRQVLGHUSODWHOHWJURZWKIDFWRUVDQGWUDQVIXVHSHUFOL QLFDO
SUDFWLFHLQVWLWXWLRQDOJXLGHOLQHV 
'HOD\RUKROGVHOLQH[RUGRVLQJXQWLOSODWHOHWVUHFRYHUWR*UDGH ¬îDQGVHH
EHORZ
)RUSDWLHQWVRQPJ%,:VWDUWLQJGRVH'RVH/HYHO 
+ROGVHOLQH[RUXQWLOUHFRYHU\WR*UDGH¬îWKHQGRVHUHGXFHWR PJ
WRWDOGRVHSHUZHHN'RVH/HYHOEXWGRV HGDW4:VFKHGXOHXQWLOIXUWKHU
UHFRYHU\WR*UDGH ¬îRUEDVHOLQHDQGWKHQPD\UHVXPHWKHWRWDOZHHNO\
GRVHVFKHGXOHGDV%,:PJGLYLGHGDVPJDQGPJ
)RUSDWLHQWVRQDOORWKHUGRVHOHYHOV 
+ROGVHOLQH[RUXQWLOUHFRYHU\WR*UDGH¬îWKHQGRVH UHGXFHE\RQHGRVH
OHYHOEXWGRVHWKHSDWLHQWDWWKHWRWDOZHHNO\GRVHDWWKH4:V FKHGXOHXQWLO
IXUWKHUUHFRYHU\WR*UDGH ¬îRUEDVHOLQHDQGWKHQPD\UHVXPHWKHWRWDO
ZHHNO\GRVHVFKHGXOHGDV%,: )RUH[DPSOHSDWLHQWVZKRZHUHRQGRVH
OHYHO¬±PJ4:RUGLYLGHGDVPJDQGPJDQGQHHGWRGH
HVFDODWHWRGRVHOHYHO ¬±PJWRWDOSHUZHHNVKRXOGEHGRVHGDWPJ
4:XQWLOSODWHOHWVUHFRYHUWR*UDGH ¬îRUEDVHOLQHDQGWKHQPD\UHVXPH
WKHVDPHWRWDOZHHNO\GRVHRIPJWRWDODVDGLYLGHGVFKHGXO HRIPJ
%,:

)RU¬ïVHFRQGRFFXUUHQFHRUZRUVHQLQJWKURPERF\WRSHQLDGHVSLWHPHDVXUH V
DERYH+ROGVHOLQH[RUXQWLOUHFRYHU\WR*UDGH ¬îRUEDVHOLQHDQGUHVXPHDW
GRVHOHYHOORZHUGRVHGDW4:VFKHGXOH


,IWKHRFFXUUHQFHIDOOVRQ'D\RIDF\FOHGHOD\WKHVWDUW RIWKHF\FOHDQG
FKHFNSODWHOHWFRXQWVZHHNO\XQWLOUHFRYHU\WR*UDGH dDQGIROORZWKH
JXLGHOLQHVDERYH 


 




*UDGH¬ï
7KURPERF\WRSHQLDZLWKEOHHGLQJ

'HOD\KROGGRVLQJXQWLOWKHEOHHGLQJKDVVWRSSHGDQGWKHSDWLHQ WLVFOLQLFDOO\
VWDEOH:KHQUHVXPLQJVHOLQH[RUVHHEHORZ 
)RUSDWLHQWVRQPJ%,:VWDUWLQJGRVH'RVH/HYHO 
8SRQUHFRYHU\WR*UDGH¬îRUEDVHOLQHGRVHUHGXFHWRPJW RWDOGRVH
SHUZHHN'RVH/HYHOEXWGRVHGDWWKH4:VFKHGXOHXQWLOIXU WKHU
UHFRYHU\WR*UDGH ¬îDQGWKHQPD\UHVXPHWKHWRWDOZHHNO\GRVH
VFKHGXOHGDV%,:PJGLYLGHGDVPJDQGPJ
)RUSDWLHQWVRQDOORWKHUGRVHOHYHOV 
8SRQUHFRYHU\WR*UDGH¬îRU EDVHOLQHGRVHUHGXFHE\RQHGRVHOHYHOEXW
GRVHWKHSDWLHQWDWWKHWRWDOZHHNO\GRVHDWWKH4:VFKHGXOHXQ WLOIXUWKHU
UHFRYHU\WR*UDGH ¬îRUEDVHOLQHDQGWKHQPD\UHVXPHWKHWRWDOZHHNO\
GRVHVFKHGXOHGDV%,:
)RUH[DPSOHSDWLHQWVZKRZHUHRQGRVHOHYHO ¬±PJ4:RUGLYLGHG
DVPJDQGPJDQGQHHGWRGHHVFDODWHWRGRVHOHYHO ¬±PJWRWDO
SHUZHHNVKRXOGEHGRVHGDWPJ4:XQWLOSODWHOHWVUHFRYHU WR
*UDGH¬îRUEDVHOLQHDQGWKHQPD\UHVXPHWKHVDPHWRWDOZHHNO\GRVHRI 
PJWRWDODVDGLYLGHGVFKHGXOHRIPJ%,:
CCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH7R[LFLW\DQG,QWHQVLW\ 6HOLQH[RU'RVH0RGLILFDWLRQ


,IWKHRFFXUUHQFHIDOOVRQ'D\RIDF\FOHGHOD\WKHVWDUW RIWKHF\FOHDQG
FKHFNSODWHOHWFRXQWVZHHNO\XQWLOWKHEOHHGLQJKDVVWRSSHGUH FRYHU\WR*UDGH
¬îDQGWKHSDWLHQWLVFOLQLFDOO\VWDEOHDQGIROORZWKHJXLGHOLQ HVDERYH


 




1HXWURSHQLD
*UDGHRU1HXWURSHQLD
ZLWKIHYHUIHE ULOH
QHXWURSHQLDRUZLWKRXWIHYHU
,QVWLWXWHFRORQ\VWLPXODWLQJIDFWRUVDQGSURSK\ODFWLFDQWLELRWL FVDV
FOLQLFDOO\LQGLFDWHGSHULQVWLWXWLRQDOJXLGHOLQHV 
,QWHUUXSWVHOLQH[RUDQGFKHFNQHXWURSKLOVZHHNO\XQWLOUHFRYHU\ WR
*UDGH—á RUEDVHOLQHDQGZLWKRXWIHYHULIIHEULOHDQGWKHSDWLHQWLV 
FOLQLFDOO\VWDEOH5HGXFHVHOLQH[RUE\GRVHOHYHOZKHQUHVXPL QJ

,IWKHRFFXUUHQFHIDOOVRQ'D\RIDF\FOHGHOD\VWDUWRIDF \FOHDQGFKHFN
QHXWURSKLOVZHHNO\XQWLOUHFRYHU\ WRGrade—á RUEDVHOLQHDQGZLWKRXW
IHYHULIIHEULOHDQGWKHSDWLHQWLVFOLQLFDOO\VWDEOH5HGXFH VHOLQH[RUE\ 
GRVHOHYHOZKHQUHVXPLQJ
$QHPLD
7UHDWSHULQVWLWXWLRQDOJXLGHOLQHVLQFOXGLQJEORRGWUDQVIXVLRQV DQGRUHU\WKURSRLHWLQV&RQVLGHUWUDQVIXVLQJ
IRUDQ\KHPRJORELQJG/,ISRVVLEOHPDLQWDLQVHOLQH[RUG RVHDVORQJDVSDWLHQWLVFOLQLFDOO\VWDEOHEXW
LIGRVHUHGXFWLRQRULQWHUUXSWLRQLVGHVLUHGGLVFXVVZLWKWKH 0HGLFDO0RQLWRU
2WKHU6HOLQH[RU5HODWHG$GYHUVH(YHQWV 
*UDGHRU 0DLQWDLQGRVH5XOHRXWRWKHUFDXVHV,QLWLDWHWUHDWPHQWDQGR UVWDQGDUG
VXSSRUWLYHFDUHSHULQVWLWXWLRQDOJXLGHOLQHV
*UDGHRU 5XOHRXWRWKHUFDXVHV,QWHUUXSWVHOLQH[RUXQWLOUHFRYHU\WR*U DGH¬îRU
EDVHOLQHDQGUHGXFHVHOLQH[RUE\GRVHOHYHO 
,VRODWHGYDOXHVRI*UDGH ¬ïDONDOLQHSKRVSKDWDVHGR127UHTXLUHGRVH
LQWHUUXSWLRQ'HWHUPLQDWLRQRIOLYHUYHUVXVERQHHWLRORJ\VKRXO GEHPDGH 
DQGHYDOXDWLRQRIJD[COMPANY_003] JOXWDP\OWUDQVIHUDVH
QXFOHRWLGDVHRURWKHU
OLYHUHQ]\PHVVKRXOGEHSHUIRUPHG
$EEUHYLDWLRQV +7 K\GUR[\WU\SWDPLQH %,: WZLFHZHHNO\1&&1&3*2 1DWLRQDO&RPSUHKHQVLYH&DQFHU 1HWZRUN
&OLQLFDO3UDFWLFH*XLGHOLQHVLQ2QFRORJ\4: RQFHZHHNO\
6HOLQH[RU'RVH5HGXFWLRQIRU'HFUHDVHG*ORPHUXODU)LOWUDWLRQ5D WH*)5
6HOLQH[RULVQRWVLJQLILFDQWO\HOLPLQDWHGE\WKHNLGQH\WKHUHI RUHQRGRVHDOWHUDWLRQRI
VHOLQH[RULVUHTXLUHGZLWKUHQDOG\VIXQFWLRQ&UHDWLQLQHFOHDUD QFHPXVWEH!P/PLQLQ
RUGHUWRLQLWLDWHWKHUDS\ZLWK6G,IFUHDWLQLQHFOHDUDQFHGHFO LQHVGXULQJWUHDWPHQWDQGLV
EHOLHYHGWREHXQUHODWHGWRVHOLQH[RUWKHGRVHRIVHOLQH[RUPD \EHPDLQWDLQHGSURYLGHGWKDW
WKHSDWLHQW¬∂VFRQGLWLRQLVFORVHO\PRQLWRUHG,IFUHDWLQLQHFOH DUDQFHVGHFOLQHWR P/PLQ
DQGWKLVLVIHOWWREHUHODWHGWRVHOLQH[RUWKHQWKHVHOLQH[RU GRVHVKRXOGEHUHGXFHGE\RQH
OHYHO,IFUHDWLQLQHFOHDUDQFHUHWXUQVWR!P/PLQIRUZHH NVWKHQWKHGRVHRIVHOLQH[RU
FDQEHUHWXUQHGWRSUHYLRXVOHYHO,IGLDO\VLVLVLPSOHPHQWHGG XULQJ6GWUHDWPHQWWKHQ6G
VKRXOGDOZD\VEHJLYHQDIWHUGLDO\VLVCCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6HOLQH[RU'RVH$GMXVWPHQWLQWKH6HWWLQJRI,QIHFWLRQ
3DWLHQWVZLWKDFWLYHXQFRQWUROOHGRUVXVSHFWHGLQIHFWLRQVVKRXO GKDYH6GWUHDWPHQWZLWKKHOG
XQWLOWKHLQIHFWLRQKDVFOLQLFDOO\UHVROYHGRUWKHSDWLHQWLVF OLQLFDOO\VWDELOL]HG
'H[DPHWKDVRQHVKRXOGEHDGMXVWHGSHULQVWLWXWLRQDOJXLGHOLQHV DQGDGUHQDOVXSSUHVVLRQ
FRQVLGHUHG$IWHUWKHLQIHFWLRQKDVUHVROYHGFOLQLFDOO\RUWKH SDWLHQW¬∂VFOLQLFDOFRQGLWLRQKDV
VWDELOL]HGWUHDWPHQWZLWKVHOLQH[RUPD\FRQWLQXHDWWKHRULJLQ DOGRVH0LVVHGGRVHVZLOOQRW
EHUHSODFHG3DWLHQWVPD\FRQWLQXHRQDQWLELRWLFVRURWKHUDQWL PLFURELDODJHQWVIRUSURORQJHG
SHULRGVZKLOHUHLQLWLDWLQJWKHLUVHOLQH[RUUHJLPHQDWWKHGLVF UHWLRQRIWKH,QYHVWLJDWRU
&RQGLWLRQV1RW5HTXLULQJ6HOLQH[RU'RVH5HGXFWLRQ
7KHIROORZLQJFRQGLWLRQVDUHH[FHSWLRQVWRWKHGRVHPRGLILFDWLR QJXLGHOLQHV6HOLQH[RUGRHV
QRWQHHGWREHKHOGLQWKHIROORZLQJFDVHV
x$ORSHFLDRIDQ\JUDGH
x(OHFWURO\WHRUVHUXPDQDO\WHHJXUDWHDEQRUPDOLWLHVWKDWD UHUHYHUVLEOHZLWK
VWDQGDUGLQWHUYHQWLRQV
0LVVHGRU9RPLWHG'RVHV
1RWH$PD[LPXPRIGRVHVRIVHOLQH[RUPD\EHJLYHQSHUZHHN 
0LVVHG'RVHV
,IDGRVHZDVPLVVHG WKHVFKHGXOHRIWKDWZHHNVKRXOGEHDOWHUHGWRDFFRPPRGDWHWZ RGRVHV
LQWKDWZHHNZLWKDWOHDVWKRXUVEHWZHHQWZRFRQVHFXWLYHGRV HV
,IDGRVHPXVWEHVNLSSHG HJGXHWRUHFRPPHQGDWLRQRIWUHDWLQJSK\VLFLDQWKHQH[W
GRVHZLOOEHWDNHQDVSHUVFKHGXOH'RVHVVKRXOGQRWEHDGPLQLV WHUHGOHVVWKDQKRXUVDSDUW
DQGDOOPLVVHGDQGGHOD\HGGRVHVVKRXOGEHGRFXPHQWHG
,IDSDWLHQWPLVVHGDIXOORQHRUWZRZHHNSHULRGRIGRVLQJIRU QRQVWXG\GUXJUHODWHGHYHQWV
HJDUHTXLUHGPHGLFDOSURFHGXUHRUDQXQDQWLFLSDWHGSHUVRQD OHPHUJHQF\WKHGD\VPLVVHG
ZLOOEHUHSODFHG)RUH[DPSOHLISDWLHQWPLVVHG&\FOH'D\ WR&\FOH'D\WKHQ
SDWLHQWZLOOVWDUWWKHLUQH[WGRVLQJRQ&\FOH'D\IROORZLQJ WKHEUHDN6LPLODUO\LID
SDWLHQWPLVVHV&\FOH'D\WR&\FOH'D\WKHQWKHSDWLHQ WZLOOVWDUWWKHLUQH[WGRVLQJ
RQ&\FOH'D\,QWKLVIDVKLRQODERUDWRU\DQGUDGLRJUDSKLF DVVHVVPHQWVUHPDLQ
DSSURSULDWHIRUWLPLQJRIWKHDGPLQLVWUDWLRQRIDQWLFDQFHUWKH UDS\
9RPLWHG'RVHV
,IDGRVHLVYRPLWHG¬î KRXURILQJHVWLRQLWZLOOEHUHSODFHG,IYRPLWLQJRFFXUV! KRXU
DIWHUGRVLQJLWZLOOEHFRQVLGHUHGDFRPSOHWHGRVH
'RVH(VFDODWLRQ
,QVHOHFWFDVHVHJIRUSDWLHQWVVKRZLQJVWDEOHGLVHDVHRUS DUWLDOUHVSRQVHDQGWROHUDWLQJ
WUHDWPHQWSDUWLFXODUO\ZHOOWKHVHOLQH[RUGRVHPD\EHLQFUHDV HGE\PJDIWHUGLVFXVVLRQ
ZLWKWKH0HGLFDO0RQLWRU+RZHYHULQQRFDVHPD\WKHGRVHIRU DQ\SDWLHQWH[FHHG
PJP3ULRUWRDQ\SRWHQWLDOGRVHLQFUHDVHWKH%6$IRUWKHSDWLHQW VKRXOGEHFDOFXODWHG
CCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH3DWLHQWVZLOOEH
IROORZHGDVORQJDVSRVVLEOHRUXQWLOGLVHDVHSURJUHVVLRQDQGGH DWK
 6WXG\'UXJ6WRUDJH
6HOLQH[RUWDEOHWVVKRXOGEHVWRUHGLQDORFNHGDQGVHFXUHGDUHD ZLWKDFFHVVUHVWULFWHGWRWKH
VLWHVWDIISKDUPDFLVWRUGHVLJQHHVDWRUEHORZ¬É)¬É&L HURRPRUUHIULJHUDWHG
WHPSHUDWXUH5RRPWHPSHUDWXUHVWRUDJHLVSUHIHUUHG7KHWDEOHW VVKRXOGQRWEHVWRUHGDW
IUHH]HUWHPSHUDWXUHVRUIUR]HQ
6HOLQH[RUWDEOHWVPJZLOOEHVXSSOLHGLQSODVWLFILOPEOLVW HUVZLWKDQDOXPLQXPI[INVESTIGATOR_555236]LQDVHFRQGDU\SDSHUZDOOHWZLWKFKLOGSURRILQJ6H H$SSHQGL[ IRUGHWDLOHG
LQIRUPDWLRQRQVHOLQH[RUSUHSDUDWLRQVWRUDJHVWDELOLW\DQGD GPLQLVWUDWLRQ
'H[DPHWKDVRQHWDEOHWVVKRXOGEHVWRUHGDVUHFRPPHQGHGRQWKHSU RGXFWODEHO
 6WXG\'UXJ$FFRXQWDELOLW\
7KH,QYHVWLJDWRURUGHVLJQHHPXVWPDLQWDLQDQDFFXUDWHUHFRUGR IWKHVKLSPHQWDQG
GLVSHQVLQJRIVWXG\WUHDWPHQWLQFOXGLQJORWNLWQXPEHUVLQD GUXJDFFRXQWDELOLW\ORJ'UXJ
DFFRXQWDELOLW\ZLOOEHQRWHGE\WKHFOLQLFDOUHVHDUFKDVVRFLDWH &5$GXULQJVLWHYLVLWVDQGDW
WKHFRPSOHWLRQRIWKHVWXG\3DWLHQWVZLOOEHDVNHGWRUHWXUQD OOXQXVHGVWXG\WUHDWPHQWDQG
SDFNDJLQJRQDUHJXODUEDVLVDWWKHHQGRIWKHVWXG\RUDWWKH WLPHRIVWXG\WUHDWPHQW
GLVFRQWLQXDWLRQ
$VDSSURSULDWHGXULQJWKHFRXUVHRIWKHVWXG\DQGDWVWXG\FOR VHRXWWKH,QYHVWLJDWRUZLOO
UHWXUQDOOXVHGDQGXQXVHGVWXG\WUHDWPHQWDQGDFRS\RIWKHFR PSOHWHGGUXJDFFRXQWDELOLW\
ORJWRWKH&5$
6HOLQH[RUVKRXOGQRWEHXVHGIRUDQ\SXUSRVHRXWVLGHWKHVFRSH RIWKLVSURWRFROQRUFDQ
VHOLQH[RUEHWUDQVIHUUHGRUOLFHQVHGWRDQ\SDUW\QRWSDUWLFLSD WLQJLQWKHFOLQLFDOVWXG\'DWD
IRUVHOLQH[RUDUHFRQILGHQWLDODQGSURSULHWDU\DQGVKDOOEHPDL QWDLQHGDVVXFKE\WKH
,QYHVWLJDWRUV
7KH,QYHVWLJDWRURUDUHVSRQVLEOHSDUW\GHVLJQDWHGE\WKH,QYH VWLJDWRUPXVWPDLQWDLQD
FDUHIXOUHFRUGRIWKHLQYHQWRU\DQGGLVSRVLWLRQRIXQXVHGPDWHU LDO
$OOGUXJVXSSOLHVSURYLGHGE\.DU\RSKDUP7KHUDSHXWLFV,QFPXVW EHNHSWLQDQDSSURSULDWH
OLPLWHGDFFHVVVHFXUHSODFHXQWLOXVHGRUUHWXUQHGWR.DU\RSKD UP7KHUDSHXWLFV,QFRU
GHVLJQHHIRUGHVWUXFWLRQ'UXJVXSSOLHVZLOOEHFRXQWHGDQGUHF RQFLOHGDWWKHVLWHEHIRUH
EHLQJUHWXUQHG7KHVWXG\VLWHZLOOEHUHTXLUHGWRPDLQWDLQDO RJRIWKHWHPSHUDWXUHZKHUHWKH
VWXG\PHGLFDWLRQLVVWRUHG
 &RQFRPLWDQW7UHDWPHQWV
 5HTXLUHG+7$QWDJRQLVWV
,QRUGHUWRPLQLPL]HQDXVHDXQOHVVFRQWUDLQGLFDWHGDOOSDWLHQ WVPXVWUHFHLYH
K\GUR[\WU\SWDPLQH+7DQWDJRQLVWVRQGDQVHWURQPJRUHTXLY DOHQWVWDUWLQJEHIRUHWKH
ILUVWGRVHRIVHOLQH[RUDQGFRQWLQXHGWZRRUWKUHHWLPHVGDLO\ DVQHHGHG$OWHUQDWLYHDQWL
HPHWLFDJHQWVPD\EHXVHGLIWKHSDWLHQWGRHVQRWWROHUDWH+7 DQWDJRQLVWVCCI
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-[ADDRESS_728998] treatment plan, and required 5-HT3 prophylaxis 
(Section 11.4.1), supportive care including anti-nausea/anti-emetic therapy, a cid suppression 
(proton pump inhibitors [PPI] and/or H2-blockers) and other tre atments may be administered 
as described below:
xAppetite stimulants: megester ol acetate at a dose of 80-400 mg daily. 
xCentrally acting agents: per Nati onal Comprehensive Cancer Netw ork¬Æ[NCCN] 
Clinical Practice Guidelines¬Æfor antiemesis and anorexia/cachexia [palliative 
care])
xNeurokinin [ADDRESS_728999] (NK1R antagonist): aprepi[INVESTIGATOR_053] o r equivalent 
should be considered and will be covered for selected patients who have severe 
nausea and vomiting.
11.4.3. lnfection
Appropriate broad-spectrum intrav enous antibiotics and antifunga l agents should be started 
immediately in patients who develop fever or other signs of sys temic infection. Selinexor 
should be suspended in any patient with Grade 4 infection or cli nical sepsis (in the absence of 
documented infection) until the c ondition is stabilized. Seline xor can then be re-started at the 
same dose.
[IP_ADDRESS]. Other Glucocorticoid Side Effects
The management of common glucocorticoid side effects is well do cumented. Aggressive use 
of proton-pump inhibitors (PPIs), anti-hypertensives and other agents is strongly encouraged 
in order to maintain the use of dexamethasone in combination wi th selinexor in this study.
Patients with documented osteopenia or osteoporosis should continue to take dexamethasonewith selinexor as indicated in the study. Standard precautions such as use of bisphosphonates should be instituted unless contraindicated.
11.4.4. Concomitant Medication and Treatment
Concomitant medication is defi ned as any prescription or over-t he-counter preparation, 
including vitamins, dietary supplements, over-the-counter medic ations, and oral herbal 
preparations. Patients may conti nue their baseline medication(s ). All concomitant 
medication(s) must be reported in the eCRF. Any diagnostic, the rapeutic, or surgical 
procedure performed during the study period should be recorded,  including the dates, 
description of the procedure(s), and any clinical findings, if applicable. 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-[ADDRESS_729000] care. Medica tions to treat concomitant 
diseases like diabetes, hypertension, etc., are allowed.
11.4.5. Restricted Medications 
Medications: Although acetaminophen (paracetamol) use in combination with se linexor 
was restricted in previous selinexor studies based on theoretic al interactions 
with glutathione (GSH), ongoing clinical safety evaluations on the use of 
these drugs together have not shown any significant clinical or laboratory 
abnormalities with doses of acetaminophen up to 1 gram and seli nexor up to 
55 mg/m2(approximately 80-100 mg). Therefore, there are no longer any 
restrictions on the use of acetami nophen or acetaminophen-conta ining 
products in combination with selinexor, EXCEPT on days of selin exor 
dosing, when acetaminophen must not exceed a total daily dose o f 1 gram.
Diet: There are no dietary restrictions on this study. Patients should maintain adequate caloric and fluid intake.
11.4.6. Prohibited Medications
Concurrent 
therapi[INVESTIGATOR_014]: Concurrent therapy with any non-study anticancer therapeutic is  not 
allowed. Other investigational agents should not be used during  the study. 
Use of any immunosuppressive agents during the study must be co nfirmed 
by [CONTACT_1689]. 
.
Medications: Patients should not take glutathione (GSH)-, S-adenosylmethioni ne (SAM)-,
or N-acetylcysteine (NAC)-containing products during this study  as these 
products may enhance the metabolism of selinexor. Please see Appendix [ADDRESS_729001] agree to use 2 methods of 
contraception (1 highly effectiv e and 1 effective) and have a ne gative serum pregnancy test at 
Screening, and male patients must use an effective barrier meth od of contraception if 
sexually active with a female of childbearing potential. 
Highly effective methods include: 
1. Hormonal contraceptives (e.g., c ombined oral contraceptives, patch, vaginal ring, 
injectables, and implants) 
2. Intrauterine device or intrauterine system
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 683. Vasectomy or tubal ligation
Effective methods include: 
1. Barrier methods of contracep tion (e.g., male condom, female c ondom, cervical cap, 
diaphragm, and contraceptive sponge)
Of particular note,
xNo barrier method by [CONTACT_555273] a highly effective standar d of contraception
xThe proper use of diaphragm or cervi cal cap includes use of spe rmicide and is 
considered 1 barrier method.
xThe cervical cap and contraceptive sponge are less effective in parous women.
xThe use of spermicide alone is not considered a suitable barrie r method for 
contraception.
xA combination of male condom with either cap, diaphragm or sponge with 
spermicide (double barrier methods) are also considered accepta ble (i.e., 
effective), but not highly effective, birth control methods.
xMale and female condoms should not be used together as they can  tear or become 
damaged.
Alternatively, the following fulfill the contraception requirem ents:
1. A sexual partner who is permanently surgically sterilized or post-menopausal.
2. Total (true) abstinence (whe n this is in line with the prefer red and usual lifestyle of 
the patient) is an acceptable method of contraception. Note: Pe riodic abstinence (e.g., 
calendar, ovulation, symptothermal, and post-ovulation methods)  and withdrawal are 
not acceptable methods of contraception.
The methods of acceptable contraception must be explained to bo th male and female 
potential patients. In order to be eligible for the study, patients must agree to use the methods 
of birth control described above throughout the study and for [ADDRESS_729002] 
dose of study treatment at the time of consent for the study.
Please see Section 4.4.1 for additional safety information related to pregnancy.
11.4.8. Radiation Treatment
If clinically indicated, palliative radiation therapy to non-ta rget lesions is permitted but study 
drug should be held for ‚â• 1 day before the start of palliative radiation therapy and ‚â• [ADDRESS_729003] the patient on study medication self-administration.
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729004] regardless of a caus al relationship with this 
treatment. An AE can therefore be any unfavorable sign and unin tended sign (including an 
abnormal laboratory finding), symptom, or disease temporarily associated with the use of a study drug, whether or not related to the study drug. 
Any treatment-emergent abnormal laboratory result or test resul t (e.g., PE, ECG, Echo, 
vitals, etc.), which is clinically significant, (i.e., meets on e or more of the conditions listed 
below), should be recorded as a single diagnosis on the AE page  in the eCRF:  
1. Accompanied by [CONTACT_4659]  
2. Leading to a change in study medication (e.g., dose modificatio n, interruption or 
permanent discontinuation)  
3. Requiring a change in concomitant therapy (e.g., addition of, i nterruption of, 
discontinuation of, or any other change in a concomitant medica tion, therapy or 
treatment) 
It is the responsibility of the Investigator to document all AE s that occur during the study. 
AE information will be elicited by [CONTACT_99020] a non-lea ding question, for example, 
‚ÄúHave you experienced any new or changed symptoms since we last  asked/since your last 
visit?‚Äù AEs should b e reported on the appropri ate page of the eCRF. 
AEs should be reported for thei r actual grade and duration. 
The term ‚Äúsevere‚Äù is used to describe the intensity of an AE; t he event itself could be of 
relatively minor clinical significance (e.g., ‚Äòsevere‚Äô he adache). This is not the same as 
‚Äúserious.‚Äù  Seriousness of AEs is based on the outcome of an AE and usually associated with 
events that pose a threat to a patient‚Äôs life or functioning.  
The severity of the AE will be graded according to the CTCAE Gr ading Scale (see the 
CTCAE web page at http://ctep.cancer.gov  for details). For AEs not covered by [CONTACT_3989], the 
severity will be characterized as ‚Äúmild,‚Äù ‚Äú moderat e,‚Äù or ‚Äúsevere‚Äù according to the following 
definitions: 
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 70xMild events are usually transient and do not interfere with the patient‚Äôs daily 
activities.
xModerate events introduce a low level of inconvenience or conce rn to the patient 
and may interfere with daily activities.
xSevere events interrupt  the patient‚Äôs usual daily activities.
The Investigator will make a judgment regarding the AE‚Äôs r elationship to study drug, as
outlined below in Table 7.
Table 7: Classification of Adverse Events by [CONTACT_555274] a temporal relationship of the event to study treat ment makes a 
causal r elationship not reasonably possi ble, or by [CONTACT_479583], 
therapeutic interventions or underlying conditions that provide  a sufficient 
explanation.
Related The temporal relationship of the event to study treatment makes  a definitive 
relationship, and the event is more likely explained by [CONTACT_555275] e to the study 
treatment than by [CONTACT_479583], therapeutic interventions or underlying 
conditions.
12.1. Serious Adverse Events
A serious adverse event (SAE) is any untoward medical occurrence that occurs at any dose 
(including after the ICF is signed and prior to dosing) that:
xResults in death
xIs life-threatening (patient is at immediate risk of death from  the event as it 
occurred)
xRequires in-patient hospi[INVESTIGATOR_059] (formal admission to a hosp ital for medical 
reasons) or prolongation of existing hospi[INVESTIGATOR_555237]/incapacity
xResults in a congenital anomaly/birth defect
Important medical events that may not result in death, are not life-threatening, or do not 
require hospi[INVESTIGATOR_37347], based on a ppropriate medical 
judgment, they may jeopardize the patient and may require medic al or surgical intervention 
to prevent one of the outcomes listed in this definition. Examp les of such events include 
allergic bronchospasm requiring i ntensive treatment in an emerg ency room or at home, blood 
dyscrasias or convulsions that do not result in in-patient hospi[INVESTIGATOR_059], or the development of drug dependency or drug abuse.
Hospi[INVESTIGATOR_555238] s that are not related to a 
treatment-emergent AE are not considered SAEs.
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 71Progression of the malignancy (including fatal outcomes) should  not be reported as an SAE 
during the study or within the safety reporting period (see bel ow). Sudden and unexplained 
death should be reported as an SAE.
12.1.1. AE and SAE Follow-up
All AEs occurring during the study are to be followed up in acc ordance with good medical 
practice until they are resolved, stabilized or judged no longe r clinically significant or, if a 
chronic condition, until fully characterized. Any AEs that are considered drug-related must 
be followed until resolution or until stabilization. 
12.1.2. Post-Study Adverse Events and Serious Adverse Events
All unresolved AEs should be followed by [CONTACT_555276], the 
patient is lost to follow-up, or the AE is otherwise explained. At the last scheduled visit, the 
Investigator should instruct each patient to report any subsequ ent event(s) that the patient, or 
the patient ‚Äôs personal physician, believes might reasonably be related to participation in this 
study.
Prior to the conclusion of the study at the site, the Investiga tor should notify the Karyopharm 
Pharmacovigilance Department (see Section [IP_ADDRESS] ) of any death or AE occurring at any 
time after a patient has discontinued or terminated study parti cipation that may reasonably be 
related to this study. 
After study conclusion, the Investigator should notify Karyopha rm Therapeutics Inc., or its 
designee, of any death or AE he or she is aware of occurring at  any time after a patient has 
discontinued or terminated study participation that may reasona bly be related to this study. 
Karyopharm Therapeutics Inc. should also be notified if the Inv estigator should become 
aware of the development of cancer or of a congenital anomaly i n a subsequently conceived 
offspring of a patient that has participated in this study.
12.1.3. Serious Adverse Event Reporting
[IP_ADDRESS]. Reporting Requirements
ALL SAEs occurring in any patient, must be reported to the Kary opharm Pharmacovigilance 
Department within [ADDRESS_729005] knowledge of the event by [CONTACT_458] [INVESTIGATOR_555239]. The following information will be requ ested from the investigational 
site:
xProtocol number
xSite and/or investigator number
xPatient number
xDemographic data
xBrief description of the event
xOnset date and time
xResolution date and time, if the event resolved
Selinexor (KPT-330) Karyopharm Therapeutics Inc.
Clinical Study Protocol: KCP-330-012
13 December 2017, Version 6.0 Confidential Page 72xCurrent status, if event not yet resolved
xAny concomitant treatment and medication
xInvestigator‚Äôs assessment of the SAE‚Äôs relationship to investig ational product 
xOutcome of the event, if available
This information will be captured in the SAE report form and/or  the study specific safety 
database and will be forwarded to:
xPharmacovigilance Department
xKaryopharm Therapeutics Inc.
xEmail: [EMAIL_633]
xNorth American sites, Fax to US:+[PHONE_3530]
European sites, Fax to [LOCATION_013]: [PHONE_3846]
Suspected unexpected serious adverse reactions will be collecte d and reported to the 
competent authorities and relevant ethics committees in accordance with the FDA‚Äôs ‚ÄúSafety 
Reporting Requirements for Investig ational New Drugs and Bioana lytical/Bioequivalence 
Studies‚Äù or as per national regu latory requirements in participating countries.
All investigators participating in ongoing clinical studies wit h the study medication will 
receive copi[INVESTIGATOR_555240] 
(IRB) or Ethics committee (EC), as applicable. Reporting of SAE s by [CONTACT_555277] g procedures and policies of 
the IRB/EC. Adequate documentation must be maintained showing that the IRB/EC was 
properly notified.
In addition, Karyopharm Therapeutics Inc. will communicate all cases of cerebellar toxicities 
of Grade 3 or higher to the regulatory authority, IRBs and inve stigators, in the format of an 
expedited Safety Report within 7 days of awareness of the event .
12.2. Overdose
An overdose is defined as a deliberate or accidental administra tion of study medication to a 
study patient at a dose above that which is assigned to that individual patient according to the 
study protocol. In the event of drug overdose, the Investigator  and Karyopharm Medical 
Monitor should be notified immediately and the patient observed  closely for AEs. The patient 
should be treated symptomaticall y as appropriate, and the incid ent of overdose and related 
AEs and/or treatment documented in the patient's medical record . In addition to documenting 
the overdose in the patient's records, the overdose must be rep orted to Karyopharm 
Pharmacovigilance on an SAE  report form.  Any AE or SAE observe d as a consequence of 
the overdose will be handled as described in Section 12.2, as appropriate.
As selinexor is metabolized by [CONTACT_555278] ,it is conceivable that hepatic GSH 
depletion can occur in case of ov erdose. Therefore, in patients who develop liver function 
test abnormalities, supportive measures such as SAM [ADDRESS_729006] GSH, should be considered.
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729007] be reported to the 
Sponsor within 24 hours of learning  of its occurrence. The preg nancy should be followed up 
to determine outcome, including spontaneous or voluntary termination, details of the birth, 
and the presence or absence of a ny birth defects, congenital abnormalities, or maternal and/or 
newborn complications. Follow -up and documentation must occur e ven if the patient 
withdraws from the study or the study is completed.  
The avoidance of fathering a c hild is recommended for [ADDRESS_729008]-study should be reported to the study investigator and 
the sponsor‚Äôs designee.  
13. STATISTICAL METHODS 
13.1. General Considerations 
13.1.1. Statistical and Analytical Plans 
This is a Phase 2b, single-arm, open-label, multicenter study o f selinexor 80 mg with 
dexamethasone 20 mg (Sd), both given orally twice weekly for ea ch week of four-week 
cycles, to patients with MM previously treated with lenalidomid e, pomalidomide, 
bortezomib, carfilzomib, and daratumumab, and refractory to pri or treatment with 
glucocorticoids, an immunomodulatory agent (IMiD), a proteasome  inhibitor (PI), and the 
anti-CD38 mAb daratumumab.  
This study consists of two parts and will enroll approximately 210 patients overall. Part 1 
(protocol V1-3) enrolled patients with both penta-refractory MM and quad-refractory MM. 
Part 2 (protocol V‚â•4.0) will enroll patients with penta -refractory MM only, but continue all 
patients enrolled in Part 1.    
The population for the primary efficacy analysis will contain only patients with penta-
refractory MM enrolled in Part 2. E fficacy results for patients  with quad-refractory MM and 
patients with penta-refractory MM enrolled in Part 1 will be an alyzed separately. Safety 
analyses will be performed on the overall population of patients who received any amount of study treatment, presented overa ll and by [CONTACT_16051], and separ ately for Part 1 penta-
refractory MM patients and quad-refractory MM patients. 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH+\SRWKHVLVWHVWLQJZLOOEHXVHGIRUWKHSULPDU\HIILFDF\HQGSRL QWGDWDLQRUGHUWRHYDOXDWHLI
VHOLQH[RUSOXVGH[DPHWKDVRQHSURYLGHVVWDWLVWLFDOO\VLJQLILFDQW LPSURYHPHQWLQHIILFDF\RYHU
DPLQLPDOO\DFFHSWDEOHOHYHORI2551RIRUPDOK\SRWKHVLVW HVWLQJZLOOEHXVHGIRU
RWKHUVWXG\GDWDVXFKDVGHPRJUDSKLFVDQGVDIHW\GDWD
7DEXODWLRQVZLOOEHSURGXFHGIRUDSSURSULDWHGLVSRVLWLRQGHPRJ UDSKLFEDVHOLQHHIILFDF\DQG
VDIHW\SDUDPHWHUV)RUFDWHJRULFDOYDULDEOHVVX[COMPANY_003]U\WDEXODWLR QVRIWKHQXPEHUDQG
SHUFHQWDJHRISDWLHQWVZLWKLQHDFKFDWHJRU\ZLWKDFDWHJRU\IR UPLVVLQJGDWDRIWKH
SDUDPHWHUZLOOEHSUHVHQWHGDVZHOODVWZRVLGHGFRQILGHQF HLQWHUYDOV&,XQOHVV
RWKHUZLVHVWDWHG)RUFRQWLQXRXVYDULDEOHVWKHQXPEHURISDWLH QWVPHDQPHGLDQVWDQGDUG
GHYLDWLRQ6'PLQLPXPDQGPD[LPXPYDOXHVZLOOEHSUHVHQWHG 7LPHWRHYHQWGDWDZLOO
EHVX[COMPANY_003]UL]HGXVLQJ.DSODQ0HLHU.0PHWKRGRORJ\XVLQJWK WKPHGLDQDQGWK
SHUFHQWLOHVZLWKDVVRFLDWHGVLGHGFRQILGHQFHLQWHUYDOVD VZHOODVSHUFHQWDJHRI
FHQVRUHGREVHUYDWLRQV
 













'LVSRVLWLRQRI3DWLHQWV
$WDEXODWLRQRISDWLHQWGLVSRVLWLRQZLOOEHSUHVHQWHGLQFOXGLQ JWKHQXPEHULQHDFKDQDO\VLV
SRSXODWLRQWKHQXPEHUZLWKQRQHYDOXDEOHGLVHDVHDFFRUGLQJWR WKH,0:*FULWHULDWKH
QXPEHUFHQVRUHGDWHDFKRIWKH3)6DQG26DQDO\VHVWKHQXPEHU ORVWWRIROORZXSWKH
QXPEHUWKDWZLWKGUHZSULRUWRFRPSOHWLQJWKHVWXG\DQGUHDVRQ VIRUZLWKGUDZDO7KLV
WDEXODWLRQZLOOEHSUHVHQWHGVHSDUDWHO\IRUHDFKVWXG\SDUWDQG E\TXDGUHIUDFWRU\00DQG
SHQWDUHIUDFWRU\SDWLHQWSRSXODWLRQVLQ3DUWCCI
6HOLQH[RU.37 .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3
'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH %OLQGLQJDQG5DQGRPL]DWLRQ
7KLVLVDQRSHQODEHOVLQJOHDUPVWXG\WKHUHIRUHEOLQGLQJDQG UDQGRPL]DWLRQDUHQRW
DSSOLFDEOH
 'RVH$GMXVWPHQW
7KHGRVHOHYHOIRUDQLQGLYLGXDOSDWLHQWPD\EHHVFDODWHGEDVH GRQHIILFDF\FRQVLGHUDWLRQV
DIWHUDPLQLPXPRIF\FOHVRIVWXG\WKHUDS\5HDVRQVIRUGRVH HVFDODWLRQFDQLQFOXGHIRU
H[DPSOHDUHVSRQVHRI6'RU35ZLWKDFFHSWDEOHVDIHW\'RVHUH GXFWLRQFDQWDNHSODFH
EDVHGRQWKHJXLGHOLQHVLQ6HFWLRQ  . 

 $QDO\VLV'DWDVHWV
 3RSXODWLRQVWREH$QDO\]HG
 0RGLILHG,QWHQWWR7UHDWP,773RSXODWLRQ
7KHPRGLILHGLQWHQWWRWUHDWP,77SRSXODWLRQZLOOFRQVLVWRI 3DUWSDWLHQWVZLWKSHQWD
UHIUDFWRU\00ZKRPHWDOOHOLJLELOLW\FULWHULDRUGLGQRWPHHW DOOHOLJLELOLW\FULWHULDEXW
UHFHLYHGZDLYHUIURP6SRQVRUWRSDUWLFLSDWHLQWKHVWXG\DQG UHFHLYHGDWOHDVWGRVHRI
VWXG\WUHDWPHQWSDUWLDORUFRPSOHWH7KLVSRSXODWLRQZLOOLQFO XGHSDWLHQWVZKRKDYH
GLVFRQWLQXHGWKHUDS\GXHWRWR[LFLW\RUGLVHDVHSURJUHVVLRQDQG SDWLHQWVZKRKDYHGLHGIURP
DQ\FDXVHLQFOXGLQJWKRVHUHODWHGWRVWXG\GUXJRUGLVHDVH7KL VSRSXODWLRQ3DUWSDWLHQWV
ZLWKSHQWDUHIUDFWRU\00RQO\ZLOOEHXVHGIRUWKHSULPDU\DQD O\VLVRIHIILFDF\
 3HU3URWRFRO3RSXODWLRQ
$SHUSURWRFRO33SRSXODWLRQZLOOFRQVLVWRIDOOSDWLHQWVLQ WKHP,77SRSXODWLRQZKRPHHW
WKHIROORZLQJFULWHULD
x+DYHVHOLQH[RUFRPSOLDQFH¬ï
x+DYHDWOHDVWRQHDGHTXDWHSRVWEDVHOLQHUHVSRQVHDVVHVVPHQWXQ OHVVGLHGRU
ZLWKGUHZIURPVWXG\EHIRUHWKDW
x1RPDMRUSURWRFROYLRODWLRQVWKDWZRXOGFRPSURPLVHWKHDVVHVVPH QWRIHIILFDF\
7KHOLVWRIPDMRUSURWRFROYLRODWLRQVWKDWDIIHFWVWDWLVWLFDOD QDO\VLVZLOOEHILQDOL]HG
EHIRUHGDWDEDVHORFN
0DMRUYLRODWLRQVZLOOEHGHWHUPLQHGLQGHSHQGHQWO\RINQRZOHGJH RIUHVSRQVHWRWKHUDS\
SULRUWRGDWDEDVHORFNDQGVWXG\DQDO\VLV7KLVSRSXODWLRQZLOO EHXVHGIRUVXSSRUWLYH
LQIHUHQFHVFRQFHUQLQJHIILFDF\KRZHYHULIWKHUHDUHPDMRUGLI IHUHQFHVEHWZHHQWKHUHVXOWVLQ
WKLVSRSXODWLRQDQGWKRVHREWDLQHGLQWKHP,77SRSXODWLRQWKLV ZLOOEHWDNHQLQWR
FRQVLGHUDWLRQLQWKHDVVHVVPHQWRIHIILFDF\
 6DIHW\3RSXODWLRQ
7KHVDIHW\SRSXODWLRQZLOOFRQVLVWRIDOOSDWLHQWVZKRKDYHUHF HLYHGDWOHDVWRQHGRVHRIVWXG\
WUHDWPHQWDQGKDYHDQ\SRVWEDVHOLQHVDIHW\LQIRUPDWLRQCCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 76 [IP_ADDRESS]. Sub-group Efficacy Analyses 
The subgroup comparisons of interest will be evaluated per the Statistical Analysis Plan 
(SAP) (version 1.0). 
13.3. Data Analysis and Presentation 
Summary tabulations will be presented separately for each study  part and by [CONTACT_555279]-refractory 
MM patients and quad-refractory MM patients in Part 1 for dispo sition as noted above, and 
for demographic, baseline, efficacy and safety data as noted in  the following sections. All 
data collected on the eCRF will be provided in by-patient data listings. 
13.3.1. Demographic Characteristics 
Demographic characteristics will be summarized for the mITT, PP , and Safety populations 
and will include gender, race, ethnicity (Hispanic origin), and  age at time of consent. For 
gender, race, and Hispanic origin, t he summary statistics will be the number and percentage 
of patients within each category. The categories for race will be those recorded in the 
database. For age at time of consent, the mean, median, minimum , maximum, and standard 
deviation will be provided for each group and the total sample.  
13.3.2. Baseline Characteristics and Medical History 
Baseline characteristics include: performance status, duration from initial diagnosis, response 
to previous therapy, types of prior therapy, and height/weight. Baseline data will be tabulated 
using summary statistics for the mITT, PP, and Safety populatio ns; no formal hypothesis 
testing will be performed. 
Medical history and physical examination results at baseline wi ll be tabulated for the same 
analysis populations. 
13.3.3. Primary Endpoint 
The primary statistical analysis of efficacy will be performed on ORR (achievement of PR, 
VGPR, CR or sCR) for the mITT population. For the primary analy sis of superiority to the 
minimal threshold ORR, analysis will be performed using a two-s ided 95% confidence 
interval, calculated for the rate of ORR, and statistical signi ficance will be declared if the 
lower bound of this interv al is greater than 10%. 
13.3.4. Secondary Endpoints 
The following secondary efficac y endpoints will be analyzed separately for mITT and PP 
populations.  
x Duration of response (DOR = Dur ation from first observation of at least PR to 
time of disease progression [PD] or death due to disease progression, whichever 
occurs first. DOR will be censored for death due to any causes other than disease 
progression. 
x Clinical Benefit Rate (CBR = sCR + CR + VGPR + PR + minimal response 
[MR]), and duration of clinical benefit (Duration from first observation of at least 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729009]. Duration of clinical benefit will be censored for  death due to any 
causes other than disease progression) 
x Disease Control Rate (DCR = CBR + stable disease [SD; for a min imum of 12 
weeks])  
x Progression Free Survival (PFS =  Duration from start of study treatment to PD or 
death [regardless of cause], whichever comes first)  
x Time to Progression (TTP = Duration from start of study treatme nt to time of 
disease progression) obtained with selinexor plus dexamethasone vs. TTP on most 
recent prior therapy 
x Time to Next Treatment (TTNT = Duration from start of study treatment to start 
of next anti-MM treatment or death due to disease progression, whichever occurs 
first)  
x Overall Survival (OS = Duration fr om start of study treatment t o death)  
x Quality of Life (QoL) using the Functional Assessment of Cancer  Therapy - 
Multiple Myeloma (FACT-MM) 
Time-to-event endpoints (including duration of response, PFS, T TP, and OS) will be 
assessed using Kaplan-Meier (KM) methods, including an estimate  of the median, as well as 
the 25th and 75th percentiles, along with two-sided 95% CIs. Duration of CBR wil l be 
regarded as descriptive adjuncts to the analyses of response ra tes. Clinical benefit (CBR) and 
disease control (DCR) rates will be statistically evaluated usi ng two-sided 95% confidence 
intervals. 
QoL will be assessed using the Functional Assessment of Cancer Therapy-Multiple Myeloma 
(FACT-MM). This instrument combines the General version of the FACT (FACT-G) with a 
MM-specific subscale (14 items). The subscales for the FACT-G a re Physical Well-Being (7 
items), Social/Family Well-Being (7 items), Emotional Well-Bein g (6 items), and Functional 
Well-Being (7 items). The trial outcomes index (TOI; total of 41 items) will be the primary 
measurement of interest, comprised of the Physical and Functional subscales plus the MM-
specific subscale. Each item is rated on a 5- point Likert scale, ranging from 0 (‚ÄúNot at all‚Äù) 
to 4 (‚ÄúVery much‚Äù), therefore the TOI has a score ranging from 0 to 120. The QoL 
assessment will be performed at Baseline (prior to first dose of study treatment), Day 1 of each cycle on or after the second, and at the Final visit. The QoL analysis will be based on 
changes in the total TOI score from Baseline using paired T-tes ts. A secondary analysis of 
QoL will be performed in a similar manner using the total of al l subscales. All 5 individual 
subscale total scores will be summarized over time using descri ptive statistics. 
Additionally, the following analyses of safety and tolerability  secondary endpoints will be 
performed on the overall populati on of patients who received an y amount of study treatment, 
presented overall and by [CONTACT_16051].  
x Safety and tolerability using National Cancer Institute (NCI) C ommon 
Terminology Criteria for Adverse Events (CTCAE), v 4.03. 
x Describe the PK properties of s elinexor in this patient populat ion (Part 1 only). 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH 








 
 
 
3KDUPDFRNLQHWLF 'DWD
3ODVPDVDPSOHVZLOOEHDQDO\]HGYLDDYDOLGDWHGKLJKSHUIRUPDQF HOLTXLG
FKURPDWRJUDSK\WDQGHPPDVVVSHFWURPHWU\+3/&0606PHWKRGIRU SODVPDVHOLQH[RU
FRQFHQWUDWLRQ6HOLQH[RUFRQFHQWUDWLRQGDWDZLOOEHDQDO\]HGIR U3DUWSDWLHQWVRQO\LQDQRQ
OLQHDUPL[HGHIIHFWVSRSXODWLRQ3.PRGHOZLWKSRWHQWLDOFRYDULD WHVLQFOXGLQJEXWQRWOLPLWHG
WRDJHERG\ZHLJKWJHQGHUGLVHDVHVWDWHEDVHOLQHKHSDWLFR UUHQDOIXQFWLRQFRQFRPLWDQW
PHGLFDWLRQVDQGWUHDWPHQW 





6DIHW\'DWD
6DIHW\DQDO\VHVZLOOEHSHUIRUPHGRQWKHRYHUDOOSRSXODWLRQRI SDWLHQWVZKRUHFHLYHGDQ\
DPRXQWRIVWXG\WUHDWPHQWSUHVHQWHGRYHUDOODQGE\VWXG\SDUW DQGVHSDUDWHO\IRU3DUW
SHQWDUHIUDFWRU\00SDWLHQWV3DUWTXDGUHIUDFWRU\00SDWLHQW VDQG3DUWSHQWD
UHIUDFWRU\00SDWLHQWV7KHRULJLQDOGRVHOHYHOIRUHDFKSDWLHQ WZLOOEHXVHGIRUVDIHW\
DQDO\VLVQRVHSDUDWHFDWHJRULHVIRUGRVHHVFDODWLRQRUUHGXFWL RQZLOOEHFRQGXFWHGLQWKH
SULPDU\DQDO\VLVRIVDIHW\ 

$GYHUVH(YHQWV
$(VZLOOEHFRGHGXVLQJWKH0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$ FWLYLWLHV0HG'5$DQG
GLVSOD\HGLQWDEOHVDQGOLVWLQJVXVLQJ0HG'5$V\VWHPRUJDQFODV V62&DQG3UHIHUUHG
7HUP37CCI
CCICCICCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729010] dose 
of study treatment, or any event considered drug-related by [CONTACT_555280]. AEs with partial dates will be assessed using the  available date information to 
determine if treatment-emergent; AEs with completely missing dates will be assumed to be 
treatment-emergent. No formal hypothesis-testing of AE incidenc e rates will be performed. 
AEs will be summarized by [CONTACT_36916] t incidence rates, therefore, i n any tabulation, a patient 
contributes only once to the count  for a given AE (preferred te rm). The number and 
percentage of patients with any treatment-emergent adverse even ts (TEAE) will be 
summarized for each treatment group, classified by [CONTACT_9315]. The number and percentage of patients with TEAEs assessed by [CONTACT_555281]. The number and percentage of patients with any Grade ‚â• [ADDRESS_729011] severity 
and/or strongest causal relationship to treatment will be used for purposes of tabulations.  
All reported SAEs will be tabulated. All AEs (treatment-emergent and post-treatment) will be listed in by-patient data listings, 
classified by [CONTACT_3148], patient and day on study. In addition,  separate by-patient listings will 
be provided for the following: deaths; SAEs; and AEs leading to  withdrawal. 
[IP_ADDRESS]. Laboratory Data 
Clinical laboratory values will  be expressed using conventional  units International System of 
Units (SI) units. The actual value and change from baseline (Da y 1, prior to the first 
administration of study drug) to each on-study evaluation will be summarized for each 
clinical laboratory parameter, including hematology, clinical chemistry, coagulation and 
urinalysis. In the event of repeat values, the last non-missing  value per study day/time will be 
used. In the event that Day 1 data are unavailable for a given patient/parameter, the 
Screening value will substi tute as the baseline value. 
Severity of select clinical la b measures will be determined usi ng CTCAE v.4.03 criteria (e.g., 
those measures that have a corresponding CTCAE grade classifica tion). Labs with CTCAE 
Grades ‚â• [ADDRESS_729012] on-study values relative to CTCAE classification ranges will be produced. 
[IP_ADDRESS]. Vital Signs, Physical Examinations, and ECOG Performance Status  
The actual value and change from baseline (Day 1) to each on-st udy evaluation will be 
summarized for vital signs.  Shift tables that present changes from baseline to worst on-study 
and last on-study ECOG performance status values will be produc ed.  By-patient listings of 
all vital sign measurements and ECOG performance status scores will be presented in data 
listings. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 80 Physical examination results at Screening, and physical examina tion results changes during 
the study, will be summarized. All physical examination finding s will be presented in by-
patient data listings. 
[IP_ADDRESS]. Electrocardiogram Results 
Electrocardiogram results will be  summarized descriptively, inc luding heart rate and PR, 
QRS, QT, and QTc intervals (calcu lated by [CONTACT_555282]) intervals. If 
Bazett correction is entered by [CONTACT_779], the Fridericia correc ted QTc interval (QTcF) will be 
derived using the formula: QT/(RR ^[1/3]), where RR = 60/heart r ate. Actual values and 
changes from baseline will be  reported for each study visit. 
Electrocardiogram data for each patient will be provided in a d ata listing. 
[IP_ADDRESS]. Ophthalmic Examinations 
Ophthalmic examination findings will be summarized descriptivel y by [CONTACT_765]. All ophthalmic 
examination findings will be presented in the data listings. 
[IP_ADDRESS]. Concomitant Medications 
The use of concomitant medications will be included in by-patie nt data listings. 
13.3.8. Procedures for Handling Missing Data 
The procedures for handling missing data will be performed per the SAP (version 1.0). 
13.4. Changes in the Conduct of the Study or Planned Analysis 
All deviations from the original statistical analysis plan will  be documented and provided in 
the final clinical study report.  
14. REGULATORY, ETHICAL AND LEGAL OBLIGATIONS  
14.1. Regulatory and Ethical Compliance  
This clinical study was designed, and shall be implemented and reported in accordance with, 
the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable local 
regulations (including European Directive 2001/20/EC and US Cod e of Federal Regulations 
Title 21), Division 5 of the Health Canada Food and Drug Regula tions - Drugs For Clinical 
Trials Involving Human Subjects, and with the ethical principle s laid down in the Declaration 
of Helsinki. 
14.2. Institutional Review Boards/Ethics Committees 
The protocol and the proposed informed consent form (ICF) must be reviewed and approved 
by a properly constituted Institutional Review Board/Independen t Ethics 
Committee/Research Ethics Board (IRB/IEC/REB) before study start. Prior to study start, the 
Investigator is required to sign a protocol signature [CONTACT_555292]/her agreement to 
conduct the study in accordance with these documents and all of  the instructions and 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJHSURFHGXUHVIRXQGLQWKLVSURWRFRODQGWRJLYHDFFHVVWRDOOUHO HYDQWGDWDDQGUHFRUGVWR
.DU\RSKDUP4XDOLW\$VVXUDQFHUHSUHVHQWDWLYHVGHVLJQDWHGDJHQW VRI.DU\RSKDUP
,5%V,(&V5(%VDQGUHJXODWRU\DXWKRULWLHVDVUHTXLUHG
5HJXODWRU\$XWKRULW\$SSURYDO
%HIRUHLPSOHPHQWLQJWKLVVWXG\WKHSURWRFROPXVWEHDSSURYHGE \WKHUHOHYDQWFRPSHWHQW
UHJXODWRU\DXWKRULW\
3URWRFRO$GKHUHQFH
,QYHVWLJDWRUVDVFHUWDLQWKH\ZLOODSSO\GXHGLOLJHQFHWRDYRLG SURWRFROGHYLDWLRQV$OO
VLJQLILFDQWSURWRFROGHYLDWLRQVZLOOEHUHFRUGHGDQGUHSRUWHGL QWKH&65
$PHQGPHQWVWRWKH3URWRFRO
$Q\FKDQJHRUDGGLWLRQWRWKHSURWRFROFDQRQO\EHPDGHLQDZU LWWHQSURWRFRODPHQGPHQW
WKDWPXVWEHSURYLGHGE\.DU\RSKDUPDQGDSSURYHGE\+HDOWK$XW KRULWLHVZKHUHUHTXLUHG
DQGWKH,5%,(&5(%2QO\DPHQGPHQWVWKDWDUHUHTXLUHGIRUSDWL HQWVDIHW\PD\EH
LPSOHPHQWHGSULRUWR,5%,(&5(%DSSURYDO1RWZLWKVWDQGLQJWKH QHHGIRUDSSURYDORI
IRUPDOSURWRFRODPHQGPHQWVWKH,QYHVWLJDWRULVH[SHFWHGWRWDN HDQ\LPPHGLDWHDFWLRQ
UHTXLUHGIRUWKHVDIHW\RIDQ\SDWLHQWLQFOXGHGLQWKLVVWXG\ HYHQLIWKLVDFWLRQUHSUHVHQWVD
GHYLDWLRQIURPWKHSURWRFRO,QVXFKFDVHV.DU\RSKDUPVKRXOGE HQRWLILHGRIWKLVDFWLRQDQG
WKH,5%,(&5(%DWWKHVWXG\VLWHVKRXOGEHLQIRUPHGDFFRUGLQJ WRORFDOUHJXODWLRQVHJ
WKH8.UHTXLUHVWKHQRWLILFDWLRQRIXUJHQWVDIHW\PHDVXUHVZLWK LQGD\VEXWQRWODWHUWKDQ
ZRUNLQJGD\V
,QIRUPHG&RQVHQW
(OLJLEOHSDWLHQWVPD\RQO\EHLQFOXGHGLQWKHVWXG\DIWHUSURYL GLQJZULWWHQFRQVHQW
ZLWQHVVHGZKHUHUHTXLUHGE\ODZRUUHJXODWLRQRQDQ,5%,(& 5(%DSSURYHG,&)
,QIRUPHGFRQVHQWPXVWEHREWDLQHGEHIRUHFRQGXFWLQJDQ\VWXG\V SHFLILFSURFHGXUHVLHDOO
RIWKHSURFHGXUHVGHVFULEHGLQWKHSURWRFRO7KHSURFHVVRIRE WDLQLQJLQIRUPHGFRQVHQW
VKRXOGEHGRFXPHQWHGLQWKHSDWLHQWVRXUFHGRFXPHQWV7KHGDWH ZKHQDSDWLHQW¬∂VLQIRUPHG
FRQVHQWZDVDFWXDOO\REWDLQHGZLOOEHFDSWXUHGLQWKHLUH&5)V
.DU\RSKDUPZLOOSURYLGHWRLQYHVWLJDWRUVLQDVHSDUDWHGRFXPHQ WDSURSRVHG,&)WKDWLV
FRQVLGHUHGDSSURSULDWHIRUWKLVVWXG\DQGFRPSOLHVZLWKWKH,&+ *&3JXLGHOLQHDQG
UHJXODWRU\UHTXLUHPHQWV.DU\RSKDUPRUWKHLUGHVLJQHHPXVWDJUH HWRDQ\LQYHVWLJDWRU
VXJJHVWHGFKDQJHVWRWKLV,&)EHIRUHWKHLUVXEPLVVLRQWRWKH,5 %,(&5(%DQGDFRS\RIWKH
DSSURYHGYHUVLRQPXVWEHSURYLGHGWRWKH.DU\RSKDUPRUGHVLJQHH DIWHU,5%,(&5(%
DSSURYDO 

(DFKSDWLHQW¬∂VLQIRUPHGFRQVHQWGRFXPHQWZLOOUHIOHFWWKDWVDPS OHVFROOHFWHGPD\
EHXVHGIRUSKDUPDFRJHQRPLFLQYHVWLJDWLRQVCCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729013] ensure anonymity of the patients; patient s must not be identified by 
[CONTACT_555283]. Signed informed 
consent forms and patient enrollment log must be kept strictly confidential to enable patient 
identification at the site. 
14.8. Collection, Auditing Study Docu mentation, and Data Storage 
14.8.1. Study Documentation, Record Keepi[INVESTIGATOR_555241] r esearch records for this trial, in 
compliance with Section 4.9 of the ICH E6 GCP, and regulatory a nd institutional 
requirements for the protection of confidentiality of patients.  Each site will permit authorized 
representatives of the sponsor and regulatory agencies to exami ne (and when required by 
[CONTACT_1289], to copy) clinical records for the purposes of q uality assurance reviews, audits 
and evaluation of the study safety and progress. 
Source data are all information, original records of clinical f indings, observations, or other 
activities in a clinical trial necessary for the reconstruction  and evaluation of the trial. 
Examples of these original documents and data records include, but are not limited to, 
hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes,  memoranda, evaluation 
checklists, pharmacy dispensing  records, recorded data from aut omated instruments, copi[INVESTIGATOR_555242] v erification as being accurat e and complete, microfiches, 
photographic negatives, microfilm or magnetic media, x-rays, an d subject files and records 
kept at the pharmacy, at the laboratories, and medico-technical  departments involved in the 
clinical trial. Data collection is the responsibility of the clinical trial sta ff at the site under the supervision 
of the site Investigator. The study eCRF is the primary data co llection instrument for the 
study. The Investigator should ensure the accuracy, completenes s, and timeliness of the data 
reported in the eCRFs and all othe r required reports. Data repo rted on the eCRFs, which are 
derived from source documents, s hould be consistent with the so urce documents or the 
discrepancies should be explaine d. All data requested on the eC RF must be recorded. Any 
missing data must be explained. For electronic CRFs an audit tr ail will be maintained by [CONTACT_28049].  
The Investigator/institution should maintain the trial document s as specified in Essential 
Documents for the Conduct of a Clinical Trial (ICH E6 Section 8 ) and as required by 
[CONTACT_64122]/or guidelines. The Investigator/inst itution should take measures to 
prevent accidental or premature de struction of these documents.  
Essential documents (writte n and electronic) should be retained  for a period of not less than 
fifteen (15) years from the completion of the Clinical Trial un less Sponsor provides written 
permission to dispose of them or, r equires their retention for an additional period of time 
because of applicable laws, regulations and/or guidelines. 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH$XGLWLQJ3URFHGXUH
,QDGGLWLRQWRWKHURXWLQHPRQLWRULQJSURFHGXUHVWKH6SRQVRUR UWKHUHJXODWRU\DXWKRULW\PD\
FRQGXFWDQDXGLWRUDQLQVSHFWLRQGXULQJWKHVWXG\RUDIWHULW VFRPSOHWLRQWRHYDOXDWH
FRPSOLDQFHZLWKWKHSURWRFRODQGWKHSULQFLSOHVRI*&3
7KH,QYHVWLJDWRUDJUHHVWKDWUHSUHVHQWDWLYHVRIWKH6SRQVRUDQG 5HJXODWRU\$XWKRULWLHVZLOO
KDYHGLUHFWDFFHVVERWKGXULQJDQGDIWHUWKHFRXUVHRIWKLVVW XG\WRDXGLWDQGUHYLHZDOO
VWXG\UHOHYDQWPHGLFDOUHFRUGV
,QWKHHYHQWWKDWDPDMRUFRPSOLDQFHRUUHJXODWRU\LVVXHVDULVH VWKH6SRQVRUPD\FRQGXFWDQ
DXGLWZLWKRXWSULRUZDUQLQJ
'LVFORVXUHRI,QIRUPDWLRQ
$OOLQIRUPDWLRQSURYLGHGWRWKH,QYHVWLJDWRUE\.DU\RSKDUPRU WKHLUGHVLJQHHZLOOEHNHSW
VWULFWO\FRQILGHQWLDO1RGLVFORVXUHVKDOOEHPDGHH[FHSWLQDF FRUGDQFHZLWKDULJKWRI
SXEOLFDWLRQJUDQWHGWRWKH,QYHVWLJDWRULQWKH&OLQLFDO7ULDO$ JUHHPHQW
1RLQIRUPDWLRQDERXWWKLVVWXG\RULWVSURJUHVVZLOOEHSURYLGH GWRDQ\RQHQRWLQYROYHGLQWKH
VWXG\RWKHUWKDQWR.DU\RSKDUPRULWVDXWKRUL]HGUHSUHVHQWDWLY HVRULQFRQILGHQFHWRWKH
,5%RUVLPLODUFRPPLWWHHH[FHSWLIUHTXLUHGE\ODZ
'LVFRQWLQXDWLRQRIWKH6WXG\
,WLVDJUHHGWKDWIRUUHDVRQDEOHFDXVHHLWKHUWKH,QYHVWLJDWR URU.DU\RSKDUPPD\WHUPLQDWH
WKH,QYHVWLJDWRU¬∂VSDUWLFLSDWLRQLQWKLVVWXG\DIWHUVXEPLVVLRQ RIDZULWWHQQRWLFH.DU\RSKDUP
PD\WHUPLQDWHWKHVWXG\DWDQ\WLPHXSRQLPPHGLDWHQRWLFHIRUD Q\UHDVRQLQFOXGLQJWKH
6SRQVRU¬∂VEHOLHIWKDWGLVFRQWLQXDWLRQRIWKHVWXG\LVQHFHVVDU\ IRUWKHVDIHW\RISDWLHQWV 
5HSRUWLQJDQG3XEOLFDWLRQRI6WXG\'RFXPHQWDWLRQ
.DU\RSKDUPDVVXUHVWKDWWKHNH\GHVLJQHOHPHQWVRIWKLVSURWRFR OZLOOEHSRVWHGLQDSXEOLFO\
DFFHVVLEOHGDWDEDVHVXFKDVZZZFOLQLFDOWULDOVJRY,QDGGLWLRQ XSRQVWXG\FRPSOHWLRQDQG
DQDO\VLVRIWKHUHVXOWLQJFOLQLFDOGDWDWKHUHVXOWVRIWKHVWX G\ZLOOEH
x5HSRUWHGWRDSSURSULDWHFRPSHWHQWUHJXODWRU\DXWKRULWLHVLQIX OOFRPSOLDQFHZLWK
,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQL]DWLRQ,&+(6WUXFWXUHD QG&RQWHQWRI
&OLQLFDO6WXG\5HSRUWV$SULPDU\FOLQLFDOVWXG\UHSRUW&65P D\EHZULWWHQ
EDVHGRQDOODYDLODEOHSDWLHQWHIILFDF\DQGVDIHW\GDWDIRUWKH SULPDU\DQDO\VLVD
ILQDO&65PD\EHVXEPLWWHGZKHQDOOHYDOXDEOHSDWLHQWVKDYHFRP SOHWHGWKHORQJ
WHUPIROORZXSSHULRGGLHGSURJUHVVHGZLWKGUDZQFRQVHQWGLV FRQWLQXHGGXHWR
WR[LFLW\RUEHHQORVWWRIROORZXS3.UHVXOWVPD\EHUHSRUWHG LQHLWKHU&65
x6XEPLWWHGIRUSXEOLFDWLRQDQGRUSRVWHGLQDSXEOLFO\DFFHVVLEO HGDWDEDVHRI
FOLQLFDOVWXG\UHVXOWV3XEOLFDWLRQZLOOEHLQDUHOHYDQWSHHU UHYLHZHGMRXUQDO
ZLWKDXWKRUVKLSVWDWXVDQGUDQNLQJGHVLJQDWHGDFFRUGLQJWRWKH DFNQRZOHGJHG
FRQWULEXWLRQVRISDUWLFLSDWLQJLQYHVWLJDWRUVLQVWLWXWLRQVDQG WKH6SRQVRU
CCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 84 15. REFERENCES 
1. ACS (American Cancer Society). Key statistics for multiple myel oma. Available on line 
at http://www.cancer.org/cancer /multiplemyeloma/detailedguide/multiple-myeloma-key-
statistics.  Accessed 03Aug2016. 
2. Altura RA, Olshefski RS, Jiang Y, Bou√© DR. Nuclear expression of survivin in paediatric 
ependymomas and choroid plexus tumours correlates with morpholo gic tumour grade. 
Brit J Cancer . 2003;89(9):1743 ‚Äì1749. 
3. Azmi AS, Al-Katib A, Aboukameel A, et al. Selective inhibitors of nuclear export for the 
treatment of non- Hodgkin‚Äôs lymphomas. Haematol . 2013;98(7):1098-1106. 
4. Bazett HC. An analysis of the time-relations of electrocardiogr ams. Heart 1920;7:[ADDRESS_729014], et al. C-terminal substitution of MDM2 interacting peptides modulates binding affinity by [CONTACT_37426]. PLoS One . 
2011;6(8):e24122. 
6. Chen C, et al. Anti-Tumor Activity of SELINEXOR (KPT-330), an O ral Selective 
Inhibitor of Nuclear Export (SINE ), ¬± Dexamethasone in Multiple  Myeloma Preclinical 
Models and Translation in Patients with Multiple Myeloma. 2014 EHA Annual Meeting, 
June 12 - June 15, 2014, Milan, Italy. 
7. Chen CI, Gutierrez M, Siegel DS, et al. Selinexor demonstrates marked synergy with 
dexamethasone (Sel-Dex) in pre-clinical models and in patients with heavily pretreated 
refractory multiple myeloma. 2014 ASH Annual Meeting, December 06 ‚Äì 09, 2014, San 
Francisco. 
8. Chesi M, Matthews GM, Garbitt VM, et al. Dose response in a genetically engineered 
mouse model of multiple myeloma is predictive of clinical effic acy. Blood  2012 (July 
12); 120(2): 376-385.  
9. Culjkovic B, Topi[INVESTIGATOR_28618] I, Skrabanek L, et al. elF4E is a cent ral node of an RNA regulon 
that governs cellular proliferation. J Cell Biol  2006;175:415-426. 
10. DuBois D, DuBois EF. A formula to estimate the approximate surf ace area if height and 
weight be known. Arch Intern Medicine.  1916;17:863-871. 
11. Durie BG, Harousseau JL, Migue l JS, et al. International unifor m response criteria for 
multiple myeloma. Leukemia 2006;20(9):1467-73. 
12. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid le ukemia carrying 
cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and cli nical features. 
Blood. 2007;1;109(3):874-85. 
13. Fragomeni RAS, Chung HW, Landesman Y, et al. CRM1 and BRAF inhi bition synergize 
and induce 
 tumor regression in BRAF-mutant melanoma. Mol Cancer Ther. 
2013;12(7):1171-9. 
14. Fridericia L. Die Systolendauer im Elektrokardiogramm bei norma len Menschen und bei 
Herzkranken. [The duration of systo le in the electrocardiogram of normal subjects and of 
patients with heart disease.]. Acta Medica Scandinavica. 1920;5 3:469-86. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 85 15. Gao J, Azmi AS, Aboukameel A, Kauffman M, Shacham S, Abou-Samra  AB, 
Mohammad RM. Nuclear retention of Fbw7 by [CONTACT_555284] o f nuclear export leads 
to Notch1 degradation in pancreatic cancer. Oncotarget . 2014 15;5(11):3444-54.  
16. Gray LJ, Bjelogrlic P, Appleyard VC, et al. Selective induction  of apoptosis by 
[CONTACT_420894] B in keratinocytes expressing HPV oncogenes. Int J Cancer . 
2007:120(11):2317-2324. 
17. Greipp PR, San Miguel J, Durie BG, et al. International staging  system for multiple 
myeloma. J Clin Oncol . 2005;23:3412-3420. 
18. International Myeloma Working Group. Criteria for the classification of monoclonal 
gammopathies, multiple myeloma and related disorders: a report of the International 
Myeloma Working Group. Br J Haematol . 2003;121:749-757. 
19. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical 
NF-kappaB pathway in multiple myeloma. Cancer Cell . 2007 Aug;12(2):131-44. 
20. Koehler A, Hurt E. Exporting RNA from the nucleus to the cytopl asm. Nat Rev Mol Cell 
Biol.  2007;8:761-73. 
21. Kojima K, Kornblau SM, Ruvolo V, e t al. Prognostic impact and t argeting of CRM1 in 
acute myeloid leukemia. Blood. 2013;121(20):4166 ‚Äì4174.  
22. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in ol der patients. Leukemia. 
2014;28(5):1122-8. 
23. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Wor king Group 
consensus criteria for response and minimal residual disease as sessment in multiple 
myeloma. Lancet Oncol. 2016;17:e328-46. 
24. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med . 2004;351:1860-1873. 
25. Lain S, Xirodimas D, Lane DP. Accumulating active p53 in the nu cleus by [CONTACT_37428]: a novel strategy to promote the p53 tumor suppr essor function. Exp Cell 
Res. 1999;253(2):315-324. 
26. Lapalombella R, Sun Q, Williams K , et al. Selective inhibitors of nuclear export show 
that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 
2012;120(23):4621-4634. 
27. Lohr JG, Stojanov P, Carter SL, et al. Widespread genetic heter o
 geneity in multiple 
myeloma: implications for tar geted therapy. Cancer Cell. 2014 J an 13;25(1):91-101.  
28. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med.  
1987;317:1098. 
29. Mutka SC, Yang WQ, Dong SD, et al. Identification of nuclear ex port inhibitors with 
potent anticancer activity in vivo. Cancer Res . 2009;69(2):510-517. 
30. National Cancer Institute. Cance r Therapy Evaluation Program [C TEP] Policy and 
Guidelines for Accountability and Storage of Investigational Ag ents, available on line at 
http://ctep.cancer.gov/protocolDevelopment.  
31. National Cancer Institute. Cance r Therapy Evaluation Program [C TEP] Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.03. Available on line at http://evs.nci.nih.gov/ftp1/CTCAE/CTC AE_4.03_2010-06-14_QuickReference_5x7.pdf  
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 86 32. National Comprehensive Cancer Net work¬Æ. NCCN Clinical Practice Guidelines in 
Oncology (NCCN CPGO). Available at http://www.nccn.org/professionals.  
33. Newlands ES, Rustin GJ, Brampton MH. Phase I trial of elactocin . Br J Cancer . 
1996;74(4):648-649. 
34. Optometric Clinical Practice Guid eline:  Care of the Adult Pati ent with Cataracts 
(CPG8). American Optometric Association at www.aoa.org . 
35. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response cri teria of the Eastern 
Cooperative Oncology Group. Am J Clin Oncol . 1982;5:649-655. 
36. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Mu ltiple myeloma. 
Lancet  2009;374: 324-339. 
37. Rajkumar SV, Harousseau JL, Dur ie B, et al, for the Internation al Myeloma Workshop 
Consensus Panel 1. Consensus re commendations for the uniform re porting of clinical 
trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011; 
117:4691-95. 
38. Ranganathan P, Yu X, Na C, et al. Preclinical activity of a nov el CRM1 inhibitor in acute 
myeloid leukemia. Blood . 2012;120(9):1765 ‚Äì1773.  
39. Roberts BJ, Hamelehle KL, Sebolt JS, Leopold WR. In vivo and in  vitro anticancer 
activity of the structurally novel and highly potent antibiotic  CI-940 and its hydroxy 
analog (PD 114,721). Cancer Chemother Pharmacol . 1986;16(2):95-101. 
40. Schmidt J, Braggio E, Kortuem KM, et al. Genome-wide studies in multiple myeloma 
identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 2013;27(12):2357-65. 
41. Selinexor/KPT- 330 Investigator‚Äôs Brochure , 2015.  
42. Senapedis WT, Baloglu E, Landesman Y. Clinical translation of n uclear export inhibitors 
in cancer. Semin Cancer Biol . 2014 Aug;27C:74-86. 
43. Sharpless NE, DePi[INVESTIGATOR_100639]. Gone but not forgotten. Nature. 2007;445(7128):606-7. 
44. Tai Y-T, Landesman Y, Acharya C, Calle Y, et al. CRM1 inhibitio n induces tumor cell 
cytotoxicity and impairs osteoclastogenesis in multiple myeloma : molecular mechanisms 
and therapeutic implications. Leukemia. 2014;28:155-165. 
45. Tan DS, Bed ard PL , Kuruvilla J
, Siu LL, Razak AR. Promising SIN Es for embargoing 
nuclear-cytoplasmic export as an anticancer strategy. Cancer Discovery. 2014 
May;4(5):527-37. 
46. Tiedemann RE, Zhu YX, Schmidt J, et al. Identification of molec ular vulnerabilities in 
human multiple myeloma cells by [CONTACT_555285]. Cancer Res . 2012 Feb 1;72(3):757-68. 
47. Turner JG, Sullivan DM. CRM1-mediated nuclear export of protein s and drug resistance 
in cancer. Curr Med Chem . 2008;15(26):2648-55. 
48. Turner JG, Dawson J, Sullivan D M. Nuclear export of proteins an d drug resistance in 
cancer. Biochem Pharmacol . 2012;83(8):1021-1032. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729015] 
LA, Sullivan DM. CRM1 Inhibition S ensitizes Drug Resistant Huma n Myeloma Cells to 
Topoisomerase II and Proteasome Inhibitors both In Vitro and Ex  Vivo. J Cancer.  2013 
Sep 10;4(8):614-25. 
50. Turner JG, Dawson J, Cubitt CL, Baz R, Sullivan DM. Inhibition of CRM1-dependent 
nuclear export sensitizes malignant cells to cytotoxic and targ eted agents. Semin Cancer 
Biol. 2014 Aug;27C:62-73. 
51. Van der Watt PJ, Maske CP, Hendricks DT, et al. The Karyopherin  proteins, Crm1 and 
Karyopherin beta1, are overexpressed in cervical cancer and are critical for cell survival 
and proliferation. Int J Cancer . 2009;124(8):1829-1840. 
52. Vogl DT, Dingli D, Cornell RF, et al. Selinexor and low dose de xamethasone (Sd) in 
patients with lenalidomide, po malidomide, bortezomib, carfilzom ib and anti-CD38 Ab 
refractory multiple myeloma (MM): STORM Study. Blood. 2016; 128, 491-491. 
53. Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinica l efficacy of XPO1/CRM1 
inhibition by [CONTACT_68014]-330 in Ph+ leukemia s. Blood . 
2013;22(17):3034 ‚Äì3044.  
54. Xu D, Farmer A, Chook YM. Recognition of nuclear targeting sign als by [CONTACT_37427]-
beta proteins. Curr Opin Struct Biol . 2010;20(6):782-790. 
55. Yang J, Bill MA, Young GS, La Perle K, Landesman Y, Shacham S, Kauffman M, 
Senapedis W, Kashyap T, Saint-Martin JR, Kendra K, Lesinski GB.  Novel Small 
Molecule XPO1/CRM1 Inhibitors Induce Nuclear Accumulation of TP 53, 
Phosphorylated MAPK and Apoptosis in Human Melanoma Cells.  PLoS One . 2014 Jul 
24;9(7):e102983. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 88 APPENDIX 1.  EASTERN COOPERATIVE ONCOLOGY GROUP 
(ECOG) PERFORMANCE STATUS CRITERIA 
Table 8: Eastern Cooperative Oncology Group (ECOG) Performance Status 
Criteria 
Source: Oken MM, Creech RH, Tormey DC, et al. Toxicity and resp onse criteria of the Eastern Cooperative 
Oncology Group. Am J Clin Oncol . 1982;5:649-655) 
 
 ECOG Performance Status Scale 
Grade Descriptions 
0 Normal activity. Fully active, a ble to carry on all pre-disease performance without 
restriction.  
1 Symptoms, but ambulatory. Restricted in physically strenuous ac tivity, but ambulatory 
and able to carry out work of a light or sedentary nature ( e.g., light housework, office 
work).  
2 In bed < 50% of the time. Ambulatory and capable of all self-ca re, but unable to carry 
out any work activities. Up and about more than 50% of waking hours.  
3 In bed > 50% of the time. Capable  of only limited self-care, co nfined to bed or chair 
more  than 50% of waking hours. 
4 100% bedridden. Completely disabled. Cannot carry on any self-c are. Totally confined 
to bed or chair.  
5 Dead. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 89 APPENDIX 2.  INTERNATIONAL STAGING SYSTEM FOR 
MULTIPLE MYELOMA 
Table 9: International Staging System for Multiple Myeloma 
 Source: Greipp PR, San Miguel J, Durie BG, et al. Internationa l staging system for multiple myeloma. J Clin Oncol . 2005;23:3412-3420 
 
 Stage Characteristics 
Stage I Œ≤2-microglobulin <3.5 mg/L, albumin ‚â•3.5 g/dL  
Stage II Œ≤2-microglobulin <3.5 mg/L and albumin <3.5 g/dL, or Œ≤ 2-
microglobulin 3.5 -5.5 mg/L irrespective of the serum albumin 
Stage III Œ≤2-microglobulin ‚â•5.5 mg/L  
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 90 APPENDIX 3.  INTERNATIONAL MYELOMA WORKING GROUP 
RESPONSE CRITERIA, MYELOMA 
Table 10: International Myeloma Working Group Response Criteria ( Kumar 2016) 
Standard IMWG Response Criteria1,2,3 
Response Subcategory Response Criteria 
Complete response (CR) Negative immunofixation of serum and urine, disappearance of an y 
soft tissue plasmacytomas (SPDs), and <  5% plasma cells in bone 
marrow aspi[INVESTIGATOR_159374] 
(sCR)  CR as defined above plus normal FLC ratio4 and absence of clonal 
cells in bone marrow biopsy by [CONTACT_9064] (Œ∫/Œª ratio ‚â§ 4:1 
or ‚â• 1:2 for Œ∫ and Œª patients, respectively, after counting ‚â•  100 plasma 
cells5 
Very good partial response 
(VGPR)  Serum and urine M-protein detectable by [CONTACT_159444] ‚â•  90% reduction in serum M-protein plus urine 
M-protein level < 100 mg per 24 hr 
Partial response (PR)  ‚â• 50% reduction of serum M-protein plus reduction in 24-hr urina ry 
M-protein by ‚â•  90% or to < 200 mg/24 hr.  
If the serum and urine M -protein are not measurable, a ‚â•  50% decrease 
in the difference between involved and uninvolved FLC levels is  
required in place of the M -protein criteria. 
If serum and urine M -protein and serum FLC assay are not 
measurable, ‚â•  50% reduction in plasma cells is required in place of 
M-protein, provided baseline bone mar row plasma cell percentage w as 
‚â• 30%. 
In addition to the above criteria, if present at baseline, a ‚â•  50% 
reduction in the size (SPD) of soft tissue plasmacytomas is als o 
required.6  
Minimal response (MR)  ‚â• 25% but < 49% reduction of serum M-protein and reduction in 24 -hr 
urine M -protein by 50 ‚Äì89%. 
In addition to the above criteria, if present at baseline, a ‚â•  50% 
reduction in the size (SPD) of soft tissue plasmacytomas  is also 
required.6 
Stable disease (SD) Not recommended for use as an indicator of response; stability of 
disease is best described by [CONTACT_555286]. Not m eeting 
criteria for CR, VGPR, PR, MR, or PD.  
Progressive disease (PD)7,8 Any 1 or more of the following criteria: 
Increase of 25% from lowest con firmed response value in 1 or mo re of 
the following criteria:  
Serum M- protein with absolute increase of ‚â•  0.5 g/dL; 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729016] IMWG Response Criteria1,2,3 
Response Subcategory Response Criteria 
Serum M- protein increase ‚â•  1 g/dL if the lowest M-component 
was ‚â•  5 g/dL; 
Urine M- protein (absolute increase must be ‚â•  200 mg/24 hr);  
In patients without measurable serum and urine M- protein levels: 
the difference between involved and uninvolved FLC levels 
(absolute increase must be > 10 mg/dL); 
In patients without measurable serum and urine M- protein levels 
and without measurable involved FLC levels: bone marrow 
plasma cell percentage irrespective of baseline status (absolut e 
increase must be ‚â• 10%);  
Appearance of a new lesion(s), ‚â•  50% increase from nadir in SPD6 of 
> 1 lesion, or ‚â•  50% increase in the longest diameter of a previous 
lesion >  1 cm in short axis; 
‚â• 50% increase in circulating pl asma cells (minimum of 200 cells per 
ŒºL) if this is the only measure of disease  
Clinical relapse Clinical relapse requires 1 or more of the following criteria: 
Direct indicators of increasing disease and/or end organ 
dysfunction (CRAB features) related to the underlying clonal 
plasma- cell proliferative disorder. It is not used in calculation of 
TTP or PFS but is listed as something that can be reported 
optionally or for use in clinical practice; 
Development of new soft tissue plasmacytomas or bone lesions 
(osteoporotic fractures do not constitute progression); 
Definite increase in the size of existing plasmacytomas or bone  
lesions. A defini te increase is defined as a 50% (and ‚â• 1 cm) 
increase as measured serially by [CONTACT_159447]6 of the measurable 
lesion; 
Hypercalcaemia (> 11 mg/dL); 
Decrease in haemoglobin of ‚â• 2 g/dL not related to therapy or 
other non-myeloma-related conditions; 
Rise in serum creatinine by 2 mg/dL or more from the start of the 
therapy and attributable to myeloma; 
Hyperviscosity related to serum paraprotein 
Relapse from CR (to be used 
only if the endpoint is 
disease -free survival) Any 1 or more of the following criteria: 
Reappearance of serum or urine M- protein immunofixation or 
electrophoresis; 
Development of ‚â• 5% plasma cells in the bone marrow;  
Appearance of any other sign of progression (i.e,. new 
plasmacytoma, lytic bone lesion, or hypercalcaemia see above) 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729017] negative 
(to be used only if the endpoint 
is disease -free survival) Any 1 or more of the following criteria: 
Loss of MRD negative state (evidence of clonal plasma cell on 
NGF or NGS, or positive imaging study for recurrence of 
myeloma); 
Reappearance of serum or urine M- protein by [CONTACT_145169]; Development of ‚â• 5% clonal plasma cells in the bone marrow;
 
Appearance of any other sign of progression (i.e., new 
plasmacytoma, lytic bone lesion, or hypercalcaemia) 
Abbreviations: ASCT = autologous stem-cell transplantation; CR = complete response; CRAB feat ures = calcium elevation, 
renal failure, anemia, lytic bone lesions; CT = computed tomogr aphy; DOR = duration of response; FDG = 
fluorodeoxyglucose; FLC = free light chain; hr = hour ; Ig = immunoglobulin; IMWG = International Myeloma Working 
Group; MM = multiple myeloma; MR = minimal response; MRD = mini mal residual disease; MRI = magnetic resonance 
imaging; NGF = next -generation flow; NGS = next-generation sequencing; PD = progre ssive disease; PET = positron emission 
tomography; PFS = progression -free survival; PR = partial response; sCR = stringent complete response; SD = stable disease; 
SPD =  sum of the products of the maximal perpendicular diameters of m easured lesions; TTP = time to progression; VGPR = 
very good partial response.  
Source: Kumar, 2016 
 
1 All response categories require 2  consecutive assessments made  any time before starting any new therapy; for 
MRD there is no need for [ADDRESS_729018] after each treatment stage is 
recommended (e.g., after induction, high-dose therapy/ASCT, con solidation, maintenance). MRD tests should 
be initiated only at the time of suspected CR. All categories o f response and MRD require no known evidence 
of progressive or new bone lesions if radiographic studies were  performed. However, radiographic studies are 
not required to satisfy these res ponse requirements except for the requirement of FDG PET if imaging 
MRD-negative status is reported. 
[ADDRESS_729019] ivities occur. See ‚ÄúPractical 
considerations for application of  IMWG consensus criteria‚Äù sect ion of the guidelines (page e340; 
Kumar, 2016). 
3 Derived from international uniform response criteria for MM ( Durie 2011 ). MR definition and clarifications 
derived from Rajkumar ( Rajkumar 2011 ). When the only method to measure disease is by [CONTACT_555287]: 
CR can be defined as a normal FLC ratio of 0.26 to 1.65 in addi tion to the CR criteria listed previously. 
VGPR in such patients requires a ‚â•  90% decrease in the difference between involved and uninvolved  FLC 
levels. All response categories require 2 consecutive assessments made at any time before the institution of 
any new therapy; all categories also require no known evidence of progressive or new bone lesions or 
extramedullary plasmacytomas if radiographic studies were perfo rmed. Radiographic studies are not required 
to satisfy these response requirements. Bone marrow assessments  do not need to be confirmed. Each category, 
except for SD, will be considered unconfirmed until the confirm atory test is performed. The date of the initial 
test is considered as the date of  response for evaluation of ti me dependent outcomes such as DOR. 
[ADDRESS_729020] (Binding Site, Birmin gham, [LOCATION_008]). 
5 Presence/absence of clonal cells on immunohistochemistry is bas ed upon the Œ∫/Œª/L ratio. An abnormal Œ∫/Œª 
ratio by [CONTACT_128760] a minimum of 100 plasma cells for analysis. An abnormal ratio 
reflecting presence of an abnormal clone is Œ∫/Œª of >  4:1 or < 1:2. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729021] portion of the PET/CT, or MRI scans, or dedicated 
CT scans where applicable. For patients with only skin involvem ent, skin lesions should be measured with a 
ruler. Measurement of tumor size will be determined by [CONTACT_159447].  
[ADDRESS_729022] should be used only when calculating disease-free surv ival. 
8 In the case where a value is fe lt to be a spurious result per Investigator discretion (e .g., a possible laboratory 
error), that value will not be considered when determining the lowest value.  
 
Questions regarding interpreta tion of these criteria may be addressed by [CONTACT_159448], ‚ÄúPra ctical 
considerations for application of I MWG consensus criteria,‚Äù sec tion of the guidelines (page e340, Kumar 2016 ). 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 94 APPENDIX 4.  SELINEXOR FORMULATION AND 
ADMINISTRATION 
Description of Selinexor (KPT-330)  
Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound. Selinexor specifically 
blocks nuclear export by [CONTACT_555288]1. 
The chemical name [CONTACT_832] : (Z)-3-(3-(3,5-bis(trifluoromethyl)phenyl)-1H-1,2,4-triazol-1-yl)- N'-
(pyrazin-2-yl)acrylohydrazide 
The molecular formula  is: C 17H11F6N7O.  
The molecular weigh t is: 443.31 
Form 
Selinexor will be supplied and a dministered as 20 mg, coated, i mmediate-release tablets.  
Storage and Stability  
Selinexor tablets (20 mg) will be s upplied in plastic film blis ters with an aluminum foil 
lidding packaged in a secondary paper wallet with childproofing. Selinexor should be stored 
in a locked and secured area with access restricted to the site  staff pharmacist or designee(s), 
with temperat ure at or below 30ÀöC (86ÀöF). Room temperature storage is recomm ended, 
refrigerated is suitable. Tablets should not be stored frozen. 
Selinexor tablets are currently in on-going stability studies. The expi[INVESTIGATOR_555243]. 
Handling 
Qualified personnel, familiar w ith procedures that minimize und ue exposure to themselves 
and the environment, should undertake the preparation, handling , and safe disposal of the 
chemotherapeutic agent in a sel f-contained and protective environment. 
Availability  
Selinexor is an investigationa l agent and will be supplied free -of-charge from Karyopharm 
Therapeutics Inc. 
Preparation 
No special preparation required. 
NOTE: Tablets of selinexor should not be crushed because of inc reased risk of dermatologic 
toxicity if powder comes in contact [CONTACT_37381]. 
Administration  
Selinexor will be provided as tablets for oral administration. Selinexor is to be taken within 
[ADDRESS_729023] 120  mL (4 ounces) of fluids 
(water, milk, etc.). 
Patients in the present study will receive selinexor 80 mg (45 mg/m2 BSA) plus 
dexamethasone (20 mg), both twice weekly, during Weeks 1-4 of each four-week cycle. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729024] of the inventory and disposition of the agent (investigational or free of charge) 
using the NCI Drug Accountability Record or another comparable drug accountability form. 
(see the Cancer Therapy Evaluation Program [CTEP] website at http://ctep.cancer.gov/protocolDevelopment for the ‚ÄúPolicy and Guidelines for Accountability 
and Storage of Investigational Agents‚Äù or to obtain a copy o f the drug accountability form). 
Destruction and Return 
At the end of the study, unused supplies of selinexor should be  destroyed according to 
institutional policies. Destruction will be documented in the D rug Accountability Record 
Form. 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729025] will be grad ed according to the grading 
system shown below. 
Table 11: Lens Opacities Classification System 
Grading of Cataracts*  
Cataract Type Grade 1 Grade 2 Grade 3 Grade 4 
Nuclea r 
Yellowing and sclerosis of the 
lens nucleus Mild Moderate Pronounced Severe 
Cortical 
Measured as aggregate percentage 
of the intrapupi[INVESTIGATOR_555244] 10% 
of 
intrapupi[INVESTIGATOR_555245] 
10% -50% of 
intra-pupi[INVESTIGATOR_555245] 
50% -90% of 
intra-pupi[INVESTIGATOR_555245] >90% 
of 
intrapupi[INVESTIGATOR_555246] 10% 
of the area of 
the posterior 
capsule  Obscures 30% 
of the area of 
the posterior 
capsule  Obscures 50% 
of the area of 
the posterior 
capsule  Obscures >50% 
of the area of 
the posterior 
capsule  
*Designation of cataract severity that falls between grade leve ls can be made by [CONTACT_68016] a + sign (e.g., 
1+, 2+). Grading of cataracts is usually done when pupil is dil ated.  
Source: Optometric Clinical Practice Guideline:  Care of the Ad ult Patient with Cataracts (CPG8). American Optometric 
Association at www.aoa.org. 
 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 97 APPENDIX 6.  GLUTATHIONE (GSH)-, S-ADENOSYLMETHIONINE 
(SAM)-, OR N-ACETYLCYSTEINE (NAC)-CONTAINING PRO DUCTS (REPRESENTATIVE LIST) 
Table 12: Glutathione (GSH)-, S-Adenosylmethionine (SAM)-, OR N -Acetylcysteine 
(NAC)-Containing Products (Representative List) 
Glutathione (GSH)  N-acetylcysteine (NAC) S-adenosylmethionine (SAM) 
Product Name [CONTACT_555293] -e 
Complete  S-adenosyl-
methionine  
L-Glutathione L-glutathione Cerefolin NAC: 
medical food for age
-related 
memory loss L-methylfolate 
vitamin B12 N
-acetyl 
cysteine SAMe  S-adenosyl-L -
methionine  
Glutathione 
reduced  glutathione  NAC  N-acetyl 
cysteine  Double Strength 
SAMe 400  S-adenosyl-
methionine  
Reduced 
glutathione with alpha lipoic acid Setria L -
glutathione  N-A-C Sustain N-acetyl L-
cysteine    
Glutathione, 
Cysteine &  C glutathione  
L-cysteine 
vitamin C  Best NAC 
Detox 
Regulators N-acetyl 
cysteine    
(Mega -) 
Liposomal 
Glutathione  glutathione       
Lypospheric 
GSH  glutathione      
Ivory Caps Skin 
Enhancement Formula
 glutathione      
 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH$33(1',; 6800$5<2)&+$1*(6
$PHQGPHQW
$PHQGPHQW5DWLRQDOH
7KHSULPDU\SXUSRVHIRUWKLVDPHQGPHQWLVWR
x$GGUHVVWKHIROORZLQJ)'$GHILFLHQF\DQGFRPPHQWVSURYLGHGLQD QHPDLOPHVVDJH
ZLWKWKHVXEMHFW¬≥,1' .37 'HILFLHQF\DQG&RPPHQWV¬¥GDWHG
-DQ
o'HILFLHQF\ 
7REHHOLJLEOH IRUWKHWULDOSDWLHQWVVKRXOGKDYHUHWXUQHGWR¬î*UDGHQRQ
KHPDWRORJLFDOWR[LFLWLHVIURPSUHYLRXVWUHDWPHQW
o&RPPHQWV 
7KHSULPDU\HQGSRLQWVKRXOGEHSHUFHQWUDOLQGHSHQGHQWUHYLHZ FRPPLWWHH
LQFOXGLQJUDGLRORJ\UHYLHZ
7LPHWRHYHQWHQGSRLQWVVXFKDV3)626DQG3DWLHQW5HSRUWHG2 XWFRPHVDUH
QRWHYDOXDEOHLQQRQFRQWUROOHGWULDOV
7KHUHYLVHGSURWRFRO9HUVLRQGDWHG)HEZLOOEHVXEPL WWHGE\WKH3ULQFLSDO
,QYHVWLJDWRUVWRDOODSSOLFDEOH,QVWLWXWLRQDO5HYLHZ%RDUGV ,5%V,QGHSHQGHQW(WKLFV
&RPPLWWHHV,(&VRU5HVHDUFK(WKLFV%RDUGV5(%VDQGE\.DU \RSKDUP7KHUDSHXWLFV
,QFWRDOODSSOLFDEOH5HJXODWRU\$XWKRULWLHV
$VX[COMPANY_003]U\RINH\FKDQJHVWKDWZHUHPDGHWRSURWRFRO9HUVLRQ LQFOXGLQJUDWLRQDOHVIRU
WKHVHFKDQJHVLVSURYLGHGEHORZ
&KDQJHVWRWKH3URWRFRO
$GPLQLVWUDWLYH&KDQJHV
x,QWHUQDOFKDQJHVWRLPSURYHFODULW\DQGHOLPLQDWHLQFRQVLVWHQFL HVEHWZHHQVHFWLRQV
0RGLILHGVHFWLRQV *OREDO
x8SGDWHGWKHYHUVLRQQXPEHUDQGGDWHRISURWRFROIURP9HUVLRQ GDWHG$SU
WR9HUVLRQGDWHG)HE 0RGLILHGVHFWLRQV *OREDO
6SHFLILF&RQWHQW&KDQJHV
6\QRSVLV
7DEOH
x&KDQJHGWKH6FUHHQLQJ3HULRGIURPGD\VWRGD\VSULRUWR& '
x5HPRYHGPHQWLRQRIUDQGRPL]DWLRQ
 
6HFWLRQ'DWD0RQLWRULQJ&RPPLWWHH
x$GGHGVXEVHFWLRQVWRFODULI\WKHUROHVRIWKH'0&IRUUHYLHZLQ JVDIHW\DQGUHVSRQVHGDWDWKHODWWHU
ZDVDGGHGLQUHVSRQVHWRFRPPHQWVE\WKH)'$
6HFWLRQ,QFOXVLRQ&ULWHULD
x$GGHGUHVROXWLRQRIKHPDWRORJLFWR[LFLWLHVIURPSUHYLRXVWUHDWP HQWVWR¬î*UDGHLQUHVSRQVHWRD
GHILFLHQF\UHSRUWHGE\WKH)'$CCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6HFWLRQ6XUYLYDO)ROORZ8S
x63(383(3DQG)/&HYHU\PRQWKVWRDVVHVVGXUDELOLW\RIUHVSR QVHZDVDGGHGWREHFRQVLVWHQWZLWK
WKH62$
6HFWLRQ6NHOHWDO6XUYH\
x0RGLILHGWRLQFOXGHFHQWUDOUHDG
6HFWLRQ3KDUPDFRNLQHWLF(QGSRLQWV
x7DEOHZDVUHYLVHGWRUHIOHFW3. 
6HFWLRQ&RQFRPLWDQW7UHDWPHQWV
x5HGXQGDQWZRUGLQJIRUUHVWULFWHGPHGLFDWLRQVZDVGHOHWHG
6HFWLRQ6HFRQGDU\(QGSRLQWV
x7H[WZDVUHYLVHGWRFODULI\WKDW3)64R/DQG26ZLOOQRWEHWH VWHGIRUVWDWLVWLFDOVLJQLILFDQFHLQ
UHVSRQVHWRFRPPHQWVIURPWKH)'$
CCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 100 Amendment 2  
Amendment Rationale 
The primary purposes for this amendment were to: 
1. Revise the study target patient population from ‚Äúquad-refractor y‚Äù to ‚Äúdual-refractory‚Äù 
as shown in the following modified inclusion criteria: 
From : Patients must have ‚ÄúMM refrac tory to lenalidomide, pomalidomi de, 
bortezomib, and carfilzomib.‚Äù  
To: ‚ÄúPatients must have been previously exposed to lenalidomide, pomalidomide, 
bortezomib, and carfilzomib‚Äù and have  ‚ÄúMM double refractory to previous treatment 
with both the PI [INVESTIGATOR_555247]‚Äù  
2. Change the study treatment (selinexor plus dexamethasone) dose schedule from 
‚Äútwice weekly for three weeks of every four-week cycle‚Äù to ‚Äútwi ce weekly for every 
week of each four-week cycle.‚Äù 
The revised protocol Versi on 3.0, dated 25 September 2015 will be submitted by [CONTACT_1268](s) to all applicable Institutional Revie w Boards (IRBs), Independent 
Ethics Committees (IECs), or Research Ethics Boards (REBs), and by [CONTACT_555289]. to all applicable Regulatory Authorities. 
A summary of key changes that were made to protocol Version 2.0 , including rationales for 
these changes, is provided below. 
Changes to the Protocol 
Administrative Changes 
x Revisions were made to harmonize procedures and assessments with those in clinical 
protocol KCP-330-017 (STOMP): A Phase 1b/2 Study of Selinexor ( KPT-330) in 
Combination with Backbone Treatme nts for Resistant/Refractory M ultiple Myeloma. 
x Internal changes were made to improve clarity and eliminate inc onsistencies across 
sections ( Modified sections :  Global) 
x Updated the version number and date of protocol from Version 2. 0 dated 05 February 
2015 to Version 3.0 dated 25 September 2015 (Modified sections : Global) 
Specific Content Changes 
Title 
From: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330)  plus Low-
Dose Dexamethasone in Patients with Multiple Myeloma Quad-refra ctory to Previous 
Therapi[INVESTIGATOR_555248]: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330 ) plus 
Dexamethasone in Patients with Multiple Myeloma Double-refracto ry to Previous 
Therapi[INVESTIGATOR_555249] : Multiple myeloma quad-refractory to prior treatment with bort ezomib, 
carfilzomib, lenalidomide, and pomalidomide 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJHTo0XOWLSOHP\HORPDUHIUDFWRU\WRSULRUWUHDWPHQWZLWKDQLPPXQR PRGXODWRU\DJHQW
,0L'DQGDSURWHDVRPHLQKLELWRU3,
6\QRSVLV
2EMHFWLYHV
x5HYLVHGWKH3ULPDU\2EMHFWLYHIRUVHOLQH[RUWREHGRVHGIRXUZH HNVLQVWHDGRIWKUHH
ZHHNVRIHDFKIRXUZHHNF\FOH
x0RYHGWKHIROORZLQJREMHFWLYHIURP([SORUDWRU\2EMHFWLYHVWR6H FRQGDU\2EMHFWLYHV
¬≥'HWHUPLQH255'253)6DQG26LQWKHVXE JURXSRISDWLHQWVZLWKIUHHOLJKW
FKDLQ)/&00¬¥ 
x5HYLVHGREMHFWLYHVWRVWDWHWKDWSDWLHQWVPXVWKDYHEHHQ exposedWROHQDOLGRPLGH
SRPDOLGRPLGHERUWH]RPLEDQGFDUILO]RPLEEXWWKHLUGLVHDVHPX VWRQO\EHVKRZQWR
EHUHIUDFWRU\WRWKHGUXJFODVVHV3,VDQG,0L'VLHRQHGUXJ LQHDFKFODVV
x 

%DFNJURXQGDQG6WXG\5DWLRQDOH 
x8SGDWHGUHSRUWHGSUHOLPLQDU\LQIRUPDWLRQRQDOOIRXUWUHDWPHQ WJURXSVLQ.&3
LHVHOLQH[RU¬îPJPVHOLQH[RU¬ïPJPVHOLQH[RUPJP
GH[DPHWKDVRQHPJDQGVHOLQH[RUPJPGH[DPHWKDVRQHPJDOODVRI
'HF
0HWKRGRORJ\
x&KDQJHGWKHVHOLQH[RUSOXVGH[DPHWKDVRQHGRVHVFKHGXOHIURP¬≥WZ LFHZHHNO\IRU
WKUHHZHHNVRIHYHU\IRXUZHHNF\FOH¬¥WR¬≥WZLFHZHHNO\IRUIRXU ZHHNVRIHYHU\IRXU
ZHHNF\FOH
,QFOXVLRQ([FOXVLRQ&ULWHULD
x5HYLVHGWRVWDWHWKDWSDWLHQWVPXVWKDYHEHHQ exposedWROHQDOLGRPLGHSRPDOLGRPLGH
ERUWH]RPLEDQGFDUILO]RPLEEXWWKHLUGLVHDVHPXVWRQO\EHVKR ZQWREHUHIUDFWRU\WR
WKHGUXJFODVVHV3,VDQG,0L'V
6WXG\'XUDWLRQ
x$GGHGDQ(QGRI6WXG\GHILQLWLRQ7KHVWXG\ZLOOHQGZKHQDOOS DWLHQWVKDYH
FRPSOHWHGWKHRQH\HDU)ROORZXS3HULRGLHZKHQWKHODVWSD WLHQWKDVH[SLUHGEHHQ
IROORZHGIRUPRQWKVDIWHUODVWGRVHRIVWXG\GUXJEHHQORVW WRIROORZXSRUKDV
ZLWKGUDZQFRQVHQWZKLFKHYHURFFXUVILUVW
&ULWHULDIRU(YDOXDWLRQ 
x&KDQJHGWKHFDXVDOLW\DVVHVVPHQWV
FromXQUHODWHGSRVVLEO\UHODWHGRUUHODWHG
ToQRWUHODWHGXQOLNHO\UHODWHGSRVVLEO\UHODWHGRU UHODWHG
x$GGHGDOLVWRIWKH,0:*UHVSRQVHFULWHULD
7DEOH
x5HRUJDQL]HGWKHWDEOHIRUFODULW\DQGFRQVLVWHQF\RIWDEOHIRR WQRWHVDQG6HFWLRQ
6WXG\'D\3URFHGXUHVLQFOXGLQJCCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH$GGHGFROXPQIRU¬≥6DIHW\)ROORZXS&DOO¬¥
$GGHGFROXPQVIRU¬≥&\FOH'D\¬¥DQG¬≥&\FOHV¬ï¬¥
2UJDQL]HGPXOWLSOHVWXG\SURFHGXUHURZVXQGHU¬≥&OLQLFDO/DEV¬¥D QG¬≥0XOWLSOH
0\HORPD6SHFLILF3URFHGXUHV¬¥
5HYLVHGZRUGLQJIRU00GLVHDVHVSHFLILFDVVHVVPHQWV
5HYLVHGVWXG\VFKHGXOHVIRU00GLVHDVHVSHFLILFDVVHVVPHQWV
$GGHGURZIRU¬≥%ORRGGUDZVIRU3.DQDO\VLV¬¥
 

6HFWLRQ2YHUYLHZ
x8SGDWHGRYHUDOOVHOLQH[RUFOLQLFDOVWXG\LQIRUPDWLRQIRU! SDWLHQWVZKR
UHFHLYHGVHOLQH[RUDVRI0D\DVVWDWHGLQWKHPRVWO\U HFHQWO\LVVXHG
6HOLQH[RU Investigator‚Äôs Brochure YHUVLRQUHOHDVHGRQ$XJXVW
6HFWLRQ0XOWLSOH0\HORPD
x5HYLVHGHVWLPDWHGPRUWDOLW\WRGHDWKVDQWLFLSDWHGGXHWR 00LQWKH86LQ
DVVWDWHGLQhttp://www.cancer.org/cancer/multiplemyeloma/detailedguide/multiple-myeloma-key-statistics
6HFWLRQ&OLQLFDO([SHULHQFH
x3URYLGHGDGGLWLRQDOVX[COMPANY_003]U\LQIRUPDWLRQDERXWSUHOLPLQDU\UHVXO WVVHHQZLWK
VHOLQH[RUDQGVHOLQH[RUSOXVGH[DPHWKDVRQHLQWKH00DUPRIWKH RQJRLQJVWXG\
.&3DVRI'HFDVSUHVHQWHGLQ Chen et al. ASH 2014 
6HFWLRQ5DWLRQDOHIRUWKH6WXG\
x5HYLVHGVWXG\WDUJHWSDWLHQWSRSXODWLRQIURP¬≥TXDGUHIUDFWRU\¬¥ WR¬≥GXDOUHIUDFWRU\¬¥
6HFWLRQ5DWLRQDOHIRU6HOLQH[RU'RVH6FKHGXOH
x&KDQJHGWKHVWXG\WUHDWPHQWGRVHVFKHGXOHIURP¬≥WZLFHZHHNO\IR UWKUHHZHHNVRI
HYHU\IRXUZHHNF\FOH¬¥WR¬≥WZLFHZHHNO\IRUIRXUZHHNVRIHYHU\ IRXUZHHNF\FOH¬¥
6HFWLRQ3ULPDU\2EMHFWLYH
x5HYLVHGVWXG\WDUJHWSDWLHQWSRSXODWLRQIURP¬≥TXDGUHIUDFWRU\¬¥ WR¬≥GXDOUHIUDFWRU\¬¥
6HFWLRQ6HFRQGDU\2EMHFWLYHV
x0RYHGWKHIROORZLQJREMHFWLYHIURP([SORUDWRU\2EMHFWLYHVWR6H FRQGDU\2EMHFWLYHV
¬≥'HWHUPLQH255'253)6DQG26LQWKHVXE JURXSRISDWLHQWVZLWKIUHHOLJKW
FKDLQ)/&00¬¥ 
x5HYLVHGREMHFWLYHVWRVWDWHWKDWSDWLHQWVPXVWKDYHEHHQ exposedWROHQDOLGRPLGH
SRPDOLGRPLGHERUWH]RPLEDQGFDUILO]RPLEEXWWKHLUGLVHDVHPX VWRQO\EHVKRZQWR
EHUHIUDFWRU\WRWKHGUXJFODVVHV3,VDQG,0L'V

 
CCICCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6HFWLRQ2YHUYLHZ
x5HYLVHGVWXG\VX[COMPANY_003]U\WRUHIOHFWWKHFKDQJHVVX[COMPANY_003]UL]HGDERYH LHGXDOUHIUDFWRU\
WDUJHWSDWLHQWSRSXODWLRQDQGVWXG\WUHDWPHQWZLOOEHGRVHGIRU IRXUZHHNVSHUIRXU
ZHHNF\FOH
6HFWLRQ,QFOXVLRQ&ULWHULD
x&KDQJHG
From3DWLHQWVPXVWKDYH¬≥00UHIUDFWRU\WROHQDOLGRPLGHSRPDOLGRPL GH
ERUWH]RPLEDQGFDUILO]RPLE¬¥ 
To¬≥3DWLHQWVPXVWKDYHEHHQSUHYLRXVO\H[SRVHGWROHQDOLGRPLGH SRPDOLGRPLGH
ERUWH]RPLEDQGFDUILO]RPLE¬¥ and have¬≥00GRXE OHUHIUDFWRU\WRSUHYLRXV
WUHDWPHQWZLWKERWKWKH3,DQG,0L'GUXJFODVVHV¬¥ 
x$GGHG
&RQILUPDWLRQRISDWLHQWHOLJLELOLW\IRUVWXG\SDUWLFLSDWLRQZLW KWKH0HGLFDO
0RQLWRU
6HFWLRQ6WXG\3ODQDQG3URFHGXUHV
x0RGLILHGSURFHGXUHVDQGDVVHVVPHQWVWREHFRQVLVWHQWZLWK7DEOH 6FKHGXOHRI
$VVHVVPHQWVDQG6WXG\$FWLYLWLHV
x$GGHGDGHILQLWLRQRI(QGRI6WXG\(R6RQH\HDUDIWHUWKHO DVWSDWLHQWWREH
HQUROOHGKDVEHHQWUHDWHGIRURQH\HDU
6HFWLRQ0XOWLSOH0\HORPD'LVHDVH$VVHVVPHQW
x$GGHG7DEOHDVX[COMPANY_003]U\RIWKH00GLVHDVHVSHFLILFDVVHVVPHQWV SHU,0:*
JXLGHOLQHV
6HFWLRQ
x5HYLVHGRSKWKDOPLFH[DPWRUHIHUHQFHERWK/2&6,,,RULJLQDOSUR WRFRODQG$2$
DGGHGLQWKLVDPHQGPHQW
6HFWLRQ3KDUPDFRNLQHWLF(QGSRLQWV
x5HYLVHG7DEOH&ROOHFWLRQ7LPH3RLQWVDQG6DPSOH9ROXPHVI RU3. 



 
 

 

6HFWLRQ7UHDWPHQWCCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 104 x Table 12.2 (Dose Adjustment Guidelines for Selinexor) ‚Äì removed dose adjustment 
guidelines for dexamethasone 
Section 13 Adverse Events 
x Table 13.1 (Classification of Adverse Events by [CONTACT_67983]) ‚Äì Ad ded a fourth option 
of ‚Äúunlikely related‚Äù (to treatment with study drug) 
Section 15.11 Reporting and Publication of Study Documentation  
x Revised to include options for reporting study results in more than one CSR 
  
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 105 Amendment 3 
Protocol Version 4  
Amendment Rationale 
The primary purposes for this amendment were to: 
1. Expand the population of patients with penta-refractory MM by e nrolling 
approximately 130 additional patients. The overall study popula tion is now ~210 
patients. 
2. Revise the study design to make the expansion population (Part 2) the mITT 
population for the primary efficacy analysis (using ORR); ORR f or patients enrolled 
in Part [ADDRESS_729026] 2016 will be submitted by [CONTACT_9532](s) to all applicable Institutional Review Boards ( IRBs), Independent Ethics 
Committees (IECs), or Research Ethics Boards (REBs), and by [CONTACT_555290]. to all applicable Regulatory Authorities. 
A summary of key changes that were made to protocol Version 3.0 , including rationales for 
these changes, is provided below. 
Changes to the Protocol 
Administrative Changes 
x Revisions were made to simplify the protocol, including the eli mination of repetitive 
references to schedules. ( Modified sections : Global; Section 9 [in previous versions] 
was removed in its entirety) 
x Added the abbreviation ‚ÄúSd‚Äù to denote selinexor plus low -dose dexamethasone (i.e., 
selinexor [80 mg] plus dexamethasone [20 mg]) 
x Internal changes were made to improve clarity and eliminate inc onsistencies across 
sections ( Modified sections :  Global) 
x Updated the version number and date of protocol ( Modified sections : Global) 
Specific Content Changes Title 
From:  A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330 ) plus 
Dexamethasone in Patients with Mul tiple Myeloma Double-refracto ry to Previous 
Therapi[INVESTIGATOR_555250]: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-33 0) Plus Low-Dose 
Dexamethasone (Sd) in Patients with Multiple Myeloma Previously  Treated with 
Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an ant i-CD38 Monoclonal 
Antibody (mAb) and Refractory to Prior Treatment with Glucocort icoids, an 
Immunomodulatory Agent, a Proteasome Inhibitor and an anti-CD38  mAb 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH,QGLFDWLRQ
From0XOWLSOHP\HORPDUHIUDFWRU\WRSULRUWUHDWPHQWZLWKDQLPPXQR PRGXODWRU\DJHQW
,0L'DQGDSURWHDVRPHLQKLELWRU3,
To0XOWLSOHP\HORPD00SUHYLRXVO\WUHDWHGZLWKOHQDOLGRPLGHS RPDOLGRPLGH
ERUWH]RPLEFDUILO]RPLEDQGDQDQWL&'PRQRFORQDODQWLERG\ P$ELH
GDUDWXPXPDERULVDWX[LPDEDQGUHIUDFWRU\WRSULRUWUHDWPHQWZL WKJOXFRFRUWLFRLGVDQ
LPPXQRPRGXODWRU\DJHQW,0L'DSURWHDVRPHLQKLELWRU3,DQG DQDQWL&'P$E
6\QRSVLV
7LWOHDQG,QGLFDWLRQDVGHVFULEHGDERYH
2EMHFWLYHV DOVRLQ6HFWLRQ
5HYLVHGWRUHIOHFWWKHFKDQJHWRLQFOXGHWKH3DUWH[SDQVLRQD QGWKHQHZSULPDU\
REMHFWLYHHQGSRLQWIRU255LQSHQWDUHIUDFWRU\SDWLHQWVHQUROOH GLQ3DUW
$GGHGWKDWWKHVHFRQGDU\REMHFWLYHV'253)6'&5&%5773DQG 26ZLOOEH
DQDO\]HGVHSDUDWHO\LQGLIIHUHQWSDWLHQWVXESRSXODWLRQVLH 3DUWSDWLHQWVZLWK
TXDGUHIUDFWRU\003DUWSDWLHQWVZLWKSHQWDUHIUDFWRU\00D QG3DUWSDWLHQWV
ZLWKSHQWDUHIUDFWRU\00
 

 


5DWLRQDOHDOVRLQ6HFWLRQ
$GGHGDVX[COMPANY_003]U\RISUHOLPLQDU\UHVSRQVHUHVXOWVVHHQWKXVIDUL QVWXG\.&3
DQGWKHFXUUHQWVWXG\.&3
0HWKRGRORJ\ DOVRLQ6HFWLRQ
$GGHGDEULHIGHVFULSWLRQRI3DUWVDQG
,QFOXVLRQ([FOXVLRQ&ULWHULD DOVRLQ6HFWLRQVDQG
0HUJHGLQFOXVLRQFULWHULDZLWKWRUHTXLUHPHDVXUDEOH00E DVHGRQPRGLILHG
,0:*JXLGHOLQHV
0RGLILHGLQFOXVLRQFULWHULDQRZWRLQFOXGHHLWKHUGDUDW XPXPDERULVDWX[LPDE
0RGLILHGLQFOXVLRQFULWHULDQRZWRLQFOXGHSDWLHQWVZLW K00UHIUDFWRU\WR
SUHYLRXVWUHDWPHQWZLWKRQHRUPRUHJOXFRFRUWLFRLGVSDUHQWHUDO 3,LHERUWH]RPLE
LQDQGRUFDUILO]RPLE,0L'LHOHQDOLGRPLGHDQGRUSRPDOLG RPLGHDQGDQWL
&'P$ELHHLWKHUGDUDWXPXPDERULVDWX[LPDE
0RGLILHGLQFOXVLRQFULWHULDQRZPXOWLSOHP\HORPDWKDW LVUHIUDFWRU\WRWKH
SDWLHQW¬∂VPRVWUHFHQ WDQWL00UHJLPHQ7KHQHZZRUGLQJLQVWDWHVWKDW
¬≥GRFXPHQWHGVHYHUHLQWROHUDQFHWRWKHSDWLHQW¬∂VODVWWKHUDS\LV DOORZHGXSRQDSSURYDO
E\WKH0HGLFDO0RQLWRU¬¥ CCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 107  Adjusted inclusion criteri on #13 (now #12), requiring adequate platelet count of ‚â• 
50,000/mm3 (patients in whom ‚â• 50% of bone marrow nucleated cells are plas ma 
cells) at baseline. 
 Added inclusion criteria #13, regarding baseline hemoglobin lev el ‚â• 8.5 g/dL.  
 Deleted exclusion criteria #3, MM that does not express either M-protein of FLC is 
no longer excluded.  
 Added exclusion criteria #20 and #21, also to require adequate hematopoietic 
function at baseline. 
 Added exclusion criterion #22, to ens ure that patients can tole rate dexamethasone. 
 Added exclusion criterion #23, a standard item in protocols. 
Documentation Requirements  (also in Section 8.3) 
 A formal statement was added to describe what documentation is needed to establish 
that patients are refractory to prior treatments. 
Study Numbers  (also in Section 13.1.2) 
 Revised estimated enrollment fo r N=122 (for power analysis), and ~130 for 
enrollment. 
Study Duration: 
 Revised enrollment period from 15 months to 24 months.  
Statistical Methods (also in Section 13) 
 Re-stated the statistical assumptions underlying the revised pr imary endpoint. 
Table 1 (Schedule of Assessments)  
 Added FLC on C1D15 and C2D15 
 Added emphasis that MM-specific lab assessments (i.e., SPEP, UP EP, FLC and 
quantitative Ig) must be performed at the time of PD to evaluat e response. This is an 
essential requirement of the IMW G and was included in previous versions of this 
protocol, but its visibility is being increased in this version  to support investigatory 
site staff. 
 Reduced size of footnotes and added cross-referencing to protocol sections 
List of Abbreviations :  
 Deleted abbreviations that were not in use and added several ne w abbreviations 
Protocol, Main Body  
Sections 7.2, 7.3 and 9.9.1 
 Establish an IRC to perform the central read of response data (for the efficacy analysis) that had been previously included under the Data Safe ty Monitoring 
Committee (DSMC) in previous versions of this protocol. The DSMC, now referred to as Data Safety Monitoring Board (DSMB) will retain its role of reviewing all study 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJHVDIHW\GDWD6LQFHWKLVVWXG\PD\EHSLYRWDOIRUDUHJXODWRU\V XEPLVVLRQLWLV
LPSRUWDQWWKDWWKHLQYROYHPHQWRIDQ,5&ZDVUHDGLO\DSSDUHQW
6HFWLRQ 
$GGHG&DQDGDDQG(8IRUSRWHQWLDOLQYHVWLJDWRU\VLWHV
3UHYLRXV6HFWLRQ ¬±6WXG\3ODQDQG3URFHGXUHV 
'HOHWHGWRLPSURYHRYHUDOOSURWRFROVLPSOLFLW\
6HFWLRQ 
6HSDUDWHG3K\VLFDO([DPLQDWLRQVDQG(&2*LQWRVHSDUDWHVXEVHFW LRQV
6HFWLRQ 
$GGHGFRQILUPDWRU\UHYLHZRI00VSHFLILFDVVHVVPHQWVE\FHQWUDO ODERUDWRU\WR
FRQILUP&5DQGV&5
$GGHG¬≥PRGLILHG¬¥WR,0:*DQGDGGHGFLWDWLRQRI3DOXPER 
7DEOH'HOHWHGFROXPQFRQWDLQLQJYLVLWVFKHGXOHIRUVLPSOLFLW \
$GGHGWR83(3WKDWLIWKHSDWLHQWIDLOVWRSURYLGHWKHKRXU XULQHVDPSOHWKLV
VKRXOGEHGRFXPHQWHG$OODWWHPSWVVKRXOGEHPDGHWRFROOHFWW KHKRXUXULQH
VDPSOHDWWKHUHTXLUHGWLPHSRLQWV
 
6HFWLRQ
$GGHG¬≥PRGLILHG¬¥WR,0:*DQGDGGHGFLWDWLRQRI3DOXPER 
6HFWLRQ 
'HOHWHGVHYHUDOSDUDPHWHUVHJEDQGQHXWURSKLOVWKDWZHUHQ RWQHHGHG
6HFWLRQ
5HYLVHGVHFWLRQWRLQGLFDWHEORRGGUDZVIRU3.DQDO\VLVRQO\UH TXLUHGLQ3DUW
6HFWLRQ
$GGHGWKDWUHDVRQVIRUGLVFRQWLQXDWLRQPXVWEHFOHDUO\GRFXPHQW HGLQWKHVRXUFHDQG
LQWKHVWXG\&5)VLQFOXGLQJUHDVRQVIRUSDWLHQWZLWKGUDZDODQG ,QYHVWLJDWRUGHFLVLRQ
WRGLVFRQWLQXHSDWLHQW
6HFWLRQ 
0RGLILHG7DEOHVDQGWRUHIOHFWRXUFXUUHQWXQGHUVWDQGLQJUH JDUGLQJKRZWKH
VHOLQH[RUGRVHVKRXOGEHPRGLILHGLQWKHSUHVHQFHRI$(VGXULQJ WKHVWXG\
6HFWLRQDQG$SSHQGL[ 
'HOHWHGVHOLQH[RUPJDQGPJWDEOHWVWUHQJWKVEHFDXVHWKH\ DUHQRWXVHGLQWKLV
VWXG\CCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH6HFWLRQ 
0RYHG5HVWULFWHG0HGLFDWLRQVWRWKLVVHFWLRQIURPSUHYLRXVORFD WLRQLQ6HFWLRQ
6HFWLRQ
0RYHG3URKLELWHG0HGLFDWLRQVWRWKLVVHFWLRQIURPSUHYLRXVORFD WLRQLQ6HFWLRQ
6HFWLRQ 
0RYHG¬≥2YHUGRVH¬¥WRLWVRZQVXE VHFWLRQ
6HFWLRQ
5HYLVHGWKHGHILQLWLRQRIWKHP,77SRSXODWLRQIRUWKHSULPDU\H IILFDF\DQDO\VLVWR
LQFOXGHWKHVWDWHPHQW¬≥FRQVLVWRI3DUWSDWLHQWVZLWKSHQWD UHIUDFWRU\00ZKRPHHW
DOOHOLJLELOLW\FULWHULD¬¥LQDGGLWLRQWRWKHH[LVWLQJGHILQLWL RQRI¬≥ZKRUHFHLYHDWOHDVW
RQHGRVHRIVWXG\WUHDWPHQW¬¥ 
8SGDWHGWKHGHILQLWLRQRIWKHSHUSURWRFRO33SRSXODWLRQWRH QFRPSDVVDOOSDWLHQWV
LQWKHP,77SRSXODWLRQZKRKDYHFRPSOHWHGDWOHDVWRQHF\FOHRI WUHDWPHQWDQGKDYH
QRPDMRUSURWRFROYLRODWLRQVWKDWZRXOGFRPSURPLVHWKHDVVHVVPH QWRIHIILFDF\
 

6HFWLRQ 
$GGHG3DOXPERWRWKHOLVWRIUHIHUHQFHV
$SSHQGL[ 
5HSODFHG,0:*5HVSRQVH&ULWHULDIURP.\OHZLWKFRPSDUDEOH WDEOHIURP
3DOXPERCCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-[ADDRESS_729027] received isatuximab as the anti-CD38 agent for inclusi on in the study because it is 
not approved at this time. 
The revised protocol Version 4.1 (US-specific amendment), dated  06 February 2017 will be 
submitted by [CONTACT_079](s) to all applicable In stitutional Review Boards 
(IRBs), Independent Ethics Committees (IECs), or Research Ethics Boards (REBs), and by 
[CONTACT_159480]. to all applicable Regulatory Autho rities. 
A summary of key changes that were made to protocol Version 4.0 , including rationales for 
these changes, is provided below. 
Changes to the Protocol 
Administrative Changes (Modified Sections : Global)  
x Updated the version number and date of protocol  
x Updated the number of patients who have received selinexor to the number based on 
the most recent Investigator‚Äôs Brochure (14 November 2016)  
x Replaced ‚Äúminor‚Äù with ‚Äúmi nimal‚Äù in regard to response  
x Removed the qualifier ‚Äúmodified‚Äù from IMWG response criteria beca use the response 
criteria were updated to that based on Kumar 2016  
x Internal changes to improve clarity  
Specific Content Changes 
Title (Modified Sections : Global)  
From:  A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330 ) Plus Low-
Dose Dexamethasone (Sd) in Patients with Multiple Myeloma Previ ously Treated with 
Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an ant i-CD38 Monoclonal 
Antibody (mAb) and Refractory to Prior Treatment with Glucocort icoids, an 
Immunomodulatory Agent, a Proteasome Inhibitor and an anti-CD38  mAb 
To: A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-33 0) Plus Low-Dose 
Dexamethasone (Sd) in Patients with Multiple Myeloma Previously  Treated with 
Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and Daratu mumab, and 
Refractory to Prior Treatment with Glucocorticoids, an Immunomodulatory Agent, a 
Proteasome Inhibitor, and the anti-CD38 mAb Daratumumab 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 111 Indication (Modified Sections : Global)  
From : Multiple myeloma (MM) previously treated with lenalidomide, p omalidomide, 
bortezomib, carfilzomib, and an anti-CD38 monoclonal antibody ( mAb) (i.e., 
daratumumab or isatuximab) and refractory to prior treatment wi th glucocorticoids, an 
immunomodulatory agent (IMiD), a proteasome inhibitor (PI), and  an anti-CD38 mAb 
To: Multiple myeloma (MM) previously treated with lenalidomide, p omalidomide, 
bortezomib, carfilzomib, and daratumumab, and refractory to pri or treatment with 
glucocorticoids, an immunomodulatory agent (IMiD), a proteasome  inhibitor (PI), and 
the anti-CD38 mAb daratumumab 
Protocol Approval Signature [CONTACT_3490] 
 Replaced Michael Kauffman, MD, PhD, Acting Chief Medical Office r, with 
Humphrey Gardner, M.D., Senior Vice President, Clinical Develop ment, as a 
signatory. 
Inclusion/Exclusion Criteria (also in Sections 8.4 and 8.5)  
 Modified inclusion criteria #3d to remove turbidometry as an ac ceptable method to 
measure quantitative Ig levels. 
 Modified inclusion criteria  #4 and #[ADDRESS_729028] 
 Corrected inclusion criteria #7 t o refer to exclusion criteria #17 
 Corrected inclusion criteria #12 t o refer to exclusion criteria  #20 
 Changed inclusion criteria #12a to total WBC count > 1,000/mm3 to update criteria 
for this patient population. 
 Corrected exclusion criteria  #17 to add ‚â• before Grade 2 painful neuropathy  
 Modified exclusion criteria  #22 to add or contraindication for before glucocorticoids 
to further clarify the medical intent of the original language.  
 Added a new exclusion criterion immediately after exclusion cri teria #22 and moved 
the previous #23 to #24. The addition of exclusion criteria #23 , prior exposure to a 
SINE compound, including selinexor, provides consistency across  Karyopharm 
protocols. 
IMWG Response Criteria (also in Sections 6.1, 9.3, and Appendix  3) 
 Updated the IMWG response criteria for myeloma to align with th e most recent 
IMWG criteria (Kumar, Lancet. 2016;17:328-346). The definition for MR was 
changed from ‚Äúminor‚Äù to ‚Äúminimal‚Äù response to align with the IMWG Consensus 
Criteria. 
Documentation Requirements (also in Section 8.3) 
 Removed the requirement to show a patient was refractory to isa tuximab to align with 
feedback on isatuximab from FDA.  
Table 1 (Schedule of Assessments and also in Section [IP_ADDRESS])  
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH0RGLILHGIRRWQRWHWRUHPRYHWH[WWKDWVFDQVDQGDFFRPSDQ\LQ JUHSRUWVZLOOEH
VHQWWRWKHFHQWUDOODERUDWRU\WRUHIOHFWFXUUHQWDQDO\WLFDOSU RFHGXUHV
 

/LVWRI$EEUHYLDWLRQV 
$GGHGWKHGHILQLWLRQVIRU+7$&6DQG)/&NDSSDODPEDUDWL RIRUFODULILFDWLRQ
3URWRFRO0DLQ%RG\ 
6HFWLRQ
8SGDWHGWH[WWRUHIOHFWWKHFXUUHQWVHOLQH[RUVDIHW\LQIRUPDWLR Q
6HFWLRQ
8SGDWHGWKHLQIRUPDWLRQRQ$&6WRLQFOXGHWZRSHGLDWULFSDWLHQW VWRUHIOHFWWKH
FXUUHQWVHOLQH[RUVDIHW\LQIRUPDWLRQ
6HFWLRQDOVRLQ6HFWLRQ
0RGLILHGWRUHTXLUHWKDWDQ,5&FRQILUPGLVHDVHSURJUHVVLRQSUL RUWRDSDWLHQW
GLVFRQWLQXLQJVWXG\WUHDWPHQWWRLPSURYHWKHFRQVLVWHQF\RIFOL QLFDOGHFLVLRQVDFURVV
WKHVLWHV
6HFWLRQVDOVRLQ$SSHQGL[
5HYLVHGWKHPRGLILFDWLRQVWRWKH,0:*UHVSRQVHFULWHULDPRGLILH GWRDOORZIRU
TXDQWLWDWLYH,JOHYHOVE\QHSKHORPHWU\WREHXVHGLQSODFHRI6 3(3IRUURXWLQH
0SURWHLQPHDVXUHPHQWVIRUSDWLHQWVZLWK,J$RU,J'P\HORPD
7DEOH
8SGDWHGWH[WWRFODULI\83(3VHUXP)/&4XDQWLWDWLYH,JOHYHOV 6NHOHWDOVXUYH\DQG
&OLQLFDOSODVPDF\WRPDDVVHVVPHQWV
5HPRYHGWKHIROORZLQJWH[WIRUVNHOHWDOVXUYH\WRUHIOHFWFXUUH QWDQDO\WLFDO
SURFHGXUHV¬≥WKHVFDQVDQGDFFRPSDQ\LQJUDGLRORJ\UHSRUWVZLOOEHVHQW WRDFHQWUDO
ODE'HWDLOVUHJDUGLQJWKHFHQWUDOODESURFHGXUHVLQFOXGLQJFRO OHFWLRQDQGVKLSPHQWRI
GDWDZLOOEHGHVFULEHGLQWKH6WXG\0DQXDO¬¥ 
6HFWLRQDOVRLQ6HFWLRQ
0RGLILHGWRLQFOXGHWKH)ULGHULFLDFRUUHFWLRQIRUPXODIRUFRQVL VWHQF\ZLWKLQWKH
SURWRFRODQGDGGHGUHIHUHQFHVIRU%D]HWW¬∂VDQG)ULGHULFLD¬∂VIRU PXODV

 


7DEOH
$GGHGWKHIROORZLQJWH[WDERYHWKHWDEOHWRUHIOHFWFXUUHQWJXL GDQFH3OHDVHQRWHWKH
IROORZLQJUHFRPPHQGDWLRQV$IWHUFRQVXOWDWLRQZLWKWKH0HGLFDO 0RQLWRUDQGDWWKHCCI
CCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 113 discretion of the Investigator, selinexor dosing may be maintai ned for all 
hematological or non-hematological AEs that are NOT related to selinexor. For all 
selinexor-related AEs, if the prescribed dose reductions/interr uptions in Table 8 result 
in a stabilization of ‚â• 4 w eeks, a re-escalation may be cons idered after approval from 
the Medical Monitor. 
 Updated text throughout table to reflect the most recent suppor tive care information 
available. 
Section 11.2 and Appendix 4 
 Modified text to state that selinexor tablets (20 mg) will be supplied in polyvinyl 
chloride/polychlorotrifluoroethylene/polyvinyl chloride (PVC/PC TFE/PVC) film 
blisters (or equivalent) with a n aluminum foil lidding in a sec ondary paper wallet 
with childproofing to reflect current information. 
Section 11.4.6 
 Removed text to align with the selinexor Investigator‚Äôs Brochure : Alcohol:
 Ethanol should be avoided on selinexor dosing days as it may co mpete for 
GSH-mediated metabolism 
Section 12.1.1 
 Revised text to align with Table 9. 
Section 15 :  
 Added references to the list that were inadvertently removed fr om previous versions 
of the protocol. 
 Added Durie 2006, Kumar 2016, and R ajkumar [ADDRESS_729029] of references 
 Removed Kyle [ADDRESS_729030] of references 
Appendix 7 :  
Some of the detailed information in the Protocol Version 4 ROW SOC was not included in 
the Protocol Version 4 SOC for the US because the Protocol Vers ion 4 ROW SOC was 
revised after Protocol Versi on 4 for the US was published. 
 
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 114 Amendment 4 
Protocol Version 5.0 
Amendment Rationale 
The primary purpose for this amendment was to address comments received from Regulatory 
Authorities. 
The revised protocol Version 5.0 dated 28 April 2017 will be submitted by [CONTACT_9532](s) to all applicable Institutional Review Boards ( IRBs), Independent Ethics 
Committees (IECs), or Research Ethics Boards (REBs), and by [CONTACT_555290]. to all applicable Regulatory Authorities. 
A summary of key changes that were made to protocol Version 4.1 , including rationales for 
these changes, is provided below. 
Changes to the Protocol 
Administrative Changes 
x Updated the version number and date of protocol ( Modified sections : Global) 
x Updated the number of patients who have received selinexor to the number based on 
the most recent Investiga tor‚Äôs Brochure (31 March 2017) (Modified sections: Global)  
x Internal changes to improve clarity (Modified sections:  Global) 
Specific Content Changes 
Protocol Approval Signature [CONTACT_3490] 
 Replaced Humphrey Gardner, M.D., Senior Vice President, Clinica l Development, 
with Michael Kauffman, MD, PhD, Acting Chief Medical Officer, a s a signatory. 
Synopsis  
 Added the following text to the Background and Study Rationale to align with the most 
recent IB, ‚Äú across all patients was 21% and the clinical benefit rate (CBR)  is 33%. 
Similar ORR were seen in the pat ients with ‚Äúpenta‚Äù and ‚Äúquad‚Äù M M, with higher CBR 
in patients who received 8 vs. 6 doses/cycle consistent with improved disease control 
with continuous dosing .‚Äù 
 Added the following text, ‚ÄúIf any patient is not able to t olerate this dose, then a potential 
discontinuation or further decrease in dosage would be allowed after a discussion with 
the Medical Monitor on a case by [CONTACT_413],‚Äù to allow for adju stments to the dosing of 
dexamethasone. 
Inclusion/Exclusion Criteria  (also in Synopsis and Sections 8.4 and 8.5) 
 Modified inclusion criteria  #[ADDRESS_729031] agree to use 2 methods of contraception (includi ng 1 highly effective 
and 1 effective method of contraception). 
 Modified inclusion criteria #13 to remove ‚Äúon Cycle 1 Day 1‚Äù for hemo globin level ‚â• 
8.5 g/dL. 
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH0RGLILHGLQFOXVLRQFULWHULDWRDGG¬≥NH\¬¥WR VSHFLILFFULWHULD
&RUUHFWHGH[FOXVLRQFULWHULDWRDGG¬ï WR*UDGHSDLQIXOQHXURSDWK\
7DEOH6FKHGXOHRI$VVHVVPHQWV DOVRLQ6HFWLRQ
0RGLILHGIRRWQRWHWR¬≥ )RUIHPDOHVRIFKLOGEHDULQJSRWHQWLDOQHJDWLYHVHUXPK&*
SUHJQDQF\WHVWPXVWEHREWDLQHGZLWKLQGD\VEHIRUHWKHILUVW GRVHRIVWXG\
WUHDWPHQW3UHJQDQF\WHVWLQJVHUXPK&*RUXULQHLVDOVRUHTXL UHGIRUIHPDOHVRI
FKLOGEHDULQJSRWHQWLDOSULRUWRGRVLQJRQ'D\RI&\FOHV¬ïD QGDWWKH(R79LVLW
VHUXPK&*3UHJQDQF\WHVWLQJPD\DOVREHSHUIRUPHGDVFOLQLFD OO\LQGLFDWHGGXULQJ
WKHVWXG\ ¬¥WRUHTXLUHGWKDWWHVWLQJLVSH UIRUPHGRQ'D\RI&\FOHV¬ï 
 

 
/LVWRI$EEUHYLDWLRQV 
5HPRYHGGHILQLWLRQIRU)/&NDSSDODPEDUDWLRIRUFODULILFDWLR Q
$GGHGGHILQLWLRQIRU75$(WUHDWPHQWHPHUJHQWDGYHUVHHYHQW
3URWRFRO0DLQ%RG\ 
6HFWLRQ
8SGDWHGWKHFOLQLFDOH[SHULHQFHVHFWLRQVWRWKHPRVWUHFHQWVDI HW\DQGHIILFDF\
LQIRUPDWLRQIRU00LQWKH.&3VWXG\DQGIRU.&3 VWXG\LQWKH,%
6HFWLRQ
8SGDWHGWKHLQIRUPDWLRQRQ$&6WRUHIOHFWWKHFXUUHQWVHOLQH[RU VDIHW\LQIRUPDWLRQ
6HFWLRQ
$GGHGWKHIROORZLQJWH[W¬≥,IDQ\SDWLHQWLVQRWDEOHWRWROHUD WHWKLVGRVHWKHQDSRWHQWLDO
GLVFRQWLQXDWLRQRUIXUWKHUGHFUHDVHLQGRVDJHZRXOGEHDOORZHG DIWHUDGLVFXVVLRQZLWK
WKH0HGLFDO0RQLWRURQ DFDVHE\FDVHEDVLV¬¥WRDOORZIRUDGMXVWPHQWVWRWKHGRVLQJR I
GH[DPHWKDVRQH
6HFWLRQ
8SGDWHGWH[WWRUHIOHFW,0:*UHTXLUHPHQWIRUVHTXHQWLDOVDPSOH WRFRQILUPUHVSRQVH
¬≥63(3ZLWKVHUXPSURWHLQLPPXQRIL[DWLRQTXDQWLWDWLYH,JVHUXP )/&DQG KRXU
83(3ZLWKLPPXQRIL[DWLRQPXVWEHFROOHFWHGDWHDFKUHTXLUHGW LPHSRLQW$Q
DOLTXRWRIWKHEORRGDQGXULQHVDPSOHVVKRXOGEHUHWDLQHG,I WKHORFDOODERUDWRU\
UHVXOWVLQGLFDWHD&5RUV&5DVHTXHQWLDOVDPSOHSHU,0:*VK RXOGEHFROOHFWHG
DQGDQDO\]HG$OLTXRWVIURPWKHLQLWLDODQGVXEVHTXHQWFROOHFW LRQZLOOEHVHQWWRWKH
FHQWUDOODERUDWRU\WRFRQILUPWKH&5RUV&5UHVSRQVH¬¥ 
&RUUHFWHGLQ7DEOHWKDWNDU\RW\SLQJDQG),6+ZLOOEHSHUIRUPH GDWDFHQWUDO
ODERUDWRU\QRWDORFDOODERUDWRU\CCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH
 

6HFWLRQ
8SGDWHGWH[WWRVSHFLI\WKDWDOO00DVVHVVPHQWVDUHUHTXLUHGDW HDFKWLPHSRLQW
$GGHGWH[WWRFODULI\WKHWLPLQJRIFROOHFWLRQRIVHTXHQWLDO00 DVVHVVPHQWVDPSOHV
¬≥7ZRFRQVHFXWLYHVDPSOHVDUHUHTXLUHGWRFRQILUPWKHUHVSRQVH 7KHWLPHSHULRG
EHWZHHQVDPSOHVPD\EHGLVFXVVHGZLWKWKH0HGLFDO0RQLWRUDQGF DQRFFXURQWKH
VDPHGD\DVORQJDVWKHVDPSOHVDUHDQDO\]HGVHSDUDWHO\ ¬≥
6HFWLRQ
$GGHGQHZ6HFWLRQ3UHJQDQF\7HVWLQJZLWKWKHIROORZLQJWH[W¬≥ )RUIHPDOHVRI
FKLOGEHDULQJSRWHQWLDODQHJDWLYHVHUXPKXPDQFKRULRQLFJRQDGR WURSLQK&*
SUHJQDQF\WHVWPXVWEHREWDLQHGZLWKLQGD\VEHIRUHWKHILUVW GRVHRIVWXG\
WUHDWPHQW7HVWVHQVLWLYLW\IRUK&*PXVWEH¬ï P,8P/3UHJQDQF\WHVWLQJVHUXP
K&*RUXULQHLVDOVRUHTXLUHGIRUIHPDOHVRIFKLOGEHDULQJSRWH QWLDOSULRUWRGRVLQJRQ
'D\RI&\FOHV¬ïGXULQJWKHVWXG\DQGDWWKH(R79LVLW VHUXPK&*3UHJQDQF\
WHVWLQJPD\DOVREHSHUIRUPHGDVFOLQLFDOO\LQGLFDWHGGXULQJWK HVWXG\¬¥
6HFWLRQVDQG7DEOH 
5HSODFHGWH[WLQWKHVHVHFWLRQVZLWK¬≥$VRISURWRFROYHUVL RQWKHVHVDPSOHVDUHQR
ORQJHUFROOHFWHG¬¥7DEOHZDVUHPRYHGDVWKH3. EORRGVDPSOHV DUHQR
ORQJHUEHLQJFROOHFWHGDVLVLWQRWQHFHVVDU\WRFRQWLQXHFROOH FWLQJWKHVHVDPSOHV

 



 


6HFWLRQ
$GGHGWKHIROORZLQJWH[W¬≥,IDQ\SDWLHQWLVQRWDEOHWRWROHUD WHWKLVGRVHWKHQDSRWHQWLDO
GLVFRQWLQXDWLRQRUIXUWKHUGHFUHDVHLQGRVDJHZRXOGEHDOORZHG DIWHUDGLVFXVVLRQZLWK
WKH0HGLFDO0RQLWRURQDFDVHE\FDVHEDVLV¬¥WRDOORZIRUDGMX VWPHQWVWRWKHGRVLQJRI
GH[DPHWKDVRQH
 

 
6HFWLRQDQG$SSHQGL[CCI
CCICCI
CCICCI
CCI
CCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 117  Modified text to simplify the description of the blister packag ing. 
Section 11.4.7 
 Revised Prevention of Pregnancy language to Contraception Requi rements to clarify 
that female patients of childbearin g potential must agree to us e 2 methods of 
contraception (including 1 highly effective and 1 effective method of contraception). 
Section [IP_ADDRESS]  
 Added the Karyopharm German PV fax number for European sites. 
 Revise text to modify reporting suspected unexpected serious ad verse reactions to the 
competent authorities and relevant ethics committees in accorda nce with the FDA‚Äôs 
‚ÄúSafety Reporting Requirements for Investigational New Drugs an d 
Bioanalytical/Bioequiva lence Studies‚Äù or as per national regulatory requirements in 
participating countries in order to ensure safety information i s reported to authorities 
in all countries participating in the study. 
Section 14.11 
 Clarified the publication language to include the following text, ‚ÄúPublication will be 
in a relevant peer- reviewed journal, with authorship status an d ranking designated 
according to the acknowledged contributions of participating investigators, 
institutions and the Sponsor.‚Äù  
Section 15  
 Added Vogl [ADDRESS_729032] of references 
Appendix 7 :  
 Revised Changes to the Protocol for Protocol Version 4.1 to acc urately capture 
changes made to that version of the protocol. 
  
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH$PHQGPHQW
3URWRFRO9HUVLRQ
$PHQGPHQW5DWLRQDOH
7KHSULPDU\SXUSRVHIRUWKLVDPHQGPHQWZDVWRXSGDWHVWDWLVWLFD OODQJXDJHHJGHILQLWLRQ
RIDQDO\VLVSRSXODWLRQV DQGWRDGGUHVVLQFRQVLVWHQFLHV
7KHUHYLVHGSURWRFRO9HUVLRQGDWHG'HFHPEHUZLOOEH VXEPLWWHGE\WKH3ULQFLSDO
,QYHVWLJDWRUVWRDOODSSOLFDEOH,QVWLWXWLRQDO5HYLHZ%RDUGV ,5%V,QGHSHQGHQW(WKLFV
&RPPLWWHHV,(&VRU5HVHDUFK(WKLFV%RDUGV5(%VDQGE\.DU \RSKDUP7KHUDSHXWLFV
,QFWRDOODSSOLFDEOH5HJXODWRU\$XWKRULWLHV
$VX[COMPANY_003]U\RINH\FKDQJHVWKDWZHUHPDGHWRSURWRFRO9HUVLRQ LQFOXGLQJUDWLRQDOHVIRU
WKHVHFKDQJHVLVSURYLGHGEHORZ
&KDQJHVWRWKH3URWRFRO
Administrative Changes 
x8SGDWHGWKHYHUVLRQQXPEHUDQGGDWHRISURWRFRO 0RGLILHGVHFWLRQV *OREDO
x,QWHUQDOFKDQJHVWRLPSURYHFODULW\0RGLILHGVHFWLRQV*OREDO 
Specific Content Changes 
3URWRFRO$SSURYDO6LJQDWXUH3DJH
5HSODFHG0LFKDHO.DXIIPDQ0'3K'$FWLQJ&KLHI0HGLFDO2IILF HUZLWK-DWLQ
6KDK.DXIIPDQ0'9LFH3UHVLGHQW&OLQLFDO6WUDWHJ\DVDVLJQ DWRU\
6\QRSVLV
2EMHFWLYHVXSGDWHGIRUFRQVLVWHQF\ZLWKWKH6WDWLVWLFDO$QDO\V LV3ODQ
o8SGDWHGGHILQLWLRQVRI'XUDWLRQVRI&%5DQG'&5
 
6WDWLVWLFDO 0HWKRGV  XSGDWHG WKH GHILQLWLRQ RI P,77 DQG 33 SRS XODWLRQV IRU
FRQVLVWHQF\ZLWK6$3 

7DEOH6FKHGXOHRI$VVHVVPHQWV DOVRLQ6HFWLRQ
0RGLILHGIRRWQRWHVDQGWRLQGLFDWHWKDWUHVXOWVRISUHVF UHHQLQJ00
DVVHVVPHQWVDW'D\ZLQGRZ6FUHHQLQJ ¬±ZHHNVDQG'D\¬ìGD\VZLOO
EHSURYLGHG7KLVLQIRUPDWLRQLVUHTXLUHGWRPRUHIXOO\XQGHUV WDQGKLVWRU\RI
SDWLHQW¬∂V00H[WHQWRIGLVHDVHUDWHRISURJUHVVLRQ 
3URWRFRO0DLQ%RG\ 
6HFWLRQ
8SGDWHGWKH,QWURGXFWLRQIRUFODULW\DQGDFFXUDF\
6HFWLRQCCI
CCICCI
6HOLQH[RU.37  .DU\RSKDUP7KHUDSHXWLFV,QF
&OLQLFDO6WXG\3URWRFRO.&3  

'HFHPEHU9HUVLRQ &RQILGHQWLDO 3DJH8SGDWHGGHILQLWLRQVRI'XUDWLRQVRI&%5DQG'&5IRUFRQVLVWHQF\ ZLWKWKH6$3
6HFWLRQ
'HOHWHGWKHIROORZLQJWH[WDV,5&GRHVQRWUHYLHZGLVHDVHDVVH VVPHQWVDWWKHWLPHRI
SURJUHVVLRQDQGGLVFRQWLQXDWLRQRIWUHDWPHQWGRHVQRWUHTXLUHF RQILUPDWLRQRI3'E\
,5&¬≥¬´DQGPXVWUHYLHZDWWLPHRISURJUHVVLRQ3URJUHVVLRQEDVHGRQVL WHJHQHUDWHG
GLVHDVH DVVHVVPHQW GDWD PXVW EH FRQILUPHG E\ WKH ,5& SULRU WR G LVFRQWLQXLQJ
WUHDWPHQW¬¥ 
6HFWLRQ
5HPRYHG&DQDGDIURPWKHOLVWRIFRXQWULHVZKHUHWKHVWXG\LVEH LQJFRQGXFWHGWR
UHIOHFWWKDWWKHVWXG\LVQRWEHLQJFRQGXFWHGLQ&DQDGD
6HFWLRQ
$GGHGWKHIROORZLQJWH[WDIWHU GDWHRIELUWK¬≥DVDOORZHGE\UHJXODWRU\DXWKRULWLHV¬≥WR
FODULI\WKDWLQYHVWLJDWRUVKRXOGSURYLGHELUWKGDWHLQIRUPDWLRQ LQFRPSOLDQFHZLWKWKHLU
UHJXODWRU\DXWKRULWLHV
6HFWLRQ
$GGHGWH[WWRLQGLFDWHWKDWUHVXOWVRISUHVFUHHQLQJ00DVVHVVP HQWVDW'D\
ZLQGRZ6FUHHQLQJ ¬±ZHHNVDQG'D\¬ìGD\VZLOOEHSURYLGHG7KLV
LQIRUPDWLRQLVUHTXLUHGWRPRUHIXOO\XQGHUVWDQGKLVWRU\RISDW LHQW¬∂V00H[WHQWRI
GLVHDVHUDWHRISURJUHVVLRQ 
7H[WHGLWHGLQ6HFWLRQWRFODULI\VDPSOHFROOHFWLRQDQGDQD O\VLVSURFHGXUHVLQWKH
HYHQWRID&5RUV&5WRDOLJQZLWKWKHODEPDQXDO

 



 

6HFWLRQ
)RUFRQVLVWHQF\ZLWK6WDWLVWLFDO$QDO\VLV3ODQ
o8SGDWHGWKHGHILQLWLRQRIP,77DQG33SRSXODWLRQV
 
o8SGDWHG6XEJURXS(IILFDF\$QDO\VHV
6HFWLRQ
8SGDWHGWKHGHILQLWLRQRIP,77DQG33SRSXODWLRQV 
IRUFRQVLVWHQF\ZLWK6WDWLVWLFDO$QDO\VLV3ODQCCI
CCICCI
CCI
Selinexor (KPT-330)  Karyopharm Therapeutics Inc. 
Clinical Study Protocol: KCP-330-012   
 
13 December 2017, Version 6.0 Confidential Page 120 Appendix 7 :  
 Added Summary of Changes for Protocol Version 6.0 to describe c hanges made to 
version 5.0.  
 